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Background: There is a high prevalence of smoking among people with severe mental ill health (SMI).
Helping people with SMI to quit smoking could improve their health and longevity, and reduce health
inequalities. However, those with SMI are less likely to access and engage with routine smoking cessation
services than the general population.
Objectives: To compare the clinical effectiveness and cost-effectiveness of a bespoke smoking cessation
(BSC) intervention with usual stop smoking services for people with SMI.
Design: A pragmatic, two-arm, individually randomised controlled trial.
Setting: Primary care and secondary care mental health services in England.
Participants: Smokers aged ≥ 18 years with SMI who would like to cut down on or quit smoking.
Interventions: A BSC intervention delivered by mental health specialists trained to deliver evidence-
supported smoking cessation interventions compared with usual care.
Main outcome measures: The primary outcome was self-reported, CO-verified smoking cessation at
12 months. Smoking-related secondary outcomes were self-reported smoking cessation, the number of
cigarettes smoked per day, the Fagerström Test for Nicotine Dependence and the Motivation to Quit
questionnaire. Other secondary outcomes were Patient Health Questionnaire-9 items, Generalised Anxiety
Disorder Assessment-7 items and 12-Item Short-Form Health Survey, to assess mental health and body
mass index measured at 6 and 12 months post randomisation.
Results: The trial randomised 526 people (265 to the intervention group, 261 to the usual-care group)
aged 19 to 72 years (mean 46 years). About 60% of participants were male. Participants smoked between
3 and 100 cigarettes per day (mean 25 cigarettes per day) at baseline. The intervention group had a higher
rate of exhaled CO-verified smoking cessation at 6 and 12 months than the usual-care group [adjusted
odds ratio (OR) 12 months: 1.6, 95% confidence interval (CI) 0.9 to 2.8; adjusted OR 6 months: 2.4, 95% CI
1.2 to 4.7]. This was not statistically significant at 12 months (p = 0.12) but was statistically significant at
6 months (p = 0.01). In total, 111 serious adverse events were reported (69 in the BSC group and 42 in the
usual-care group); the majority were unplanned hospitalisations due to a deterioration in mental health
(n = 98). The intervention is likely (57%) to be less costly but more effective than usual care; however,
this result was not necessarily associated with participants’ smoking status.
Limitations: Follow-up was not blind to treatment allocation. However, the primary outcome included
a biochemically verified end point, less susceptible to observer biases. Some participants experienced
difficulties in accessing nicotine replacement therapy because of changes in service provision. Efforts were
made to help participants access nicotine replacement therapy, but this may have affected participants’
quit attempt.
Conclusions: People with SMI who received the intervention were more likely to have stopped smoking
at 6 months. Although more people who received the intervention had stopped smoking at 12 months,
this was not statistically significant.
Future work: Further research is needed to establish how quitting can be sustained among people
with SMI.
Trial registration: Current Controlled Trials ISRCTN72955454.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 50.
See the NIHR Journals Library website for further project information.
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Plain English summary
Smoking is an important health issue, especially among people who have experienced mental ill healthsuch as schizophrenia or bipolar disorder. This is because people with severe mental ill health (SMI)
are more likely to smoke than the general population. Despite this, they are less likely to get help to stop
smoking, and it may be that people with mental ill health problems need greater support to help them
stop smoking.
To address this problem, we developed and tested a ‘bespoke smoking cessation’ (BSC) service tailored to
people with SMI. People aged ≥ 18 years who said that they would like to stop smoking were randomly
allocated to either a BSC service or the usual stop smoking services. Those in the BSC service were
allocated a mental health professional who had been trained to deliver smoking cessation interventions.
The mental health professional worked with the participant and their care team to advise on stop smoking
medication and provide information, support and motivation. Usual-care participants were signposted to
local smoking services, but their subsequent care was not directly provided or supervised by trial smoking
cessation advisors.
Between October 2015 and December 2016, 526 people with SMI were recruited into the study: 265 of
these people were randomly assigned to the BSC service and 261 were randomly assigned to usual care.
At 6 and 12 months after randomisation, participants completed questionnaires that asked about their
smoking status and health. Participants had their smoking status tested by measuring the amount of carbon
monoxide in their breath.
After 6 months, more people who received the BSC intervention had stopped smoking than those who
had received usual care. At 12 months, the results were less clear in terms of the difference in the number
of people who had stopped smoking.
The BSC service cost less than or similar to usual care, when considering the overall health-care services.
The improvement in health of people who received the BSC service remains uncertain. In addition, we do
not know whether or not this was related to people stopping smoking.
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Scientific summary
Background
Smoking is highly prevalent among patients who have experienced severe mental ill health (SMI). This is
despite the fact that smoking is a known health hazard, a cause of cancer and associated with numerous
diseases such as heart disease. People with SMIs such as bipolar disorder and schizophrenia smoke more
heavily and are more likely to be nicotine dependent than the general population. Despite the ‘culture’
of smoking in mental health services, over half of people with SMI who are smokers express a desire to
quit smoking. However, the services currently available to aid quitting may not be suitably responsive to or
effective for patients with SMI. A bespoke smoking cessation (BSC) intervention tailored to the needs of
people with SMI was developed and its acceptability to people with SMI was tested in a pilot randomised
controlled trial (RCT) – the SCIMITAR (smoking cessation intervention for severe mental ill health) trial. The
intervention was found to be acceptable to people with SMI and, therefore, the role of this study was to
test the SCIMITAR intervention in a full-scale RCT.
Objectives
The specific objectives of the SCMITAR+ trial were to establish:
l the clinical effectiveness of a BSC intervention compared with usual care for people with SMI
l the cost-effectiveness of a BSC intervention for people with SMI.
Methods
Design
A pragmatic, two-arm, parallel-group, individually randomised controlled trial.
Interventions
Participants were randomised to receive either a BSC service or usual care. The BSC service was delivered
by a mental health professional [mental health smoking cessation practitioner (MH-SCP)] trained to deliver
smoking cessation interventions. The MH-SCP provided an individually tailored smoking cessation service,
based on current guidelines for smoking cessation services, but with enhanced levels of contact and support.
Participants randomised to usual care were advised to see their general practitioner (GP) or to consult with
usual NHS quit smoking services with no specific adaptation or enhancement in relation to SMI.
Participants
Potential participants were identified by (1) GP database screening, (2) direct GP referral or primary care referral
following an annual health check, (3) direct referral via community mental health teams and psychiatrists,
(4) recruitment from service user groups and (5) recruitment via an ongoing interventional cohort study
[the Lifestyle Health and Wellbeing Cohort; see www.york.ac.uk/healthsciences/closing-the-gap/cohort/
(accessed 25 April 2019)].
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To be eligible, potential participants needed to be aged ≥ 18 years, have experienced severe mental ill
health (e.g. bipolar disorder, schizophrenia or a related psychotic illness), smoke and have expressed a
desire to either give up smoking or cut down to quit smoking.
Outcomes
The primary outcome was exhaled CO-verified smoking cessation at 12 months. Secondary smoking-
related outcomes were CO-verified smoking cessation at 6 months, reduction in the number of cigarettes
smoked, the Fagerström Test for Nicotine Dependence and the Motivation to Quit questionnaire. Other
secondary outcomes were measures of depression and anxiety (Patient Health Questionnaire-9 items and
Generalised Anxiety Disorder Assessment-7 items) and health status (Short Form questionnaire-12 items)
to measure general physical and mental health, and a measure of health utility (EuroQol-5 Dimensions,
five-level version) and the Health Economics/Service Utilisation Questionnaire as measures of cost-effectiveness.
Secondary outcomes were each measured at 6 and 12 months. Body mass index was measured at both
follow-ups to explore whether or not smoking cessation was associated with weight gain.
Results
Between October 2015 and December 2016, 526 participants were recruited into the SCIMITAR+ RCT.
The most common severe mental health problems were schizophrenia or other psychotic illness (n = 342,
65.0%), bipolar disorder (n = 115, 21.9%) and schizoaffective disorder (n = 66, 12.5%). Two hundred
and sixty-five participants were randomised to a BSC service and 261 were randomised to usual care.
Participants were aged between 19 and 72 years (mean 46 years), and there were more male (n = 309)
participants than female (n = 216) participants, with one participant identifying as transgender. At baseline,
participants reported smoking an average of 25 cigarettes per day and had long smoking histories
(mean 30 years).
Out of 265 participants allocated to the BSC intervention, 232 (88%) attended at least one session
(average number of sessions attended was 6.4, range 1–14). The intervention group had a higher rate of
CO-verified smoking cessation at 6 and 12 months than the usual-care group [adjusted odds ratio (OR)
12 months: 1.6, 95% confidence interval (CI) 0.9 to 2.8; OR 6 months: 2.4, 95% CI 1.2 to 4.7]. This was
not statistically significant at 12 months (p = 0.12) but was statistically significant at 6 months (p = 0.01).
Participant follow-up exceeded 85% at 12 months. In total, 111 serious adverse events (SAEs) were
reported (69 in the BSC group and 42 in usual care); the majority were unplanned hospitalisations due
to unrelated deterioration in mental health condition (n = 98). The remaining SAEs were unplanned
hospitalisations associated with pre-existing health problems (n = 6) or death (n = 7). One event was
deemed to be possibly related to the trial procedures (inpatient hospitalisation due to infective chronic
obstructive pulmonary disease).
The mainstay of pharmacological treatment was nicotine replacement therapy. People in receipt of usual
care rarely accessed any form of smoking cessation treatment, but often purchased over-the-counter
nicotine replacement products.
The BSC intervention for people with SMI is likely (57%) to be less costly but more effective than usual
care, from a NHS and Personal Social Services perspective. Depending on the threshold considered, the
probability of BSC being cost-effective could range from 62% at a willingness to pay threshold of £0 to
nearly 90% at £100,000 per quality-adjusted life-year (QALY) gained. Although the difference in neither
costs nor QALYs was statistically significant in itself, there was an indication that the intervention costs
might be offset by the reduction in wider health-care services costs. However, this result was not necessarily
associated with participants’ smoking status.
SCIENTIFIC SUMMARY
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Conclusions
In the SCIMITAR+ trial, we have shown that people with SMI are more ready to engage with a bespoke
intervention that results in increased 6-month quit rates.
Implications for health care
Clinicians are sometimes reluctant to offer smoking cessation advice to patients under their care, and
this is in part due to concerns that treatment is ineffective or that quitting might cause a deterioration in
mental health. The results of the SCIMITAR+ trial will be helpful in informing clinical practice, as we have
shown that quitting can be achieved for people who use mental health services just as much as it can be
for all smokers. Clinicians should therefore ask all of their patients about their smoking status and offer
referrals to effective smoking cessation services such as those described in the SCIMITAR+ trial. Clinicians
can also be confident, on the basis of the results of this trial and systematic review evidence, that smoking
cessation is likely to either be beneficial to mental health or not harm mental health.
The results of the SCIMITAR+ trial will be helpful for service commissioners who seek to implement
guidance for smoking cessation among hard-to-reach groups, such as people with SMI.
Recommendations for future research
Research is needed to establish how quitting can be sustained among people with SMI who engage with
an evidence-supported quit smoking intervention. The role of e-cigarettes in helping people with SMI to
cut down on or quit smoking also needs to be explored.
In addition, research is needed to complement the findings of the SCIMITAR+ trial, to establish the clinical
effectiveness and cost-effectiveness of very brief opportunistic interventions among people with SMI.
Trial registration
This trial is registered as ISRCTN72955454.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Some of the information in this chapter is reported in Peckham et al.
1 This contains information licensed
under the Non-Commercial Government Licence v2.0.
Smoking and severe mental ill health
People with severe mental ill health (SMI), such as schizophrenia and bipolar disorder, are more likely to
smoke and to smoke more heavily than those without SMI.2,3 Estimates of the percentage of people
with SMI who smoke vary depending on the setting, with up to 70% of inpatients smoking.4 The presence
of mental ill health is associated with an elevated risk of smoking by a factor of odds ratio (OR) 2.2 [95%
confidence interval (CI) 1.7 to 2.8].2 Smokers with SMI are more nicotine dependent, more likely to become
medically ill with smoking-related diseases and less likely to access help in quitting than the general
population.5 People with SMI tend to:
l begin smoking at a higher rate before diagnosis or treatment for SMI than smokers without SMI6,7
l smoke each cigarette more intensely, extracting more nicotine per cigarette.8
People with SMI are also more likely to be unemployed than the general population. Smoking is known
to be part of the ‘culture’ of mental health services, among both staff and patients. In addition, people with
SMI often lack self-esteem and see the future as ‘bleak’; as a consequence, they may not be motivated to
look after their physical health.9 Many people with SMI are also misinformed about the risks and benefits
of smoking versus nicotine dependence treatment.10 They often fear and overestimate the medical risks
of nicotine replacement therapy (NRT).11 Many believe that smoking relieves depression and anxiety12
(nicotine increases anxiety13).
Smoking contributes to the poor physical health of those with SMI. In the UK, the standardised mortality
rate for all causes of death for people with schizophrenia was 289 (95% CI 247 to 337), amounting to a
threefold increase in mortality compared with the population of England and Wales.14 Although people
with SMI are more likely to smoke than the general population, there is evidence that general practitioners
(GPs) are less likely to intervene with smokers who have a mental disorder than those who do not have
a mental disorder.5 Although the number of people in the general population who smoke has declined
over the last 20 years, the number of people with SMI who smoke has not seen a similar decline.3 The
smoking rate among people with SMI in England is 40.5%,15 which is more than double that of the general
population.16 Smoking rates in people with SMI vary across settings, with up to 70% of people in psychiatric
units smoking.4
It is within this context that a number of policy initiatives have emerged that emphasise improving
the physical care of those with SMI, including taking initiatives to facilitate smoking cessation and the
promotion of smoke-free environments in secondary care services.2,17,18
Existing knowledge
Smokers most commonly cite ‘stress relief and enjoyment’ as their main ‘reason’ for smoking,19 although
the major cause is nicotine dependence. Nicotine acts in the midbrain, creating impulses to smoke in the
face of stimuli associated with smoking20 and producing what may be thought of as a kind of ‘nicotine
hunger’ (a feeling of needing to smoke) when blood nicotine concentrations are depleted. Smokers also
experience nicotine withdrawal symptoms, such as unpleasant mood swings and physical symptoms, that
occur on abstinence and are relieved by smoking.21 Nicotine dependence is the main reason that most
unassisted quit attempts fail within a week.22 Cochrane systematic reviews23–30 and guidance from the
DOI: 10.3310/hta23500 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 50
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Peckham et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
National Institute for Health and Care Excellence (NICE)31 highlight the following smoking cessation
interventions (including medications used as smoking cessation aids) that help smokers reduce their
tobacco intake and quit smoking.
Nicotine replacement therapy
At the time of the trial, there were seven different available forms of administering NRT for use as smoking
cessation aids. These were the nicotine patch, gum, lozenge, inhaler, spray (oral or nasal) and sublingual
tablet (microtab). These provide a ‘clean’ alternative source of nicotine without the other 4000 toxic
chemicals found in cigarette smoke. All deliver a lower dose of nicotine than the dose that would be
received through smoking, with the only difference being the differing absorption rates owing to different
methods of delivery. Nicotine replacement products can be used singly or in combination, for example a
patch combined with a product that delivers nicotine faster, such as the nasal spray. A meta-analysis of
> 100 randomised controlled trials (RCTs) shows that any form of NRT is effective in terms of smoking
cessation (risk ratio 1.55, 95% CI 1.49 to 1.61).32 For those who are not ready to stop smoking but are
interested in cutting down, NRT prescription has been shown to reduce smoking and to facilitate quit rates
later on (reduce to stop, or cut down to quit).33
Antidepressants and nicotine receptor agonists
Two non-nicotine pharmacotherapies have been licensed as smoking cessation aids. These are varenicline
[Chantix® (USA) and Champix® (the European Union and other countries); Pfizer Inc., New York, NY, USA],
a nicotinic acetylcholine receptor partial agonist, and bupropion (Zyban®; GlaxoSmithKline plc, Brentford UK),
a noradenaline and dopamine reuptake inhibitor, which was first introduced as an atypical antidepressant.
Varenicline is almost certainly the most effective treatment to date (OR for 12-month continuous abstinence
for varenicline vs. placebo 3.22, 95% CI 2.43 to 4.27). It is more efficacious than bupropion (OR for
varenicline vs. bupropion 1.66, 95% CI 1.28 to 2.16).29 However, its use in people with SMI may be limited
by case reports of depression or mental health worsening in populations with a previous history of mental
health difficulties. Yet, a recent systematic review found there to be no increase in adverse effects in people
with SMI taking varenicline compared with those without SMI,34 and a recent trial among people with a
range of mental health problems showed varenicline as being effective and having a good safety profile.35
Therefore, these fears appear to be unfounded.
Behavioural support
Advice, discussion and encouragement can be delivered via a range of means: individually or in a group, in
an open (rolling) or closed group, face to face or over the telephone or internet. Meta-analyses of trials of
multisession ‘intensive behavioural support versus brief advice’ found ORs of 1.56 (95% CI 1.32 to 1.84)
for individual support and 2.04 (95% CI 1.60 to 2.60) for group support.25,26 Regular support over the
telephone is also effective. A meta-analysis of 10 trials of telephone support for people stopping smoking
gave an OR of 1.64 (95% CI 1.41 to 1.92).28 There is some evidence to suggest that group support may
be more effective in general than one-to-one support36 and that it should involve multiple sessions.36
The accumulated evidence for the use of current smoking cessation interventions has been distilled into
clear recommendations for health professionals31 and a manual for those designing and delivering smoking
cessation services.37 In addition, guidance has been issued by NICE to guide the use of smoking cessation
interventions for those with SMI.38
Evidence on the effectiveness of smoking cessation strategies in SMI comes from a systematic review
of randomised trials by Banham and Gilbody,39 which was updated in 2017.40 These reviews draw on the
results of 26 RCTs of smoking cessation interventions among those with SMI and show that combinations
of behavioural support and pharmacotherapy (NRT and bupropion) are effective in facilitating smoking
cessation. The evidence is strongest from varenicline, through the use of which the odds of quitting were
improved fourfold (five trials; risk ratio 4.13, 95% CI 1.36 to 12.53).
BACKGROUND
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Rationale for the SCIMITAR+ trial
Despite the higher prevalence of smoking, a substantial proportion of people with SMI express a desire to
quit, but they expect to find it harder than those in the general population.41 The introduction in 2004 of a
new General Medical Services (GMS) contract42 created a policy impetus to improve the quality of primary
care in priority areas. In terms of mental health, the new GMS contract specified that primary care is
responsible for the provision of physical health care. Importantly, for smoking cessation initiatives, it
‘incentivised’ GPs to (1) produce a register of people with severe long-term mental health [Quality and
Outcomes Framework (QOF) indicator MH8 – the SMI register] and (2) ensure that at least 90% of SMI
patients have had a review that includes smoking status recorded within the previous 15 months (QOF
indicator MH9 – SMI health check). This check included patients seen in primary care, secondary care and
under shared care arrangements. Though this GMS target has now been withdrawn, this was an incentive at
the time of conception of the SCIMITAR+ (smoking cessation intervention for severe mental ill health) trial.
In addition, for those who are admitted to hospital (including inpatient psychiatric units), the introduction
of smoke-free policies provides an opportunity to address smoking (Public Health Guidance 4817). The
admission of an individual to hospital, while being stressful and occurring at a time of personal crisis, also
provides a unique opportunity to provide general health advice and to engage individuals in interventions
targeted at smoking reduction and cessation.
Recent guidance issued by NICE17 offers clear statements of purpose to make secondary care services
(including mental health services) entirely smoke free and to promote a smoke-free culture among staff
and users of the services. Mental health services are highlighted as an area of priority and an unmet need
in relation to smoking cessation, and there is clear guidance that services should be developed and
implemented as a matter of some priority.
In 2009, the SCIMITAR pilot trial was devised to test whether or not a bespoke smoking cessation (BSC)
intervention tailored to the needs of people with SMI would be acceptable to people with SMI.43 In
addition, it tested whether or not it was feasible to recruit and retain participants in a RCT to test this
intervention. Recruitment to the pilot trial took place between May 2011 and May 2012. Results from the
SCIMITAR pilot trial indicated that the intervention was acceptable to participants and that it was possible
to recruit and retain participants in such a trial.43 Although the trial was not powered to detect a difference
between the bespoke intervention and usual care, the results indicated that there was a potential but
non-statistically significant benefit of the bespoke intervention over usual care in terms of the proportion
of self-reported quitters [12/33 (36%) vs. 8/35 (23%) adjusted OR 2.9, 95% CI 0.8 to 10.5]. Following
this, the National Institute for Health Research Health Technology Assessment programme commissioned a
fully powered RCT (SCIMITAR+) to explore the clinical effectiveness and cost-effectiveness of the SCIMITAR
BSC intervention.
Research objectives44
l To establish the clinical effectiveness of a BSC intervention compared with usual care for people
with SMI.
l To establish the cost-effectiveness of a BSC intervention for people with SMI.
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Chapter 2 Methods
Some of the information in this chapter is reported in Peckham et al.
1 This contains information licensed
under the Non-Commercial Government Licence v2.0.
Study design
This study was a pragmatic, two-arm, parallel-group RCT. The setting was in primary care and specialist
mental health services within secondary care. Given that patients with SMI are a ‘hard-to-reach population’,
a range of complementary strategies were used to try to identify and recruit eligible participants. A two-stage
recruitment process was employed to check for eligibility, to check understanding of the study and to obtain
consent. Participants were individually randomised to receive usual care or usual care plus a BSC service.
Participants were followed up over the course of 12 months, with data collected at 6 and 12 months post
randomisation.44
Approvals obtained
Ethics approval was sought and granted on 15 March 2015 by Leeds East Research Ethic Committee
(reference number 15/YH/0051). Approval was also obtained from the relevant research and development
departments (see Appendix 1).
Trial sites
The study was conducted in 22 sites in England. Sites recruited throughout the duration of the study.
Participant eligibility
Inclusion criteria
To be eligible for inclusion in this study, participants needed to meet the following inclusion criteria:
l aged ≥ 18 years
l have SMI
l be a smoker who expresses an interest in wanting to cut down on smoking (though not
necessarily quitting)
l smoke at least five cigarettes per day.
There is no agreed definition of SMI, so we adopted a pragmatic definition, that is, a documented diagnosis
of schizophrenia or delusional/psychotic illness [International Classification of Diseases, Tenth Edition
(ICD-10),45 F20.X and F22.X or Diagnostic and Statistical Manual of Mental Disorders (DSM)46 equivalent] or
bipolar disorder (ICD F31.X or DSM equivalent). This SMI-inclusive diagnosis needed to have been made
by specialist psychiatric services and to have been documented in either GP notes or psychiatric notes.
Exclusion criteria
People were ineligible if they met the following criteria:
l currently pregnant or breastfeeding
l with comorbid drug or alcohol problems (as ascertained by the GP or mental health worker)
l non-English speakers
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l lacking capacity to participate in the trial (guided by the 2005 Mental Capacity Act 7147)
l currently receiving advice from a smoking cessation advisor.
People with SMI who smoke while concurrently abusing substances may require additional medication or
specialist advice, which was beyond the brief of the mental health smoking cessation practitioner (MH-SCP)
and this trial. Similarly, smoking cessation in pregnancy also requires specialist knowledge. It was planned
that any participant who became pregnant during the course of the trial would be fully withdrawn from the
study and referred to local smoking cessation services specific to pregnancy.
Identifying participants
We used five methods to recruit participants.
Direct general practitioner referral or referral following database screening
General practitioners are encouraged to offer opportunistic advice and information about smoking
cessation services to all people who smoke whenever they consult in primary care. GPs taking part in this
study were provided with patient study information packs to give to people with SMI who were receptive
to participating in the trial. GPs then completed and faxed a referral form and the person’s ‘consent to be
contacted’ form to the SCIMITAR+ researchers who approached the person for recruitment.
The GP practices were also asked to consult their patient databases and SMI register, if available, to screen
for potentially eligible participants. Information packs were sent from the GP practice, inviting people
willing to take part in the study to return a completed ‘consent to be contacted’ form to the SCIMITAR+
researchers, who then approached them to ascertain eligibility and recruitment.
Primary care referral following annual health check
At the time of the trial, the annual primary care health check for people with SMI (MH9) represented an
opportunity to address smoking behaviour and to offer enhanced smoking cessation services within the
context of a trial. Health checks are generally conducted by practice nurses, and we encouraged all primary
care staff to make SMI smokers aware of the trial when they received their annual primary care health
check. Information packs were given to interested and potentially eligible people during their health check.
Similar to GP referrals, practice nurses were instructed to complete referral forms and to fax the persons’
completed ‘consent to be contacted’ form to the SCIMITAR+ researchers, who then approached them for
eligibility and recruitment.
Community mental health teams
Study researchers worked with care co-ordinators and members of the community mental health team
(CMHT) to screen their caseloads for potentially eligible participants who matched the inclusion criteria.
People identified as potentially suitable for the SCIMITAR+ trial were either provided with a copy of the
information pack by their care co-ordinator or other mental health professional or sent an information
pack in the post. The information pack contained a ‘consent to be contacted’ form for potential
participants to return to the SCIMITAR+ researchers, giving permission for the researcher to contact them
by telephone or letter or in person to discuss the trial further.
Service user groups44
Service user groups were provided with information about the study along with copies of a SCIMITAR+
flyer. Interested service users could then contact the mental health professional named on the flyer or their
care co-ordinator. Alternatively, the staff member at the service user group could contact the service user’s
care co-ordinator on their behalf.
METHODS
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Lifestyle Health and Wellbeing Survey
The Lifestyle Health and Wellbeing Cohort is a prospective study that forms a platform for interventional
studies (‘Trials within cohorts’), co-ordinated by the University of York, recruiting adults with SMI aged
≥ 18 years from primary and secondary care. Participants in the Lifestyle Health and Wellbeing Survey
complete a series of questions about their health and well-being, including questions about their smoking
status. Cohort participants who reported smoking and were potentially interested in cutting down on or
quitting smoking were invited to take part in the SCIMITAR+ trial.
Screening for eligibility
After receiving an information pack and once a person gave consent to be contacted (either verbally to the
recruiting clinician or in writing to the SCIMTAR+ researchers), a SCIMITAR+ researcher approached them by
telephone, face to face or by e-mail, depending on the person’s preference. After briefly explaining the trial,
the researcher checked the person’s eligibility by asking about their smoking habits, specifically (1) whether
or not they smoke; (2) if so, how much they smoke (they needed to smoke at least five cigarettes per day
to be eligible); (3) if they would consider quitting or cutting down, with a view to quitting within the next
6 months; and (4) whether or not they were currently receiving advice from a smoking cessation advisor.
These questions ensured that the person currently smoked but was contemplating quitting. The researcher
also asked screening questions about pregnancy and breastfeeding, and drug and alcohol usage, which led
to exclusion if present. The researcher then arranged a meeting at a mutually convenient time and venue.
Consenting participants
When a potential participant met with the SCIMITAR+ researcher, they were given the opportunity to clarify
any points they did not understand and to ask any questions. A full explanation of the trial was given by
the SCIMITAR+ researcher. It was emphasised that they may withdraw their consent to participate at any time
without loss of treatment options that would otherwise be available to them. They were also informed that,
by consenting, they agreed to their GP being informed of their participation in the trial. Written informed
consent was then obtained, with both the participant and the researcher signing and dating the consent
forms prior to collecting baseline data (see Appendix 2 for participant information sheets and consent forms).
Baseline assessment
Once a participant had consented to take part in the trial, they completed the baseline questionnaires.
Height and weight measurements were completed to calculate the participant’s body mass index (BMI)
and an exhaled breath carbon monoxide (CO) reading was taken. These made up the baseline data set.
The participant was randomised on completion of this data set.
Randomisation
Eligible, consenting individuals were randomised 1 : 1 to either the BSC service or usual care. The
researcher contacted a secure telephone randomisation service run by the York Trials Unit. Simple
randomisation was used, following a computer-generated number sequence devised by an independent
data manager otherwise not involved in the conduct of the trial. Once given the details of the participant’s
allocation, the researcher immediately informed the participant of their allocation and what would happen
next. If allocated to the BSC arm, researchers at the University of York then contacted the MH-SCP in the
participant’s area and organised for them to contact the participant to arrange a mutually convenient time
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to meet. A letter was sent to the GP and mental health specialist for the participant’s records and to advise
them on subsequent smoking cessation management. Owing to the nature of the intervention, it was not
possible to blind participants, GPs, researchers or the MH-SCPs to the treatment allocation.
Ineligible and non-consenting individuals
All ineligible and non-consenting persons were referred back to their GP/mental health service.
Sample size
Results from the SCIMITAR pilot trial were used to inform the sample size calculation for this trial. In the
pilot trial, a quit rate of 23% was observed at 12 months in the usual-care arm and a quit rate of 36% was
observed in the BSC arm.43 The SCIMITAR+ trial was powered at 80% to detect a relative risk increase in
quitting of 1.7, assuming a control quit rate of 20% (an increase to a quit rate of 34% in the intervention
group), equal randomisation and a two-sided alpha of 0.05. Allowing for a 20% loss to follow-up at
12 months required a total sample size of at least 393 to be recruited and randomised. We therefore
proposed to recruit 400 participants in total to ensure sufficient power according to the preceding
statistical assumptions.
Description of interventions
Trial intervention
Participants in the intervention group were allocated to receive a BSC intervention designed specifically
to help people with SMI stop smoking. This intervention was delivered by a mental health professional
(care co-ordinator, support worker, mental health nurse) trained in smoking cessation interventions.
The training took place over 2 days and was provided by trained smoking cessation advisors. The BSC
intervention consisted of up to 12 one-to-one face-to-face meetings between the participant and the
MH-SCP, who worked in conjunction with the participant and their GP or mental health specialist to
ensure that the participant received smoking cessation medication and medication monitoring. The initial
meeting generally took 1 hour, with subsequent meetings lasting 30 minutes. Meetings were initially
weekly; however, towards the end of the programme the participant had the choice of meeting fortnightly
if preferred. Pharmacotherapies were provided for as long as was deemed necessary, in line with NICE
guidance,17 and were determined by the GP without the influence of the SCIMITAR+ trial team. In line
with NICE recommendations, MH-SCPs offered advice on the range of treatment options available to
people in the NHS (including medication, behavioural support and follow-up).31 It was not the remit
of the trial to assess specific smoking cessation pharmacotherapies or treatments per se, although data on
frequency of their use were collected. The intervention was based on that used by the National Centre for
Smoking Cessation and Training (NCSCT), but the following specific modifications were applied to tailor
the intervention to people with SMI: (1) recognising the need for several assessment sessions prior to
setting a ‘quit date’; (2) recognising the purpose of smoking in the context of their mental illness, such as
the use of smoking to relieve side effects from antipsychotic medication (and how this will be managed
during a cessation attempt); (3) recognising the need to involve other members of the multidisciplinary
team in planning a successful quit attempt for those with complex care needs and multiagency
programmes of care; (4) arranging meetings so that they take place in a mutually agreeable location,
often in the participant’s home rather than in the GP surgery or on NHS trust premises; (5) providing
additional face-to-face support following an unsuccessful quit attempt or relapse; and (6) informing the GP
and psychiatrist of a successful quit attempt so that they can review antipsychotic medication doses in line
with changes in metabolism. Participants were encouraged to (1) reduce smoking to quit, (2) set their own
quit dates and (3) make several attempts to quit if their initial attempt failed. All participants remained
under the care of their GP and continued to receive their usual NHS treatment.
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A detailed description of the development and content of the smoking cessation intervention is given in
the report of the SCIMITAR pilot trial.1
Control intervention
This was a ‘usual-care’ control group, whereby participants were encouraged to consult with their GP or local
NHS quit smoking services. GPs were given advice to follow current NICE guidelines for smoking cessation,
without the additional support of a bespoke MH-SCP. Usual care could include pharmacotherapies to aid
smoking cessation (NRTs, bupropion or varenicline either separately or in combination), access to self-help
materials and referral to local NHS stop smoking clinics (which would not be specifically tailored to the needs
of those with SMI). Participants were encouraged to reduce smoking to quit and set their own quit dates;
however, they were managed solely by their own GP or mental health specialist and, crucially, did not receive
regular visits from a MH-SCP. Details of NRT that control participants received were gathered by accessing
participants’ GP notes, and details of any smoking cessation management were requested from participants
in the follow-up questionnaires.
Smoking cessation medication provision
Clear guidance on the prescription of anti-smoking medications in the presence of SMI (including safety
considerations) has been published and was made available to all GPs to help inform their prescribing
decisions (for both control and intervention participants).48 A key feature of the SCIMITAR+ trial was to
ensure that GPs manage anti-smoking medications within this framework and in accordance with their
prior knowledge of the patient and their concomitant use of medication. This was carried out with the
aim of replicating ‘real-life practice’ of the use of anti-smoking medications in primary care. The medication
profile of the individual participants was reviewed by their GP or mental health specialist to assess any
potential safety issues (in line with the latest practice guidance on the provision of smoking cessation
interventions in the NHS2). An important aspect of the design of this study was that the SCIMITAR+ team
had no direct influence over prescribing decisions by GPs, as this was not a drug trial or an investigation of
a medicinal product(s).
Follow-up
Participants were followed up 6 months and 12 months after randomisation.
All assessments were carried out face to face where possible and, where not possible, a systematic
approach was used to explore other avenues to collect self-report data; the participant was offered the
option of completing the questionnaires over the telephone or having the questionnaires sent by post for
them to complete and return. If it was not possible to make contact with the participant, a family member
or friend, designated by the participant at their baseline interview, was contacted to verify the participant’s
current smoking status.
Outcomes
Primary outcomes
The primary outcome was self-reported abstinence from smoking at 12 months post randomisation,
defined as answering ‘not even a puff’ to the question ‘have you smoked in the last week?’, validated by
CO breath measure, with abstinence defined as a CO measurement of < 10 parts per million (p.p.m.).
Secondary outcomes
l Self-reported smoking cessation.
l Number of cigarettes smoked per day (self-report).
l Fagerström Test for Nicotine Dependence (FTND).49
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l Motivation to Quit questionnaire (MTQ).50
l Patient Health Questionnaire-9 items (PHQ-9).51
l Generalised Anxiety Disorder-7 items (GAD-7).52
l Health-related quality of life [Short Form questionnaire-12 items (SF-12) version 1 was used, as this was
used in the pilot trial].53
l EuroQol-5 Dimensions, five-level version (EQ-5D-5L).54
l BMI.
l Health service use collected via a bespoke questionnaire.
Table 1 gives details of the measures collected and the time points at which they were collected.
Withdrawal
A study participant could be withdrawn from the trial by their GP, mental health specialist or smoking
cessation practitioner, or may choose to do so themselves, at any time. If the withdrawal was due to an
adverse event, procedures followed a trial-specific standard operating procedure (SOP) for adverse events
(see Appendix 3).
Where possible, data were collected on the nature of the withdrawal. Reasons for a practitioner to withdraw
a participant included pregnancy, admission to hospital for reasons unrelated to the trial and, inability to
attend treatment or assessment sessions. Relapse to resuming smoking was not a reason to withdraw a
participant, as they could resume treatment and make several attempts to quit smoking.
Participants were given a choice of (1) withdrawal from treatment only (participants were still followed up
at 6 and 12 months), (2) withdrawal from follow-up or (3) complete withdrawal from the study, including
follow-up and medication data collection. Withdrawal from the study did not affect the participants’
treatment or access to NHS services.
Any data collected from the participant prior to withdrawal were still included in the final analysis of
the data.
Participant concordance
Mental health smoking cessation practitioners were asked to complete a treatment log that recorded all
participants’ contacts (face-to-face meetings, telephone calls and joint appointments with MH-SCPs and GPs)
to judge the degree to which the intervention, as designed on a session-by-session basis, was actually
delivered in practice by MH-SCPs.
At each meeting, MH-SCPs would take a CO measurement from the participant. Measurements of
≥ 10 p.p.m. indicated that the participant had not ceased smoking. If the participant claimed to have
stopped but their CO readings were ≥ 10 p.p.m., they were probed about when they last smoked and
whether or not they had had any minor relapses during their quit attempt.
Statistical analysis
All analyses were conducted following the principles of intention to treat, including all randomised
participants in the groups to which they were randomised, where data were available. Analyses were
conducted in Stata® version 15 (StataCorp LP, College Station, TX, USA). All statistical tests were two-sided
at the 5% significance level.
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Recruitment and retention
The flow of participants through the trial is described in Consolidated Standards of Reporting Trials (CONSORT)
flow diagrams (see Figures 3–5), two of which describe recruitment up to randomisation (one for primary care
and one for secondary care) and one of which presents the flow of participants from randomisation to analysis.
The response rates, time to return and mode of completion of the 6- and 12-month participant questionnaires
are summarised by treatment group.
TABLE 1 Assessments and the time points at which they were carried out
Assessment
Time point
Baseline
6 months post
randomisation
12 months post
randomisation
Eligibility and consent
Eligibility ✗
Consent ✗
Background and follow-up
Personal details, general health ✗
BMI ✗ ✗ ✗
Mental health details
Mental health history ✗
Current mental health status ✗ ✗ ✗
Current medications ✗ ✗ ✗
Referrals to mental health services ✗ ✗
Admissions to hospital related to mental
health
✗ ✗
Smoking details
Smoking history ✗
Current smoking status ✗ ✗ ✗
Use of electronic cigarettes ✗ ✗ ✗
Use of smoking cessation services ✗ ✗ ✗
CO measurement ✗ ✗ ✗
Adverse event reporting Ongoing collection
Questionnaires
FTND ✗ ✗ ✗
MTQ ✗ ✗ ✗
PHQ-9 ✗ ✗ ✗
GAD-7 ✗ ✗ ✗
Health-related quality of life (SF-12) ✗ ✗ ✗
Health-state utility (EQ-5D-5L) ✗ ✗ ✗
Health economics/service utilisation
questionnaire
✗ ✗ ✗
This table has been reproduced from Peckham et al.44 © The Author(s). 2017. This article is distributed under the terms of
the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in
this article, unless otherwise stated.
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Baseline data
Baseline data are summarised by treatment group, using mean standard deviation (SD), median and range
for continuous data, and count and percentage for categorical variables. No formal statistical comparisons
between the two groups were undertaken on baseline data.
Data manipulations and questionnaire scoring
Number of cigarettes smoked
Participants were asked how many cigarettes they normally smoked per day and how much tobacco they
used per day. It was assumed that 0.5 g of tobacco equates to one cigarette.55
Fagerström Test for Nicotine Dependence
The FTND is a 6-item questionnaire.49 Item scores are added together to give a total score between 1 and
10: a score of 1–2 indicates low dependence, 3–4 indicates low to moderate dependence, 5–7 indicates
moderate dependence and 8–10 indicates high dependence.
Motivation to Quit questionnaire
The MTQ is a 4-item questionnaire scored from 4 to 19, by adding together the responses to each item,
with higher scores indicating a greater motivation to stop smoking.50
Patient Health Questionnaire-9 items
The PHQ-9 is a 9-item instrument. It asks the subject to indicate how often in the last 2 weeks they have been
bothered by nine problems, which are each scored on the scale of 0 = not at all, 1 = several days, 2 = more
than half the days, and 3 = nearly every day.51 A total score is obtained from adding together the nine item
scores. Scores can be categorised as follows: 0–4 indicates minimal depression, 5–9 indicates mild depression,
10–14 indicates moderate depression, 15–19 indicates moderately severe depression and 20–27 indicates
severe depression. If one or two values are missing from the score, then they can be substituted with the
average score of the non-missing items (scored pro rata and total score rounded to nearest integer).
Questionnaires with more than two missing values are disregarded.
Generalised Anxiety Disorder Assessment-7 items
The GAD-7 is a 7-item instrument.52 For each item, scores of 0, 1, 2 and 3 are given to the possible responses
of ‘not at all’, ‘several days’, ‘more than half the days’ and ‘nearly every day’, respectively. The GAD-7 total
score ranges from 0 to 21. Scores of 5, 10 and 15 represent cut-off points for mild, moderate and severe
anxiety, respectively. If one or two values are missing from the score, then they can be substituted with
the average score of the non-missing items (scored pro rata and total score rounded to nearest integer).
Questionnaires with more than two missing values are disregarded.
Short Form questionnaire-12 items (version 1)
The SF-12 consists of two subscales – a physical component and a mental component – both of which are
scored within the range of 0–100, with 0 indicating the lowest level of health and 100 indicating the
highest level of health measured by the scale. Scoring was conducted in accordance with the SF-12 scoring
manual.53
Body mass index
A participant’s weight was measured in kilograms at each follow-up visit and their height was measured in
metres at the baseline visit. BMI was calculated by dividing weight by height squared and is expressed in
the units kg/m2.
Primary analysis
The primary outcome of CO-verified smoking cessation at 12 months was intended to be analysed via a
mixed-effect logistic regression model to compare the BSC service intervention with usual care. The model
was to include CO-verified smoking status at 6 and 12 months (repeated measures within participants)
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and be adjusted for baseline smoking severity (self-reported number of cigarettes smoked per day), time,
treatment group and a treatment group-by-time interaction, with site as a random effect. Participants
nested within site were also to be treated as a random effect to account for the repeated measures within
the subjects. However, this model failed to converge. Therefore, separate multilevel logistic regression
models were run to compare the outcomes at 6 and 12 months, that is, two models, instead of one
model that incorporates the repeated measurements. The two models were each adjusted for baseline
smoking severity, with site as a random effect. The OR, corresponding two-sided 95% CI and p-value for
the treatment effect at 6 and 12 months are presented. The treatment effect at 12 months serves as the
primary end point, and the effect at 6 months serves as a secondary end point. Participants were analysed
according to their original random group allocation and were included in the models if they provided a CO
reading and a response to the self-reported question relating to amount smoked in the previous week at
that particular time point.
Sensitivity analyses
Unadjusted odds ratio
The unadjusted, marginal OR for smoking status at 6 and 12 months is presented for comparability.
Post hoc generalised estimating equations analysis
Given that the prespecified repeated measures mixed logistic regression model did not converge, post hoc
sensitivity analyses were conducted using generalised estimating equation (GEE) techniques. This allowed
for the repeated measures within participants to be accounted for, but the multilevel nature of the data
(i.e. participants within site) cannot be controlled in the same way that including a random effect for site
in the mixed logistic regression can be. Two GEE models were run: (1) one controlling for baseline smoking
severity, and including an interaction between allocation and time, and (2) one controlling for both baseline
smoking severity and site as covariates, and including an interaction between allocation and time. Both
specified a binomial family and logit link, with an exchangeable correlation structure.
Accounting for missing carbon monoxide-verified smoking status
Self-reported smoking status was considered when CO-verified smoking status was missing. Further
sensitivity analyses were conducted treating participants who still had missing outcome data in the
following two ways: one treated participants with missing data as smokers under a worst case scenario,
and the other used multiple imputation techniques. Twenty imputations were generated by multiple
imputation using chained equations with a burn-in of 10. To avoid bias, the imputation model used all
variables that were included in the analysis models (baseline smoking severity, CO-verified smoking status
at 6 and 12 months, site and allocation).56
Secondary analyses
All data collected at 6 and 12 months are summarised descriptively by treatment group, including an
investigation into the number of missing data.
Self-reported smoking cessation
The primary analysis was repeated using self-reported smoking status at 6 and 12 months as the outcome
(cessation defined as answering ‘not even a puff’ to the question ‘have you smoked in the last week?’).
Number of cigarettes smoked per day
The number of cigarettes smoked per day, as reported as part of the FTND, at 6 and 12 months was
compared between the two groups using a mixed-effect negative binomial regression model, adjusting for
the same covariates as the primary analysis and the repeated measures within participants. Incidence rate
ratios and their associated 95% CIs and p-values are provided.
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Continuous secondary outcomes: Fagerström Test for Nicotine Dependence, Motivation
to Quit questionnaire, Patient Health Questionnaire-9 items, Generalised Anxiety
Disorder Assessment-7 items, Short Form questionnaire-12 items and body mass index
The FTND, MTQ, PHQ-9, GAD-7, SF-12 physical component and SF-12 mental component scores and BMI
were all analysed in the same way. Scores were compared between treatment groups using a covariance
pattern linear mixed model. The outcome modelled was the total score at 6 and 12 months. Each model
included baseline score, baseline smoking severity, treatment group, time and a treatment group-by-time
interaction term as fixed effects, and site as a random effect.
Different covariance structures for the repeated measurements that are available as part of Stata were
explored and the most appropriate pattern was used for the final model, based on the one that produced
the smallest Akaike information criterion (AIC). Model assumptions were checked via a Q–Q plot to assess
the normality of the standardised residuals and a scatterplot of the residuals against fitted values.
Predicted means for each group and the adjusted mean difference (with 95% CI and p-value) between
treatment groups at 6 and 12 months are given.
Other outcomes
Self-reported number of attempts to quit, periods of cessation and e-cigarette use will be summarised
descriptively by treatment group and time point.
Compliance with the intervention
Treatment session data are summarised for participants in the intervention group, including the number
of sessions attended, and the duration and location (e.g. participant’s home) of the sessions. A complier-
average causal effect (CACE) analysis for the primary outcome (CO-verified smoking status at 12 months
post randomisation) was conducted to obtain an unbiased estimate of the intervention effectiveness in the
presence of full compliance. A two-stage least squares instrumental variable approach, with randomised
group as the instrumental variable, was used. We defined compliance with the intervention for those
allocated to BSC as the number of sessions attended.
Health economic analysis
The health economic analysis for the SCIMITAR+ trial assessed the cost-effectiveness of supplementing
usual care with BSC, compared with usual care alone, within the trial. Although the impact of smoking
cessation is likely to be observed in the long term, the within-trial evaluation could provide a relatively
realistic estimate of intervention costs, necessary parameter inputs for model projection and potentially
some insights into the difference in change, in the case of lacking in capacity of a long-term follow-up.
The economic evaluation took the form of an incremental cost-effectiveness analysis from a NHS and
Personal Social Services perspective, as recommended by NICE guidance.57
The costs of BSC and usual care were identified, measured and valued. Costs and outcomes were
collected at participant level and based on the trial population. Health outcomes were measured using
quality-adjusted life-years (QALYs), as per NICE guidance.57 QALYs were constructed from the EQ-5D-5L,54
which was collected at baseline and during follow-up.
Costs
The total costs encompassed intervention costs and health-care and social services use costs. A wider range
of societal costs were collected but analysed separately.
Intervention costs
The intervention costs were identified by two stages corresponding to the timeline of the trial, which were
the pre-intervention stage and the intervention stage.
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Training and supervision
The pre-intervention stage is the training period for MH-SCPs. To deliver the intervention, four members
of the SCIMITAR+ team attended a 2-day training session delivered by the NCSCT, and then acted as
trainers for all MH-SCPs. The MH-SCPs received a 2-day training session, in line with that provided by the
NCSCT, with specific adaptations for people with SMI. This was delivered by the four trained members of
the SCIMITAR+ team, two at a time. The cost of the initial training from the NCSCT was estimated using
the invoice. The opportunity cost of time spent on the initial training by our research team and the cost
of delivering the training for MH-SCPs were costed at NHS band 6 instead of researchers’ wages to reflect
the costs to the NHS. The opportunity costs of time spent on these training sessions by the MH-SCPs were
also estimated for 2 working days for NHS band 4 staff. A full day was considered 7.5 working hours.
The staff cost included salary oncosts, overheads and capital.
Each practitioner was given a 43-page SCIMITAR+ Standard Treatment Protocol and a 51-page NCSCT
Standard Treatment Programme. These were printed in-house at £0.02 per page.
After training, all MH-SCPs received regular supervision, which was delivered by the trainer of the additional
training. Supervision time was recorded by the supervisor and allocated to each participant in the BSC group.
Intervention delivery
The intervention stage is the period during which the intervention/control treatment was delivered.
Costs were estimated for both the BSC group and the usual-care group accordingly.
For the intervention group, costs included costs of BSC and usual GP care. BSC was costed based on the
working time and caseload of MH-SCPs, including travel time to the prearranged location for the appointment.
These sessions were recorded in treatment logs by MH-SCPs. Each practitioner was equipped with a CO
monitor, which cost £120 and had a life span of 5 years. The depreciation value of the CO monitor in the
first year was calculated using double-declining balance to estimate the cost of the CO monitor during the
trial period.
Usual GP care included participants’ contact with usual-care practitioners [e.g. GPs, pharmacists, stop
smoking services (SSSs), etc.] for smoking cessation and prescriptions of pharmacotherapies for smoking
cessation. Usual-care contact was collected through self-reported questionnaires, and prescriptions were
extracted from their medical records. The overall cost of contact with practitioners was then calculated
by multiplying the number of contact sessions by their national average unit costs (see Table 2). The
prescriptions were matched by their generic names, dosage and form to the Prescription Cost Analysis –
England,58 and their costs were calculated by multiplying the weighted average net ingredient cost (NIC)
per unit by the recorded quantities used within the trial period. In the case of missing values on dosage or
form, a weighted average matching available information was used for estimation. Some medications were
recorded by prescription instead of quantity; these were consequently estimated based on the weighted
average NIC per prescription item.
Health-care and social services costs
Health-care and social service resources utilised by participants outside the trial were measured by an
adapted Health Economic/Service Utilisation Questionnaire. These included mainly secondary care and
community-based services.
This questionnaire was part of the questionnaire for baseline, 6- and 12-month follow-up and collected
the quantity of resources utilised by participants, covering the usage in the 6 months before each time
point. After the physical unit of resources was identified by the questionnaire, their quantities were
multiplied by their national average unit costs extracted from Unit Costs of Health and Social Care 2017,59
NHS Reference Costs 2016–1760 or inflated from Unit Costs of Health and Social Care 201561 if recent data
were unavailable (Table 2).
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TABLE 2 Unit costs of smoking cessation services, health care and social services, and market prices of selected NRT
products (2016/17 values)
Service items/products Unit cost (2016/17) Sources
Usual GP care for smoking cessation
Cessation consultation with GP £40/session 61
Cessation consultation with pharmacist £7/session 61
SSS £19/session 61,62
SSS helpline £7/call 61,63
Health care and social services
A&E department £175/attendance 60
Hospital admission £604/night; £1938/FCE 60
Hospital outpatient appointment £138/attendance 60
Day case/procedure £736/episode 60
Emergency ambulance £99/use 60
GP home visit £56/9.22-minute consultation plus 12 minutes of travel 59,61
GP surgery £31/9.22-minute consultation 59
GP telephone £15/call 59
Practice nurse £9/15.5-minute consultation 59,61
District nurse £36/contact 60
Community psychiatric nurse £61/contact 60
Health visitor £64/contact 60
Clinical psychologist £40/45-minute session 59
NHS counsellor £39/55-minute session 59
NHS dentist £138/contact 60
Podiatrist £44/contact 60
Occupational therapist £77/contact 60
Physiotherapist £53/contact 60
CBT £100/session 59
MBCT £15/session 59
Crisis team £192/team contact 59
CMHT £197/contact 59
Day care service £92/patient day 60
Social worker £30/30-minute visit 59
Family support worker £27/30-minute visit 59
Drug/alcohol support worker £118/contact 60
NRT products
Nasal spray £23/bottle Estimated market price
Microtab £16/pack Estimated market price
Patch £13/7-piece pack Estimated market price
Gum £13/96-piece pack Estimated market price
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All costs were presented in 2016/17 Great British pounds. Discounting was not required in this study, as
the evaluation was conducted within a 12-month time frame.
The use of antipsychotics was extracted from participants’ medical notes. As with prescription of
pharmacotherapies, they were matched by their generic names, dosage and form to the Prescription Cost
Analysis – England.58
The costs of health-care and social services use in the 6 months before baseline were used as one of the
baseline covariates for costs.
Wider societal costs
Costs incurred outside the NHS perspective were collected in the questionnaire by self-report and added
to the base-case analysis to present a separate analysis from a societal perspective. These included
out-of-pocket purchases of NRT products and e-cigarettes, and travel costs for the participants to attend
the smoking cessation appointments. As the market pricing of NRT products is highly complicated because
of deals, bundles or packaging, a set of estimated market prices was summarised, based on prices from
big supermarkets and pharmacies, such as Sainsbury’s (www.sainsburys.co.uk), Morrison’s (www.groceries.
morrisons.com), Boots (www.boots.com) and Lloyds Pharmacy (www.lloydspharmacy.com). It was further
simplified by using only one package size for patch, gum, lozenge and inhalator, as they were available in
various package sizes (see Table 2).
Health-related quality of life
The EQ-5D-5L was used to measure health-related quality of life in both the BSC group and the usual-care
group. The instrument was used at baseline and at 6- and 12-month follow-up. An index score was calculated
using the mapping function developed by van Hout et al.64 The index score ranges from –0.594 to 1, with
higher scores indicating better health-related quality of life. QALYs were then derived from EQ-5D-5L index
score at three time points by calculating the area under the curve.65 The accompanied visual analogue scale
(VAS) was also reported, ranging from 0 to 100, with higher numbers indicating better health-related
quality of life.
After the original plan was finalised, a EQ-5D-5L value set for England was released by the Office of Health
Economics.66 Following that development, NICE released a position statement in August 2017 stating that,
for the data gathered using EQ-5D-5L, the mapping function approach is still the preferred method for
reference case analysis and the five-level version valuation set is not recommended for use at this time.67
The updated statement in November 2018 retained this position.68 Therefore, we maintained the original
plan and disregarded the available five-level version valuation set for England.
TABLE 2 Unit costs of smoking cessation services, health care and social services, and market prices of selected NRT
products (2016/17 values) (continued )
Service items/products Unit cost (2016/17) Sources
Lozenge £13/96-piece pack Estimated market price
Mouth spray £19/bottle Estimated market price
Inhalator £21/20 cartridges Estimated market price
A&E, accident and emergency; CBT, cognitive–behavioural therapy; FCE, finished consultant episode; MBCT, mindfulness-
based cognitive therapy.
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Missing data
For the baseline covariates, little to no missing data were expected. These missing values were imputed
by the mean of the parameter in the whole sample because these were information collected before the
intervention began and the randomisation functioned to balance the parameters between two arms.
Methods for dealing with missing data on the primary outcome (CO-verified smoking cessation) followed
the approach used in the previous statistical analysis. The missing data on costs and quality-of-life elements
at follow-ups were imputed using multiple imputation. A chained equation model was developed, and
predictive mean matching was used as the main imputation method for continuous variables, using 10
nearest neighbours to the prediction as a set from which to draw. All missing data were imputed separately
by trial group. The imputation was performed on the aggregated level estimate, that is, EQ-5D-5L utility
value converted from data provided by participants. As a rule of thumb, the number of imputations was set
to the highest percentage of all missing values.69
Analysis
Primary analysis
The primary health economic analysis was conducted on an intention-to-treat basis, including all randomised
participants in the groups to which they were randomised. The CO-verified smoking cessation rate at
12 months was calculated for both groups in the statistical analysis. Intervention cost per CO-verified quitter
at 12 months and incremental intervention cost per additional quitter was reported to provide a comparison
with the SSS statistics.
Intervention costs and wider health-care and social services costs were used to calculate total cost per
participant. The EQ-5D-5L was used to calculate QALYs per participant. An incremental cost-effectiveness
ratio (ICER) was calculated and compared with the willingness-to-pay (WTP) threshold recommended by
NICE (£20,000–30,000).57
Sensitivity analysis
Uncertainty around the ICER was quantified using a non-parametric bootstrap technique whereby
5000 samples were generated by resampling. Confidence intervals around the ICER were estimated
and plotted on a cost-effectiveness plane to illustrate the overall uncertainty of both costs and QALYs.
Cost-effectiveness acceptability curves were constructed from the bootstrapped samples by converting
ICER to net monetary benefit.70
A complete-case analysis was also carried out to assess the uncertainty due to missing data.
Secondary analysis
Several exploratory analyses were also conducted in addition to the reference case analysis recommended
by the NICE guidance.57
Wider societal costs were summarised and presented as a separate analysis to provide an estimate of costs
outside the NHS. Using the information on the number of cigarettes smoked per day, an estimate of money
spent on cigarettes was calculated to demonstrate the monetary impact on the financial condition of the
participants. Previous evidence suggested that smokers with SMI might require a lower dosage of antipsychotics
to achieve the same effect if they stop smoking.2 Therefore, a comparison of the costs of antipsychotics between
two halves of the trial period by participants’ smoking status among this sample was conducted.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
18
Adverse events
A trial-specific procedure for detecting and reporting adverse events was implemented.
An adverse event was defined as any unexpected effect or untoward clinical event affecting the
participant. Standard criteria for serious adverse events (SAEs) were used.
The participant’s MH-SCP, GP or mental health specialist was requested to inform the research team of any
SAEs or non-SAEs. In addition, when participants indicated hospital attendance or use of emergency services
either during a visit or in questionnaire responses, this was followed up by the research team as required.
All adverse events and SAEs were independently reviewed by a clinician and were routinely reported to the
Data Monitoring and Ethics Committee and the Independent Trial Steering Committee (TSC).
Adverse event data are summarised descriptively by treatment group.
Suicide and self-harm risk protocol
A protocol for identifying and reporting potential suicide risk was implemented (see Appendix 3 for
protocol). Item 9 on the PHQ-9, which asks if the participant has had ‘thoughts that you would be better
off dead or of hurting yourself in some way’, was used to identify any suicide risk.
If the participant indicated a response of 3 (i.e. nearly every day) for this item at baseline or at any
of the follow-up interviews, then the suicide protocol was implemented and the participant was asked
if they had talked to their GP, psychiatrist or care co-ordinator/community psychiatric nurse (CPN) about
these feelings. If they had not, consent was sought to contact the participant’s GP to inform them of the
situation. If the participant refused, the relevant designated psychiatrist/health professional was contacted.
If the health professional agreed, the participant’s GP or psychiatrist was contacted immediately. A Suicidal
Intent Form was completed and, when applicable, a Suicidal Intent Form: Psychiatrist/Health Professional
was also completed. These forms were stored with the participant’s trial records.
Patient and public involvement in research
The SCIMITAR+ trial benefited from the involvement of users of mental health services and carers of people
with SMI throughout the research period. Our TSC included representation from carers and service users.
Our protocol and study materials were scrutinised and supported by users and carers in the north-west of
England.
We invited service users from a patient and public involvement (PPI) group based in the north-west to
be involved in the study. One of the collaborators works at the University of Manchester, the institution
that organised the PPI group. From this group, service users provided input on the recruitment materials.
Service users from this group were also invited to sit on the TSC; we had two service users sit on the TSC
and provide input into the running of the trial. We also had the benefit of a carer who sat on the TSC in
the pilot trial and continued to sit on the TSC in the main trial.
A service user and carer were invited to attend one of our yearly SCIMITAR+ meetings, which we held for
all the organisations taking part in the study. They gave a presentation on smoking and giving up smoking
and provided useful input into the study. They continue to remain involved and provide advice on our
work. We are seeking advice from service users regarding the dissemination of the SCIMITAR+ trial and
have recently formed a PPI group at the University of York for service users with SMI. We will be asking
this group to provide input into our dissemination plan.
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Chapter 3 Changes to the protocol
The current version of the protocol is version 2.5.
Recruitment from service user groups
After the trial had been recruiting for 3 months, recruitment from service user groups was added as an
additional recruitment method. This involved providing service user groups with information about the
SCIMITAR+ trial, along with copies of the flyer. Interested service users could then contact the mental
health professional named on the flyer or their care co-ordinator, or, if the service user preferred, the staff
member at the service user group could contact the service users’ care co-ordinator on their behalf.
This recruitment method was added to broaden the range of recruitment methods and therefore broaden
the range of participants invited to take part in the SCIMITAR+ trial. This method also had the potential to
offer service users who may not routinely be attending a clinic, and therefore not approached by a clinician,
the opportunity to take part in the study.
Recruitment from the Lifestyle Health and Wellbeing Survey
Using the Lifestyle Health and Wellbeing Survey to recruit was added as a recruitment option after the trial
had been recruiting for 8 months. The survey is a questionnaire-based prospective study involving adults
aged ≥ 18 years with SMI. Participants in the survey complete a series of questions about their health and
well-being, including questions about their smoking. Participants in the survey who consented to being
contacted by the research team and who smoked and were potentially interested in cutting down on or
quitting smoking were invited to take part in the SCIMITAR+ trial.
The use of the Lifestyle Health and Wellbeing Survey was included to broaden the range of recruitment
options and to offer people who may not have been invited by their mental health team or GP to take part
in the SCIMITAR+ trial the opportunity to do so. During the course of the SCIMITAR+ trial, we noticed that
some clinicians were gatekeeping: instead of checking whether or not a person wanted to do something
about their smoking, they were stating that the person did not want to stop smoking. In the survey, each
person was asked whether or not they wanted to do something about their smoking, thus removing the
possibility of an incorrect assumption being made.
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Chapter 4 Results
Recruitment
Recruitment started in October 2015 and ended in December 2016. Over the course of the trial, 40 GP
surgeries mailed out recruitment packs, and 21 mental health trusts were enlisted to recruit participants.
A total of 526 participants were recruited to the trial. The target and actual rates of recruitment are shown
in Figure 1, and monthly recruitment figures are shown in Figure 2. Recruitment took place at 21 mental
health trusts and 16 GP surgery sites (one GP site was a standalone site and the other GP sites were
acting as participant identification centres for the mental health trusts), although eligible and randomised
participants were primarily identified from mental health trusts. Table 3 shows the recruitment broken down
by method. Mental health trusts recruited between four and 52 participants per trust, and GP surgeries
recruited between one and five participants. Participant flow through the trial is shown in CONSORT flow
diagrams in Figures 3–5. Of the 526 participants, 265 were randomised to the BSC group and 261 were
randomised to the usual-care group.
Primary care
A total of 1162 participants were identified as potentially eligible from GP practice lists and were sent a
recruitment pack, of which 48 (4.1%) returned a ‘consent to contact’ form. Twenty-six of these were
ineligible and the remaining 22 were randomised, 11 to each trial arm. The randomisation rate for the GP
mailout was 1.9%.
Secondary care
The number of direct referrals received was 1558. Two-thirds of these were ineligible, non-consenting
and/or could not be contacted (n = 1054, 67.7%) and the remaining 504 were randomised, 254 to the
BSC group and 250 to the usual-care group. The randomisation rate for direct referrals was 32.3%.
Taking part in another study was not one of the exclusion criteria for the SCIMITAR+ trial; however, some
people were taking part in a study that precluded participants from taking part in other research studies.
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FIGURE 1 The SCIMITAR+ target and actual recruitment rates.
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Baseline data
The baseline characteristics of participants are summarised in the following tables, and the treatment groups
appear well balanced across baseline data. Table 4 summarises the sociodemographic and employment data
for the participants. Overall, 58.7% of the participants were male, 41.1% were female and one participant
identified as transgender (0.2%). The mean age of participants was 46 years, with a range from 19 to
72 years. The vast majority of participants were white (89.7%). Over two-thirds of the participants were
unemployed but not seeking work owing to ill health (67.7%).
Table 5 presents data on the general health of the participants at baseline. Most participants reported at
least moderate health in the last year (65.4%), despite most participants reporting that they experienced
at least one of the listed medical conditions (85.6%). The majority of participants (83.5%) felt that smoking
had negatively affected their health, and 70.9% reported that they had been advised to stop smoking
by their GP. The mean BMI of participants was 29.9 kg/m2 (range 16.6–59.8 kg/m2), which falls in the
overweight range.
TABLE 3 Recruitment by method
Recruitment method Number recruited (N= 526), n (%)
CMHT direct referral 377 (72)
Psychiatrist direct referral 40 (8)
CMHT database screen 37 (7)
CMHT/psychiatrist unknown 28 (5)
GP database screen 22 (4)
Recruitment from Lifestyle Health and Wellbeing Survey 13 (2)
GP direct referral 1 (0.2)
GP unknown 1 (0.2)
Service user group 1 (0.2)
Unknown 6 (1)
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FIGURE 2 Monthly recruitment into the SCIMITAR+ trial.
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Direct referrals received
(n = 1558)
Randomised
(n = 504, 32.3%)
Ineligible
(n = 1054, 67.7%)
• Did not consent, n = 228
• Could not contact, n = 205
• Does not smoke more than
   five tobacco cigarettes per
   day, n = 183 
• Does not wish to quit or cut
   down on smoking, n = 103
• Does not have eligible
   diagnosis, n = 80
• Too unwell, n = 32
• Drug or alcohol dependent,
   n = 19
• Dementia, n = 12
• Taking part in another
   study, n = 8
• Already receiving smoking
   cessation counselling, n = 3
• Pregnant or breastfeeding,
   n = 3
BSC
(n = 254, 50.4%)
Usual care
(n = 250, 49.6%)
FIGURE 4 Secondary care CONSORT flow diagram up to randomisation.
GP practice list size
(n = 387,781)
GP deemed patient potentially
eligible, recruitment pack sent
(n = 1162, 0.3%)
Consent to contact form
returned
(n = 48, 4.1%)
Randomised
(n = 22, 45.83%)
Ineligible
(n = 26, 54.17%)
• Does not smoke tobacco, n = 5
• Does not wish to quit or cut
   down on smoking, n = 3
• No SMI diagnosis, n = 3
• Unable to contact, n = 2
• Did not consent, n = 2
• Smokes fewer than five
   cigarettes per day, n = 1
• Unknown, n = 10
FIGURE 3 Primary care CONSORT flow diagram up to randomisation.
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Randomised
(n = 526)
Allocation
Follow-up
Analysis
• Received allocated intervention, n = 234
• Did not receive allocated intervention, n = 31
   (no sessions arranged, n = 27; first session
   arranged but participant did not attend,
   n = 3 or session cancelled, n = 1)
• Received allocated intervention, n = 261
• Did not receive allocated intervention, n = 0
Month 6
• Participant questionnaire, n = 236, 89.1%
   • Did not complete follow-up, n = 10
   • Withdrawn from study, n = 19
• CO measure, n = 228, 86.0%
Month 12
• Participant questionnaire, n = 227, 85.7%
   • Did not complete follow-up, n = 14
   • Withdrawn from study, n = 24
• CO measure, n = 224, 84.5%
Month 6
• Participant questionnaire, n = 230, 88.1%
   • Did not complete follow-up, n = 13
   • Withdrawn from study, n = 18
• CO measure, n = 218, 83.5%
Month 12
• Participant questionnaire, n = 223, 85.4%
   • Did not complete follow-up, n = 16
   • Withdrawn from study, n = 22
• CO measure, n = 219, 83.9%
• Excluded from analysis, n = 42 (missing
   12-month CO measurement only, n = 3; missing
   self-reported smoking status only, n = 1; missing
   12-month CO measurement and self-reported
   smoking status, n = 38)
• Excluded from analysis, n = 42 (missing
   12-month CO measurement only, n = 4; missing
   self-reported smoking status only, n = 0; missing
   12-month CO measurement and self-reported
   smoking status, n = 38)
Allocated to BSC
(n = 265)
Allocated to usual care
(n = 261)
Included in primary outcome analysis
(n = 223)
Included in primary outcome analysis
(n = 219)
FIGURE 5 The CONSORT flow diagram showing participant flow through the trial, from randomisation.
TABLE 4 Baseline participant characteristics, sociodemographic data and employment status
Characteristic BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Sex/gender, n (%)
Male 159 (60.0) 150 (57.5) 309 (58.7)
Female 105 (39.6) 111 (42.5) 216 (41.1)
Transgender 1 (0.4) 0 (0.0) 1 (0.2)
Age (years)
Mean (SD) 46.5 (12.5) 45.5 (11.7) 46.0 (12.1)
Median (min., max.) 47 (19, 72) 46 (19, 71) 47 (19, 72)
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Ethnicity, n (%)
White 241 (90.9) 231 (88.5) 472 (89.7)
Mixed 9 (3.4) 10 (3.8) 19 (3.6)
Asian 5 (1.9) 11 (4.2) 16 (3.0)
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TABLE 4 Baseline participant characteristics, sociodemographic data and employment status (continued )
Characteristic BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Black 9 (3.4) 7 (2.7) 16 (3.0)
Chinese 1 (0.4) 1 (0.4) 2 (0.4)
Missing 0 (0.0) 1 (0.4) 1 (0.2)
Highest educational qualification, n (%)
None 42 (15.8) 41 (15.7) 83 (15.8)
GCSE/O level 74 (27.9) 91 (34.9) 165 (31.4)
GCE A/AS level or Scottish Higher 20 (7.5) 23 (8.8) 43 (8.2)
NVQ/SVQ levels 1–3 39 (14.7) 21 (8.0) 60 (11.4)
GNVQ (Advanced) 2 (0.8) 7 (2.7) 9 (1.7)
BTEC certificate 4 (1.5) 2 (0.8) 6 (1.1)
BTEC diploma 7 (2.6) 11 (4.2) 18 (3.4)
National Certificate or Diploma 7 (2.6) 5 (1.9) 12 (2.3)
Qualified teacher status 0 (0.0) 1 (0.4) 1 (0.2)
Higher education diploma 5 (1.9) 7 (2.7) 12 (2.3)
Degree (first degree/ordinary degree) 24 (9.1) 13 (5.0) 37 (7.0)
Postgraduate certificate 2 (0.8) 2 (0.8) 4 (0.8)
Postgraduate diploma 2 (0.8) 1 (0.4) 3 (0.6)
Master’s degree 4 (1.5) 6 (2.3) 10 (1.9)
PhD 1 (0.4) 0 (0.0) 1 (0.2)
Other 30 (11.3) 25 (9.6) 55 (10.5)
Missing 2 (0.8) 5 (1.9) 7 (1.3)
Employment, n (%)
Employed full time 3 (1.1) 16 (6.1) 19 (3.6)
Employed part time 9 (3.4) 11 (4.2) 20 (3.8)
Self-employed 2 (0.8) 2 (0.8) 4 (0.8)
Retired 19 (7.2) 16 (6.1) 35 (6.7)
Looking after family or home 4 (1.5) 3 (1.1) 7 (1.3)
Student 5 (1.9) 5 (1.9) 10 (1.9)
Voluntary worker 11 (4.2) 18 (6.9) 29 (5.5)
Not employed but seeking work 16 (6.0) 15 (5.7) 31 (5.9)
Not employed but not seeking work because of ill health 185 (69.8) 171 (65.5) 356 (67.7)
Not employed but not seeking work for some other reason 8 (3.0) 4 (1.5) 12 (2.3)
Other 3 (1.1) 0 (0.0) 3 (0.6)
Marital status, n (%)
Single 177 (66.8) 171 (65.5) 348 (66.2)
Married 32 (12.1) 26 (10.0) 58 (11.0)
Living with a partner/co-habiting 13 (4.9) 16 (6.1) 29 (5.5)
Divorced/separated 33 (12.5) 46 (17.6) 79 (15.0)
Widowed 10 (3.8) 2 (0.8) 12 (2.3)
continued
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TABLE 4 Baseline participant characteristics, sociodemographic data and employment status (continued )
Characteristic BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Accommodation, n (%)
Detached house 10 (3.8) 18 (6.9) 28 (5.3)
Semidetached house 40 (15.1) 48 (18.4) 88 (16.7)
Terraced house 45 (17.0) 32 (12.3) 77 (14.6)
Flat 123 (46.4) 113 (43.3) 236 (44.9)
Bedsit/studio 6 (2.3) 11 (4.2) 17 (3.2)
Communal establishment 36 (13.6) 35 (13.4) 71 (13.5)
Caravan/other mobile shelter 1 (0.4) 0 (0.0) 1 (0.2)
No fixed abode 2 (0.8) 2 (0.8) 4 (0.8)
Missing 2 (0.8) 2 (0.8) 4 (0.8)
A/AS level, Advanced/Advanced Subsidiary level; BTEC, Business and Technology Education Council; GCE, General
Certificate of Education; GCSE, General Certificate of Secondary Education; GNVQ, General National Vocational
Qualification; max., maximum; min., minimum; NVQ, National Vocational Qualification; O level, Ordinary level; PhD, Doctor
of Philosophy; SVQ, Scottish Vocational Qualification.
TABLE 5 Baseline participant general health data
Characteristic BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Health over the past year, n (%)
Excellent 14 (5.3) 1 (0.4) 15 (2.9)
Good 50 (18.9) 62 (23.8) 112 (21.3)
Moderate 101 (38.1) 116 (44.4) 217 (41.3)
Poor 77 (29.1) 62 (23.8) 139 (26.4)
Very poor 23 (8.7) 18 (6.9) 41 (7.8)
Missing 0 (0.0) 2 (0.8) 2 (0.4)
Feel smoking has negatively affected health, n (%)
Yes 220 (83.0) 219 (83.9) 439 (83.5)
No 45 (17.0) 42 (16.1) 87 (16.5)
GP or doctor gave advice on quitting smoking, n (%)
Yes 192 (72.5) 181 (69.3) 373 (70.9)
No 73 (27.5) 80 (30.7) 153 (29.1)
Health problems, n (%)
Asthma 89 (33.6) 82 (31.4) 171 (32.5)
Chronic bronchitis 29 (10.9) 34 (13.0) 63 (12.0)
Other chest trouble 83 (31.3) 106 (40.6) 189 (35.9)
Diabetes 39 (14.7) 38 (14.6) 77 (14.6)
Stomach/digestive disorder 67 (25.3) 87 (33.3) 154 (29.3)
Haemorrhoids (piles) 44 (16.6) 48 (18.4) 92 (17.5)
Liver trouble 19 (7.2) 19 (7.3) 38 (7.2)
Rheumatic disorder or arthritis 43 (16.2) 56 (21.5) 99 (18.8)
Lung cancer 0 (0.0) 1 (0.4) 1 (0.2)
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TABLE 5 Baseline participant general health data (continued )
Characteristic BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Other cancer 9 (3.4) 9 (3.4) 18 (3.4)
Varicose veins 26 (9.8) 25 (9.6) 51 (9.7)
Stroke 12 (4.5) 11 (4.2) 23 (4.4)
Migraine 79 (29.8) 71 (27.2) 150 (28.5)
Back trouble 116 (43.8) 122 (46.7) 238 (45.2)
Epilepsy 17 (6.4) 11 (4.2) 28 (5.3)
ME or chronic fatigue 18 (6.8) 26 (10.0) 44 (8.4)
High blood pressure 56 (21.1) 62 (23.8) 118 (22.4)
Healthy life, n (%)
A very healthy life 17 (6.4) 11 (4.2) 28 (5.3)
A fairly healthy life 118 (44.5) 114 (43.7) 232 (44.1)
A not very healthy life 94 (35.5) 101 (38.7) 195 (37.1)
An unhealthy life 36 (13.6) 32 (12.3) 68 (12.9)
Missing 0 (0.0) 3 (1.1) 3 (0.6)
BMI (kg/m2)
Mean (SD) 30.2 (7.1) 29.7 (6.3) 29.9 (6.7)
Median (min., max.) 29.0 (16.6, 59.8) 29.4 (16.9, 48.4) 29.3 (16.6, 59.8)
Missing, n (%) 2 (0.8) 3 (1.1) 5 (1.0)
Eat five portions of fruit and vegetables a day, n (%)
Yes 113 (42.6) 106 (40.6) 219 (41.6)
No 152 (57.4) 152 (58.2) 304 (57.8)
Missing 0 (0.0) 3 (1.1) 3 (0.6)
Exercise for 20 minutes or more, n (%)
Daily 92 (34.7) 89 (34.1) 181 (34.4)
Weekly 72 (27.2) 68 (26.1) 140 (26.6)
Monthly 9 (3.4) 7 (2.7) 16 (3.0)
Seldom 33 (12.5) 43 (16.5) 76 (14.4)
Never 59 (22.3) 51 (19.5) 110 (20.9)
Missing 0 (0.0) 3 (1.1) 3 (0.6)
Drink alcohol, n (%)
Yes 141 (53.2) 140 (53.6) 281 (53.4)
No 122 (46.0) 121 (46.4) 243 (46.2)
Missing 2 (0.8) 0 (0.0) 2 (0.4)
If yes, units in last week n = 141 n = 140 n = 281
Mean (SD) 10.1 (15.8) 8.8 (16.0) 9.5 (15.9)
Median (min., max.) 4 (0, 84) 4 (0, 140) 4 (0, 140)
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
ME, myalgic encephalomyelitis; max., maximum; min., minimum.
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Table 6 summarises baseline mental health status. The most common severe mental health problems were
schizophrenia or other psychotic illness (n = 342, 65.0%), bipolar disorder (n = 115, 21.9%) and schizoaffective
disorder (n = 66, 12.5%). Nearly two-thirds of the participants had a care programme approach (CPA)
co-ordinator (64.4%) and/or a CPN (64.6%), and 83.3% were under the care of a CMHT. On average,
participants were aged 26 years when they were first diagnosed with their mental health problem and had
required psychiatric treatment in hospital an average of 2.8 times (range 0–100 times) in the last 10 years.
Most (64.3%) participants described their condition as ‘stable’, but 13.7% described their condition as
‘unstable’ (although each participant had been judged to be stable from the point of view of their condition
by either their GP or a responsible mental health professional), and 22.0% either were unsure or did not
respond to this question.
TABLE 6 Baseline participant mental health status
Characteristic BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Age at first diagnosis (years)
Mean (SD) 26.1 (10.3) 26.4 (10.5) 26.3 (10.4)
Median (min., max.) 24 (2, 60) 25 (0, 59) 24 (2, 60)
Missing, n (%) 4 (1.5) 7 (2.7) 11 (2.1)
Most recent diagnosis, n (%)
Bipolar disorder 59 (22.3) 56 (21.5) 115 (21.9)
Schizoaffective disorder 25 (9.4) 41 (15.7) 66 (12.5)
Schizophrenia 138 (52.1) 125 (47.9) 263 (50.0)
Other psychotic disorder 41 (15.5) 39 (14.9) 80 (15.2)
Missing 2 (0.8) 0 (0.0) 2 (0.4)
Type of professional seen by participant, n (%)
CPA co-ordinator 166 (62.6) 173 (66.3) 339 (64.4)
CPN 171 (64.5) 169 (64.8) 340 (64.6)
CMHT 217 (81.9) 221 (84.7) 438 (83.3)
Time since last health check (months)
Mean (SD) 5.4 (11.9) 4.4 (6.7) 4.9 (9.6)
Median (min., max.) 1.9 (0.1, 116.5) 2.1 (0.1, 63.0) 2.0 (0.1, 116.5)
Missing, n (%) 102 (38.5) 94 (36.0) 196 (37.3)
Number of times needed psychiatric treatment in hospital in last 10 years
Mean (SD) 2.9 (6.9) 2.7 (4.7) 2.8 (5.9)
Median (min., max.) 1 (0, 100) 1 (0, 50) 1 (0, 100)
Missing, n (%) 4 (1.5) 6 (2.3) 10 (1.9)
Would you describe your condition as . . . , n (%)
Stable 172 (64.9) 166 (63.6) 338 (64.3)
Unstable 40 (15.1) 32 (12.3) 72 (13.7)
Unsure 53 (20.0) 62 (23.8) 115 (21.9)
Missing 0 (0.0) 1 (0.4) 1 (0.2)
Max., maximum; min., minimum.
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Participants reported that they started smoking, on average, at the age of 16 years (range 5–50 years) and
had been smoking for a mean of 29.9 (SD 12.9) years (Table 7). The most common form of tobacco used
was factory-made cigarettes, reportedly used by 63.3% of participants, followed by hand-rolled cigarettes
(58.7%). The mean number of cigarettes smoked per day was 24.9 (range 3–100 cigarettes) (although
all participants reported smoking at least five cigarettes per day when the eligibility check was carried out,
one participant stated that they smoked three cigarettes per day in the self-complete smoking questionnaire).
The median number of attempts to quit ever was 3, with a range of 0–200. The median duration of longest
quit attempt reported was 40 days, with a range of 0 days to 188 months. The most common self-reported
previous strategies used to stop smoking were ‘cold turkey’ (55.3%) followed by NRTs (20.3%).
The reasons for smoking and their importance are summarised in Table 8. The reasons most commonly
reported as very important for smoking were helping to cope with stress (61.2%) and to give them
something to do (39.7%).
TABLE 7 Baseline participant smoking history
Characteristic BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Age started smoking (years)
Mean (SD) 15.7 (5.3) 16.5 (6.0) 16.1 (5.7)
Median (min., max.) 15 (5, 47) 15 (7, 50) 15 (5, 50)
Missing, n (%) 0 (0.0) 1 (0.4) 1 (0.2)
Length of time smoking (years)
Mean (SD) 30.7 (13.2) 29.0 (12.5) 29.9 (12.9)
Median (min., max.) 31.9 (0.1, 61.1) 29.3 (2.1, 56.2) 30.6 (0.1, 61.1)
Missing, n (%) 1 (0.4) 1 (0.4) 2 (0.4)
Type of tobacco used, n (%)
Factory-made cigarettes 173 (65.3) 160 (61.3) 333 (63.3)
Hand-rolled cigarettes 150 (56.6) 159 (60.9) 309 (58.7)
Cigars 17 (6.4) 10 (3.8) 27 (5.1)
Pipe 4 (1.5) 2 (0.8) 6 (1.1)
Chewing tobacco 0 (0.0) 0 (0.0) 0 (0.0)
Water pipe/hookah/shisha pipe 3 (1.1) 2 (0.8) 5 (1.0)
Number of cigarettes per day
Mean (SD) 24.7 (13.5) 23.2 (12.8) 24.0 (13.2)
Median (min., max.) 20 (3, 100) 20 (0, 80) 20 (0, 100)
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
If using roll-ups or pipe, amount of tobacco
used per day (g) n = 151 n = 159 n = 310
Mean (SD) 12.4 (10.7) 12.8 (10.1) 12.6 (10.4)
Median (min., max.) 10 (0.25, 75) 12 (0.5, 80) 10 (0.25, 80)
Missing, n (%) 18 (11.9) 13 (8.2) 31 (10.0)
Number of quit attempts in the past 6 months
Mean (SD) 1.4 (5.4) 1.5 (3.4) 1.5 (4.5)
Median (min., max.) 0 (0, 80) 0 (0, 30) 0 (0, 80)
Missing, n (%) 0 (0.0) 1 (0.4) 1 (0.2)
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TABLE 7 Baseline participant smoking history (continued )
Characteristic BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Total number of quit attempts
Mean (SD) 6.6 (13.2) 8.2 (19.0) 7.4 (16.3)
Median (min., max.) 3 (0, 100) 4 (0, 200) 3 (0, 200)
Missing, n (%) 4 (1.5) 8 (3.1) 12 (2.3)
Length of most recent quit attempt (months)
Mean (SD) 1.9 (9.4) 2.8 (14.5) 2.4 (12.2)
Median (min., max.) 0.1 (0.0, 105.7) 0.1 (0.0, 187.9) 0.1 (0.0, 187.9)
Missing, n (%) 13 (4.9) 12 (4.6) 25 (4.8)
Longest quit attempt (months)
Mean (SD) 8.8 (22.9) 9.3 (23.8) 9.0 (23.3)
Median (min., max.) 0.9 (0.0, 152.6) 1.5 (0.0, 187.9) 1.3 (0.0, 187.9)
Missing, n (%) 19 (7.2) 7 (2.7) 26 (4.9)
Previous methods used to stop smoking, n (%)
Cold turkey 139 (52.5) 152 (58.2) 291 (55.3)
NRT 51 (19.2) 56 (21.5) 107 (20.3)
Champix (varenicline) 18 (6.8) 34 (13.0) 52 (9.9)
Hypnosis 22 (8.3) 18 (6.9) 40 (7.6)
E-cigarettes 15 (5.7) 14 (5.4) 29 (5.5)
Acupuncture 15 (5.7) 12 (4.6) 27 (5.1)
Zyban (bupropion) 12 (4.5) 12 (4.6) 24 (4.6)
Other 2 (0.8) 9 (3.4) 11 (2.1)
Max., maximum; min., minimum.
TABLE 8 Baseline reasons for smoking and their importance
Characteristic, n (%) BSC (N= 265) Usual care (N= 261) Overall (N= 526)
I enjoy it
Very important 103 (38.9) 90 (34.5) 193 (36.7)
Quite important 106 (40.0) 96 (36.8) 202 (38.4)
Not important 55 (20.8) 74 (28.4) 129 (24.5)
Missing 1 (0.4) 1 (0.4) 2 (0.4)
It keeps my weight down
Very important 36 (13.6) 45 (17.2) 81 (15.4)
Quite important 64 (24.2) 48 (18.4) 112 (21.3)
Not important 163 (61.5) 166 (63.6) 329 (62.5)
Missing 2 (0.8) 2 (0.8) 4 (0.8)
It helps me to socialise
Very important 43 (16.2) 32 (12.3) 75 (14.3)
Quite important 68 (25.7) 72 (27.6) 140 (26.6)
Not important 153 (57.7) 154 (59.0) 307 (58.4)
Missing 1 (0.4) 3 (1.1) 4 (0.8)
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Table 9 summarises the reasons for wanting to try to give up smoking; the reasons most commonly
reported as very important were that it is bad for health (87.5%) and that it is expensive (71.9%).
Participant use of e-cigarettes is summarised in Table 10. Over two-thirds (70.3%) of the participants reported
having ever tried an e-cigarette, of whom 77 (22.0%) had used e-cigarettes at least once per week in the
TABLE 8 Baseline reasons for smoking and their importance (continued )
Characteristic, n (%) BSC (N= 265) Usual care (N= 261) Overall (N= 526)
It helps my concentration
Very important 44 (16.6) 38 (14.6) 82 (15.6)
Quite important 81 (30.6) 64 (24.5) 145 (27.6)
Not important 138 (52.1) 157 (60.2) 295 (56.1)
Missing 2 (0.8) 2 (0.8) 4 (0.8)
It gives me something to do
Very important 106 (40.0) 103 (39.5) 209 (39.7)
Quite important 106 (40.0) 109 (41.8) 215 (40.9)
Not important 53 (20.0) 48 (18.4) 101 (19.2)
Missing 0 (0.0) 1 (0.4) 1 (0.2)
It helps me to cope with stress
Very important 162 (61.1) 160 (61.3) 322 (61.2)
Quite important 71 (26.8) 72 (27.6) 143 (27.2)
Not important 29 (10.9) 27 (10.3) 56 (10.6)
Missing 3 (1.1) 2 (0.8) 5 (1.0)
It helps combat pain
Very important 32 (12.1) 15 (5.7) 47 (8.9)
Quite important 37 (14.0) 31 (11.9) 68 (12.9)
Not important 194 (73.2) 211 (80.8) 405 (77.0)
Missing 2 (0.8) 4 (1.5) 6 (1.1)
I feel bad when I try to stop
Very important 93 (35.1) 85 (32.6) 178 (33.8)
Quite important 63 (23.8) 59 (22.6) 122 (23.2)
Not important 104 (39.2) 110 (42.1) 214 (40.7)
Missing 5 (1.9) 7 (2.7) 12 (2.3)
I like being a smoker
Very important 41 (15.5) 27 (10.3) 68 (12.9)
Quite important 60 (22.6) 59 (22.6) 119 (22.6)
Not important 162 (61.1) 172 (65.9) 334 (63.5)
Missing 2 (0.8) 3 (1.1) 5 (1.0)
It gives me confidence
Very important 38 (14.3) 22 (8.4) 60 (11.4)
Quite important 48 (18.1) 53 (20.3) 101 (19.2)
Not important 177 (66.8) 183 (70.1) 360 (68.4)
Missing 2 (0.8) 3 (1.1) 5 (1.0)
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TABLE 9 Baseline reasons for trying to give up smoking
Characteristic, n (%) BSC (N= 265) Usual care (N= 261) Overall (N= 526)
It is expensive
Very important 193 (72.8) 185 (70.9) 378 (71.9)
Quite important 49 (18.5) 49 (18.8) 98 (18.6)
Not important 23 (8.7) 26 (10.0) 49 (9.3)
Missing 0 (0.0) 1 (0.4) 1 (0.2)
It is bad for my health
Very important 236 (89.1) 224 (85.8) 460 (87.5)
Quite important 20 (7.5) 31 (11.9) 51 (9.7)
Not important 9 (3.4) 5 (1.9) 14 (2.7)
Missing 0 (0.0) 1 (0.4) 1 (0.2)
I do not like feeling dependent on cigarettes
Very important 1. 170 (64.2) 1. 167 (64.0) 1. 337 (64.1)
Quite important 1. 59 (22.3) 1. 67 (25.7) 1. 126 (24.0)
Not important 1. 35 (13.2) 1. 25 (9.6) 1. 60 (11.4)
Missing 1. 1 (0.4) 1. 2 (0.8) 1. 3 (0.6)
It makes my clothes and breath smell
Very important 151 (57.0) 155 (59.4) 306 (58.2)
Quite important 74 (27.9) 64 (24.5) 138 (26.2)
Not important 40 (15.1) 40 (15.3) 80 (15.2)
Missing 0 (0.0) 2 (0.8) 2 (0.4)
It is a bad example for children
Very important 156 (58.9) 163 (62.5) 319 (60.6)
Quite important 53 (20.0) 45 (17.2) 98 (18.6)
Not important 54 (20.4) 50 (19.2) 104 (19.8)
Missing 2 (0.8) 3 (1.1) 5 (1.0)
It is unpleasant for people near me
Very important 140 (52.8) 139 (53.3) 279 (53.0)
Quite important 80 (30.2) 80 (30.7) 160 (30.4)
Not important 45 (17.0) 40 (15.3) 85 (16.2)
Missing 0 (0.0) 2 (0.8) 2 (0.4)
It makes me less fit
Very important 186 (70.2) 184 (70.5) 370 (70.3)
Quite important 60 (22.6) 55 (21.1) 115 (21.9)
Not important 19 (7.2) 21 (8.0) 40 (7.6)
Missing 0 (0.0) 1 (0.4) 1 (0.2)
People around me disapprove of my smoking
Very important 107 (40.4) 101 (38.7) 208 (39.5)
Quite important 78 (29.4) 68 (26.1) 146 (27.8)
Not important 80 (30.2) 89 (34.1) 169 (32.1)
Missing 0 (0.0) 3 (1.1) 3 (0.6)
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TABLE 9 Baseline reasons for trying to give up smoking (continued )
Characteristic, n (%) BSC (N= 265) Usual care (N= 261) Overall (N= 526)
It is bad for the health of people near me
Very important 147 (55.5) 136 (52.1) 283 (53.8)
Quite important 72 (27.2) 72 (27.6) 144 (27.4)
Not important 45 (17.0) 51 (19.5) 96 (18.3)
Missing 1 (0.4) 2 (0.8) 3 (0.6)
TABLE 10 Participant use of e-cigarettes at baseline
Characteristic, n (%) BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Ever tried an e-cigarette
Yes 186 (70.2) 184 (70.5) 370 (70.3)
No 79 (29.8) 77 (29.5) 156 (29.7)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
If yes: n = 186 n = 184 n = 370
Use of e-cigarette in last 30 days
Never 128 (68.8) 124 (67.4) 252 (68.1)
Less than once per week 21 (11.3) 18 (9.8) 39 (10.5)
Less than daily but at least once per week 22 (11.8) 20 (10.9) 42 (11.4)
Every day 14 (7.5) 21 (11.4) 35 (9.5)
Missing 1 (0.5) 1 (0.5) 2 (0.5)
Length of use of e-cigarettes
< 1 month 58 (31.2) 76 (41.3) 134 (36.2)
1–6 months 44 (23.7) 38 (20.7) 82 (22.2)
6–12 months 28 (15.1) 21 (11.4) 49 (13.2)
> 1 year 38 (20.4) 31 (16.8) 69 (18.6)
Missing 18 (9.7) 18 (9.8) 36 (9.7)
Nicotine levels in cartridges used in e-cigarette
None (0 mg) 10 (5.4) 10 (5.4) 20 (5.4)
Low (< 8mg) 24 (12.9) 26 (14.1) 50 (13.5)
Medium (8–16 mg) 56 (30.1) 60 (32.6) 116 (31.4)
High (> 16mg) 51 (27.4) 44 (23.9) 95 (25.7)
Missing 45 (24.2) 44 (23.9) 89 (24.1)
Use of tobacco changed since using e-cigarettes
Yes, I smoke less tobacco 62 (33.3) 64 (34.8) 126 (34.1)
Yes, I smoke more tobacco 11 (5.9) 5 (2.7) 16 (4.3)
No, it has not changed 97 (52.2) 101 (54.9) 198 (53.5)
Missing 16 (8.6) 14 (7.6) 30 (8.1)
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past month. Of the participants who reported ever having tried an e-cigarette, over half stated that their use
of tobacco had not changed since they started using e-cigarettes (53.5%), with only 34.1% saying that they
now smoke less tobacco. The most commonly cited reason for using e-cigarettes was to try to quit smoking
tobacco (51.1%).
Participant questionnaire return rates
Response rates to the participant questionnaires at 6 and 12 months are presented in Table 11. Over 95%
of the forms given to participants at 6 months were returned (466/489, 95.3%; 88.6% of 526 randomised
participants). The median number of days between the form being due and being returned was 6 (replacing
those that were completed early with 0 days), and the majority were completed face to face (95.9%).
At the primary time point of 12 months, 450 (93.8%) of the 480 forms sent out were returned (85.6%
of 526 randomised participants). The median time to return was 4 days, and only eight (1.8%) were not
completed face to face (six over the telephone and two on paper via post).
Primary analysis
The CO breath measurement readings are summarised by treatment group at baseline, 6 and 12 months
in Table 12. The mean reading at baseline was 24.6 (SD 15.2) p.p.m. and was similar between the two
groups. Seventy (13.3%) participants had a reading of < 10 p.p.m. at baseline. In both groups, the mean
reading decreased from baseline to 6 months and then increased slightly at 12 months.
Self-reported smoking status and quit attempt data reported on the participant questionnaires at 6 and
12 months are presented in Table 13. At 6 months, 463 participants (88.0%) provided a valid response to the
self-reported smoking status question, and 51 of these (11.0%) reported that they had not smoked even a puff
in the last week [34 (14.5%) in the BSC group and 17 (7.4%) in the usual-care group]. At the primary time
point of 12 months, 449 participants (85.4%) provided a valid response to the self-reported smoking status
question, and 57 of these (12.7%) reported that they had not smoked even a puff in the last week [35 (15.5%)
in the BSC group and 22 (9.9%) in the usual-care group). For those who said that they did still smoke, the most
common hour of the day to have the first puff of a cigarette is between 08.00 and 09.00 (20% at both time
points). At 12 months, of the participants with valid data for this question, 16.1% of BSC participants and
10.6% of usual-care participants reported that they had stopped smoking completely, and participants reported
a median of one quit attempt in the previous 6 months, with the most recent quit attempt lasting an average of
3.5 weeks before the participant returned to smoking. Responses to the items in Table 13 relating to smoking
status and smoking in the last week did not always agree, as might be expected. For example, replying ‘not a
puff’ in relation to the amount smoked in the last week did not always imply that participants reported that
TABLE 10 Participant use of e-cigarettes at baseline (continued )
Characteristic, n (%) BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Reason started using e-cigarettes
To quit smoking tobacco 92 (49.5) 97 (52.7) 189 (51.1)
To try a safer alternative to tobacco 25 (13.4) 23 (12.5) 48 (13.0)
To try something new 14 (7.5) 13 (7.1) 27 (7.3)
To smoke less tobacco 29 (15.6) 19 (10.3) 48 (13.0)
Other 14 (7.5) 20 (10.9) 34 (9.2)
Missing 12 (6.5) 12 (6.5) 24 (6.5)
RESULTS
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they had ‘stopped smoking completely’, and vice versa. For instance, one participant who reported that they
had not smoked a puff in the past week at 12 months in the usual-care group reported that they ‘smoke
cigarettes (including hand-rolled) but not every day’, and this could be because they still smoke occasionally but
just had not smoked in the previous week.
TABLE 11 Return of participant questionnaires at 6 and 12 months
Time point BSC (N= 265) Usual care (N= 261) Overall (N= 526)
6 months
Sent,a n (%) 246 (92.8) 243 (93.1) 489 (93.0)
Completed,b n (%) 236 (95.9) 230 (94.7) 466 (95.3)
Days to complete, median (IQR) 7 (0–20) 5 (0–20) 6 (0–20)
Mode of completion,c n (%)
Face to face 228 (96.6) 219 (95.2) 447 (95.9)
Telephone 4 (1.7) 10 (4.4) 14 (3.0)
Paper 4 (1.7) 1 (0.4) 5 (1.1)
12 months
Sent,a n (%) 241 (90.0) 239 (91.6) 480 (91.3)
Completed,b n (%) 227 (94.2) 223 (93.3) 450 (93.8)
Days to complete, median (IQR) 3 (0–15) 4 (0–16) 4 (0–15)
Mode of completion,c n (%)
Face to face 223 (98.2) 219 (98.2) 442 (98.2)
Telephone 3 (1.3) 3 (1.4) 6 (1.3)
Paper 1 (0.4) 1 (0.4) 2 (0.4)
IQR, interquartile range.
a Percentage of sent.
b Percentage of completed.
c Percentage of randomised participants.
TABLE 12 CO reading by treatment group and time point
Time point CO measurement BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Baseline Mean (SD) 24.9 (15.4) 24.3 (15.1) 24.6 (15.2)
Median (min., max.) 22.0 (1.0, 95.0) 21.0 (2.0, 100.0) 21.0 (1.0, 100.0)
Missing, n (%) 1 (0.4) 3 (1.1) 4 (0.8)
6 months Mean (SD) 18.0 (14.1) 19.4 (12.9) 18.7 (13.5)
Median (min., max.) 16.5 (0.0, 89.0) 17.5 (0.0, 71.0) 17.0 (0.0, 89.0)
Missing, n (%) 37 (14.0) 43 (16.5) 80 (15.2)
12 months Mean (SD) 18.1 (13.6) 20.2 (13.7) 19.2 (13.7)
Median (min., max.) 16.0 (0.0, 71.0) 20.0 (0.0, 77.0) 18.0 (0.0, 77.0)
Missing, n (%) 41 (15.5) 42 (16.1) 83 (15.8)
Max., maximum; min., minimum.
Note
CO measurements are in p.p.m.
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TABLE 13 Self-reported smoking status and quit attempts at 6 and 12 months by randomised group
Time point Outcome BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Smoked in last week, n (%)
6 months Not even a puff 34 (12.8) 17 (6.5) 51 (9.7)
Just a few puffs 5 (1.9) 0 (0.0) 5 (1.0)
Between one and five cigarettes 12 (4.5) 1 (0.4) 13 (2.5)
More than five cigarettes 183 (69.1) 211 (80.8) 394 (74.9)
Missing 31 (11.7) 32 (12.3) 63 (12.0)
12 months Not even a puff 35 (13.2) 22 (8.4) 57 (10.8)
Just a few puffs 2 (0.8) 3 (1.1) 5 (1.0)
Between one and five cigarettes 11 (4.2) 10 (3.8) 21 (4.0)
More than five cigarettes 178 (67.2) 188 (72.0) 366 (69.6)
Missing 39 (14.7) 38 (14.6) 77 (14.6)
Self-reported smoking status, n (%)
6 months Smoke the same amount of cigarettes
(including hand-rolled) every day
77 (29.1) 106 (40.6) 183 (34.8)
Cut down on the number of cigarettes
(including hand-rolled) I smoke
100 (37.7) 96 (36.8) 196 (37.3)
Smoke cigarettes (including hand-rolled)
but not every day
19 (7.2) 5 (1.9) 24 (4.6)
Stopped smoking completely 37 (14.0) 18 (6.9) 55 (10.5)
Missing 32 (12.1) 36 (13.8) 68 (12.9)
At 12 months Smoke the same amount of cigarettes
(including hand-rolled) every day
91 (34.3) 101 (38.7) 192 (36.5)
Cut down on the number of cigarettes
(including hand-rolled) I smoke
86 (32.5) 83 (31.8) 169 (32.1)
Smoke cigarettes (including hand-rolled)
but not every day
11 (4.2) 10 (3.8) 21 (4.0)
Stopped smoking completely 36 (13.6) 23 (8.8) 59 (11.2)
Missing 41 (15.5) 44 (16.9) 85 (16.2)
Quit attempts in last 6 months
At 6 months Mean (SD) 2.0 (3.7) 1.6 (2.3) 1.8 (3.1)
Median (min., max.) 1 (0, 50) 1 (0, 20) 1 (0, 50)
Missing, n (%) 39 (14.7) 40 (15.3) 79 (15.0)
At 12 months Mean (SD) 1.8 (4.0) 1.3 (1.7) 1.6 (3.1)
Median (min., max.) 1 (0, 35) 1 (0, 12) 1 (0, 35)
Missing, n (%) 49 (18.5) 44 (16.9) 93 (17.7)
Length of cessation (weeks)
At 6 months Mean (SD) 5.7 (37.2) 2.8 (5.6) 4.3 (26.6)
Median (min., max.) 0.6 (0, 520) 0.4 (0, 26) 0.4 (0, 26)
Missing, n (%) 67 (25.3) 65 (24.9) 132 (25.1)
At 12 months Mean (SD) 4.0 (10.4) 3.0 (7.1) 3.5 (8.9)
Median (min., max.) 0.3 (0, 52) 0.3 (0, 52) 0.3 (0, 52)
Missing, n (%) 87 (32.8) 71 (27.2) 158 (30.0)
Max., maximum; min., minimum.
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Smoking cessation at 6 and 12 months was defined as a CO measure of < 10 p.p.m. (indicating no smoking
in the last 12 hours) and self-reported cessation (indicating no smoking in the last week). At 6 months,
446 participants (84.8%) provided a CO reading, 463 (88.0%) had valid data for self-reported smoking
status and 443 (84.2%) had both (Table 14); 32 out of 226 (14.2%; 10.6% of 265 randomised participants)
fulfilled the definition for smoking cessation in the BSC group and 14 out of 217 (6.5%; 5.4% of 261
randomised participants) fulfilled the definition in the usual-care group. At 12 months, 443 (84.2%)
provided a CO reading, 449 (85.4%) had valid data for self-reported smoking status and 442 (84.0%) had
both; 34 out of 223 (15.2%; 12.8% of 265 randomised participants) fulfilled the definition for smoking
cessation in the BSC group and 22 out of 219 (10.0%; 8.4% of 261 randomised participants) fulfilled the
definition in the usual-care group.
The OR for the difference between the two groups from the model adjusting for baseline number of cigarettes
smoked, and site as a random effect, at 12 months was 1.6 (95% CI 0.9 to 2.8; p = 0.12). The OR at 6 months
was 2.4 (95% CI 1.2 to 4.7; p = 0.01).
Sensitivity analysis
Unadjusted odds ratio
The unadjusted, marginal ORs for CO-verified smoking cessation at 6 and 12 months are 2.4 (95% CI 1.2
to 4.6; p = 0.01) and 1.6 (95% CI 0.9 to 2.9; p = 0.10), respectively.
Post hoc generalised estimating equations analysis
Using GEE to account for the repeated measures, the OR adjusting for baseline number of cigarettes smoked is
2.3 (95% CI 1.2 to 4.5; p = 0.01) at 6 months and 1.6 (95% CI 0.9 to 2.8; p = 0.12) at 12 months. When the
GEE model was additionally adjusted for site, the treatment effects were estimated at an OR of 2.5 (95% CI
1.3 to 4.8; p = 0.01) at 6 months and 1.6 (95% CI 0.9 to 2.9; p = 0.12) at 12 months.
TABLE 14 Smoking status measures at 6 and 12 months
Time point Outcome, n (%) BSC (N= 265)
Usual care
(N= 261)
Overall
(N= 526)
6 months Number with CO measurementa 228 (86.0) 218 (83.5) 446 (84.8)
Number with CO < 10 p.p.m.b 69 (30.3) 50 (22.9) 119 (26.7)
Number with self-reporta 234 (88.3) 229 (87.7) 463 (88.0)
Number self-reporting as quitterb 34 (14.5) 17 (7.4) 51 (11.0)
Total number with CO and self-reported measurea 226 (85.3) 217 (83.1) 443 (84.2)
Total number quitb 32 (14.2) 14 (6.5) 46 (10.4)
Total number quita 32 (12.1) 14 (5.4) 46 (8.7)
12 months Number with CO measurementa 224 (84.5) 219 (83.9) 443 (84.2)
Number with CO < 10 p.p.m.b 73 (32.6) 62 (28.3) 135 (30.5)
Number with self-reporta 226 (85.3) 223 (85.4) 449 (85.4)
Number self-reporting as quitterb 35 (15.5) 22 (9.9) 57 (12.7)
Total number with CO and self-reported measurea 223 (84.2) 219 (83.9) 442 (84.0)
Total number quitb 34 (15.2) 22 (10.0) 56 (12.7)
Total number quita 34 (12.8) 22 (8.4) 56 (10.6)
a Percentage of total randomised.
b Percentage of those with non-missing data for both CO measure and self-reported smoking status.
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Accounting for missing CO-verified smoking status
When imputing self-reported smoking status when CO measures were missing in separate logistic regressions
at 6 and 12 months and adjusting for number of cigarettes smoked as a fixed effect and site as a random
effect, the following treatment effects were obtained: 6 months, OR 2.6, 95% CI 1.3 to 5.0 (p = 0.005);
12 months, OR 1.7, 95% CI 0.9 to 3.0 (p = 0.08).
Then, assuming that anyone else with missing smoking status data is a smoker yielded the following results:
6 months, OR 2.6, 95% CI 1.4 to 5.0 (p = 0.004); 12 months, OR 1.7, 95% CI 0.9 to 2.9 (p = 0.08).
When multiple imputation was used to impute missing primary outcome data, the treatment effect at
6 months was observed to be an OR of 2.4 (95% CI 1.3 to 4.4; p = 0.007), and at 12 months it was
observed to be an OR of 1.7 (95% CI 0.9 to 3.0; p = 0.08).
Secondary analysis
Self-reported smoking cessation
Among those with a valid response to the self-reported smoking status question at 6 months, 34 out
of 234 (14.5%) in the BSC group and 17 out of 229 (7.4%) in the usual-care group reported that they
had not smoked even a puff in the last week (Table 15) (adjusted OR 2.1, 95% CI 1.1 to 3.9; p = 0.02).
At 12 months, 35 out of 226 (15.5%) in the BSC group and 22 out of 223 (9.9%) in the usual-care group
reported that they had not smoked even a puff in the last week (see Table 15) (adjusted OR 1.7, 95% CI
0.9 to 3.0; p = 0.08).
Number of cigarettes smoked per day
The incidence rate ratio for number of cigarettes smoked per day at 6 months was 0.90 (95% CI 0.80 to
1.01; p = 0.08), marginally favouring the BSC group, and at 12 months it was 1.00 (95% CI 0.89 to 1.13;
p = 0.95). Neither of these differences is statistically significant.
Fagerström Test for Nicotine Dependence
The FTND score is summarised by randomised group and time point in Table 15. Adjusted FTND means
and group differences are presented in Table 21 and displayed in Figure 6. The adjusted mean difference
at 6 months was –0.18 (95% CI –0.53 to 0.17) and at 12 months it was –0.01 (95% CI –0.39 to 0.38),
both marginally favouring the BSC group but not statistically significantly (p = 0.32 and 0.97, respectively).
TABLE 15 The FIND scores by treatment group and time point
Time point FTND questionnaire BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Baseline Mean (SD) 6.5 (2.0) 6.4 (1.9) 6.4 (2.0)
Median (min., max.) 7.0 (1.0, 10.0) 6.0 (1.0, 10.0) 7.0 (1.0, 10.0)
Missing, n (%) 7 (2.6) 7 (2.7) 14 (2.7)
Month 6 Mean (SD) 5.3 (2.1) 5.4 (2.0) 5.3 (2.1)
Median (min., max.) 5.0 (1.0, 10.0) 6.0 (1.0, 10.0) 5.5 (1.0, 10.0)
Missing, n (%) 80 (30.2) 66 (25.3) 146 (27.8)
Month 12 Mean (SD) 5.6 (2.0) 5.3 (2.3) 5.5 (2.2)
Median (min., max.) 6.0 (1.0, 10.0) 6.0 (1.0, 10.0) 6.0 (1.0, 10.0)
Missing, n (%) 96 (36.2) 75 (28.7) 171 (32.5)
Max., maximum; min., minimum.
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These results were extracted from a mixed-effects model in which a participant was treated as a random
effect and observations over time (6 and 12 months) were nested within participant. The effect of
randomised treatment group was assessed while adjusting for time, group-by-time interaction, baseline
FTND score and baseline smoking severity (fixed effects), and site as a random effect. Different covariance
structures were applied to the model. An unstructured pattern that models all variances and covariances
separately resulted in the lowest AIC and so was used in the final model. Diagnostics of model fit revealed
that the standardised residuals were normally distributed and were uniform against fitted values; therefore,
data transformation was not required.
Motivation to Quit questionnaire
The MTQ score is summarised by randomised group and time point in Table 16. Adjusted MTQ means and
group differences are presented in Table 21 and displayed in Figure 7. The adjusted mean difference at
6 months was 0.58 (95% CI –0.01 to 1.17) and at 12 months was 0.64 (95% CI 0.04 to 1.24), both
marginally favouring the BSC group. The difference is almost statistically significant at the 5% level at
6 months (p = 0.06) and is below this level at 12 months (p = 0.04).
1
2
3
4
5
6
7
8
9
10
0
A
d
ju
st
e
d
 m
e
a
n
 F
T
N
D
 s
co
re
6 12
Assessment time point (months)
BSC intervention
Usual care
FIGURE 6 Adjusted means for the FTND by treatment group and time point.
TABLE 16 The MTQ scores by treatment group and time point
Time point MTQ BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Baseline Mean (SD) 13.9 (2.7) 13.7 (2.6) 13.8 (2.7)
Median (min., max.) 14.0 (6.0, 19.0) 14.0 (5.0, 19.0) 14.0 (5.0, 19.0)
Missing, n (%) 5 (1.9) 2 (0.8) 7 (1.3)
Month 6 Mean (SD) 13.2 (3.4) 12.4 (3.1) 12.8 (3.3)
Median (min., max.) 14.0 (4.0, 19.0) 12.0 (4.0, 19.0) 13.0 (4.0, 19.0)
Missing, n (%) 48 (18.1) 60 (23.0) 108 (20.5)
Month 12 Mean (SD) 13.0 (3.3) 12.3 (3.4) 12.6 (3.4)
Median (min., max.) 13.0 (5.0, 19.0) 13.0 (4.0, 19.0) 13.0 (4.0, 19.0)
Missing, n (%) 65 (24.5) 61 (23.4) 126 (24.0)
Max., maximum; min., minimum.
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These results were extracted from a mixed-effects model in which participant was treated as a random effect
and observations over time (6 and 12 months) were nested within participant. The effect of randomised
treatment group was assessed while adjusting for time, group-by-time interaction, baseline MTQ score and
baseline smoking severity (fixed effects), and site as a random effect. Different covariance structures were
applied to the model. A compound symmetric (or exchangeable) pattern that assumes equal correlation of
errors between each pair of time points within participants resulted in the lowest AIC and so was used in
the final model. Diagnostics of model fit revealed that the standardised residuals were normally distributed,
and were uniform against fitted values; therefore, data transformation was not required.
Patient Health Questionnaire-9 items
The PHQ-9 score is summarised by randomised group and time point in Table 17. Adjusted PHQ-9 means
and group differences are presented in Table 21 and displayed in Figure 8. The adjusted mean difference
at 6 months was 0.20 (95% CI –0.85 to 1.24), marginally favouring usual care, and at 12 months was
–0.12 (95% CI –1.18 to 0.94), marginally favouring BSC, but neither statistically significantly (p = 0.72 and
0.82, respectively).
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FIGURE 7 Adjusted means for the MTQ by treatment group and time point.
TABLE 17 The PHQ-9 scores by treatment group and time point
Time point PHQ-9 BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Baseline
Score
Mean (SD) 10.3 (6.7) 10.8 (6.6) 10.5 (6.6)
Median (min., max.) 10.0 (0.0, 27.0) 10.0 (0.0, 27.0) 10.0 (0.0, 27.0)
Missing, n (%) 1 (0.4) 1 (0.4) 2 (0.4)
How difficult,a n (%) n = 255 n = 254 n = 509
Not at all 65 (25.5) 64 (25.2) 129 (25.3)
Somewhat 106 (41.6) 111 (43.7) 217 (42.6)
Very 42 (16.5) 45 (17.7) 87 (17.1)
Extremely 42 (16.5) 34 (13.4) 76 (14.9)
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TABLE 17 The PHQ-9 scores by treatment group and time point (continued )
Time point PHQ-9 BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Month 6
Score
Mean (SD) 9.3 (6.7) 9.4 (6.4) 9.3 (6.6)
Median (min., max.) 8.0 (0.0, 27.0) 8.0 (0.0, 27.0) 8.0 (0.0, 27.0)
Missing, n (%) 42 (15.8) 47 (18.0) 89 (16.9)
How difficult,a n (%) n = 216 n = 210 n = 426
Not at all 67 (31) 56 (26.7) 123 (28.9)
Somewhat 89 (41.2) 98 (46.7) 187 (43.9)
Very 33 (15.3) 36 (17.1) 69 (16.2)
Extremely 27 (12.5) 20 (9.5) 47 (11)
Month 12
Score
Mean (SD) 9.0 (6.7) 9.7 (6.7) 9.3 (6.7)
Median (min., max.) 8.0 (0.0, 27.0) 9.0 (0.0, 27.0) 8.0 (0.0, 27.0)
Missing, n (%) 52 (19.6) 50 (19.2) 102 (19.4)
How difficult,a n (%) n = 206 n = 206 n = 412
Not at all 70 (34) 42 (20.4) 112 (27.2)
Somewhat 70 (34) 93 (45.1) 163 (39.6)
Very 47 (22.8) 47 (22.8) 94 (22.8)
Extremely 19 (9.2) 24 (11.7) 43 (10.4)
Max., maximum; min., minimum.
a If you checked off problems, how difficult have these problems made it for you to do your work, take care of things at
home, or get along with other people?
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FIGURE 8 Adjusted means for the PHQ-9 by treatment group and time point.
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These results were extracted from a mixed-effects model in which participant was treated as a random effect
and observations over time (6 and 12 months) were nested within participant. The effect of randomised
treatment group was assessed while adjusting for time, group-by-time interaction, baseline PHQ-9 score and
baseline smoking severity as fixed effects, and site as a random effect. Different covariance structures were
applied to the model. A compound symmetric (or exchangeable) pattern that assumes equal correlation
of errors between each pair of time points within participants resulted in the lowest AIC and so was used in
the final model. Diagnostics of model fit revealed that the standardised residuals were normally distributed,
and were uniform against fitted values; therefore, data transformation was not required.
Generalised Anxiety Disorder Assessment-7 items
The GAD-7 score is summarised by randomised group and time point in Table 18. Adjusted GAD-7 means
and group differences are presented in Table 21, and displayed in Figure 9. The adjusted mean difference
at 6 months was –0.32 (95% CI –1.26 to 0.62) and at 12 months was –0.10 (95% CI –1.05 to 0.86),
both marginally favouring BSC, but neither statistically significantly (p = 0.50 and 0.84, respectively).
These results were extracted from a mixed-effects model in which participant was treated as a random effect
and observations over time (6 and 12 months) were nested within participant. The effect of randomised
treatment group was assessed while adjusting for time, group-by-time interaction, baseline GAD-7 score
and baseline smoking severity as fixed effects, and site as a random effect. Different covariance structures
were applied to the model. A compound symmetric (or exchangeable) pattern that assumes equal
TABLE 18 The GAD-7 scores by treatment group and time point
Time point GAD-7 questionnaire BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Baseline
Score
Mean (SD) 8.4 (6.2) 8.4 (6.1) 8.4 (6.1)
Median (min., max.) 7.0 (0.0, 21.0) 8.0 (0.0, 21.0) 8.0 (0.0, 21.0)
Missing, n (%) 1 (0.4) 1 (0.4) 2 (0.4)
How difficult,a n (%) n = 249 n = 249 n = 498
Not at all 72 (28.9) 63 (25.3) 135 (27.1)
Somewhat 93 (37.3) 113 (45.4) 206 (41.4)
Very 53 (21.3) 41 (16.5) 94 (18.9)
Extremely 31 (12.4) 32 (12.9) 63 (12.7)
Month 6
Score
Mean (SD) 7.0 (5.9) 7.3 (5.8) 7.1 (5.9)
Median (min., max.) 6.0 (0.0, 21.0) 7.0 (0.0, 21.0) 6.0 (0.0, 21.0)
Missing, n (%) 41 (15.5) 44 (16.9) 85 (16.2)
How difficult,a n (%) n = 202 n = 197 n = 399
Not at all 70 (34.7) 52 (26.4) 122 (30.6)
Somewhat 73 (36.1) 86 (43.7) 159 (39.8)
Very 35 (17.3) 45 (22.8) 80 (20.1)
Extremely 24 (11.9) 14 (7.1) 38 (9.5)
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correlation of errors between each pair of time points within participants resulted in the lowest AIC and so
was used in the final model. Diagnostics of model fit revealed that the standardised residuals were normally
distributed, and were uniform against fitted values; therefore, data transformation was not required.
Short Form questionnaire-12 items
The SF-12 mental and physical health component subscale scores are summarised by randomised group
and time point in Table 19. Adjusted SF-12 means and group differences are presented in Table 21 and
displayed in Figure 10. The adjusted mean difference for the mental component score at 6 months was
–0.73 (95% CI –2.82 to 1.36) and at 12 months was –0.41 (95% CI –2.35 to 1.53), both marginally
favouring usual care, but neither statistically significantly (p = 0.49 and 0.68, respectively). The adjusted
mean difference for the physical component score at 6 months was 1.75 (95% CI 0.21 to 3.28), indicating
a statistically significant benefit of BSC (p = 0.03); however, this difference reduced at 12 months to 0.59
(95% CI –1.07 to 2.26) and was not statistically significant (p = 0.48).
TABLE 18 The GAD-7 scores by treatment group and time point (continued )
Time point GAD-7 questionnaire BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Month 12
Score
Mean (SD) 7.0 (6.3) 7.4 (6.0) 7.2 (6.2)
Median (min., max.) 5.0 (0.0, 21.0) 7.0 (0.0, 21.0) 6.0 (0.0, 21.0)
Missing, n (%) 51 (19.2) 49 (18.8) 100 (19.0)
How difficult,a n (%) n = 196 n = 202 n = 398
Not at all 62 (31.6) 51 (25.2) 113 (28.4)
Somewhat 74 (37.8) 88 (43.6) 162 (40.7)
Very 38 (19.4) 41 (20.3) 79 (19.8)
Extremely 22 (11.2) 22 (10.9) 44 (11.1)
Max., maximum; min., minimum.
a If you checked off problems, how difficult have these problems made it for you to do your work, take care of things at
home, or get along with other people?
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FIGURE 9 Adjusted means for the GAD-7 by treatment group and time point.
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TABLE 19 The SF-12 mental and physical health component scores by treatment group and time point
Time point SF-12 BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Mental component score
Baseline Mean (SD) 38.6 (12.6) 37.9 (11.7) 38.2 (12.2)
Median (min., max.) 37.2 (14.8, 63.5) 37.4 (14.4, 62.6) 37.4 (14.4, 63.5)
Missing, n (%) 8 (3.0) 5 (1.9) 13 (2.5)
Month 6 Mean (SD) 38.4 (13.1) 38.9 (12.2) 38.6 (12.6)
Median (min., max.) 37.1 (9.3, 64.4) 38.3 (14.3, 65.1) 37.9 (9.3, 65.1)
Missing, n (%) 51 (19.2) 53 (20.3) 104 (19.8)
Month 12 Mean (SD) 39.3 (11.9) 38.9 (11.9) 39.1 (11.9)
Median (min., max.) 38.7 (12.2, 65.6) 38.1 (12.4, 63.9) 38.3 (12.2, 65.6)
Missing, n (%) 53 (20.0) 54 (20.7) 107 (20.3)
Physical component score
Baseline Mean (SD) 43.7 (10.4) 42.2 (11.0) 43.0 (10.7)
Median (min., max.) 45.0 (17.0, 64.1) 42.0 (19.4, 62.1) 43.9 (17.0, 64.1)
Missing, n (%) 8 (3.0) 5 (1.9) 13 (2.5)
Month 6 Mean (SD) 45.6 (9.8) 42.9 (11.0) 44.3 (10.5)
Median (min., max.) 47.0 (22.7, 61.7) 43.4 (17.4, 63.8) 45.5 (17.4, 63.8)
Missing, n (%) 51 (19.2) 53 (20.3) 104 (19.8)
Month 12 Mean (SD) 44.3 (10.1) 42.4 (11.4) 43.3 (10.8)
Median (min., max.) 45.6 (20.2, 63.7) 44.1 (16.3, 61.3) 45.3 (16.3, 63.7)
Missing, n (%) 53 (20.0) 54 (20.7) 107 (20.3)
Max., maximum; min., minimum.
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FIGURE 10 Adjusted means for the SF-12 mental and physical health components by treatment group and time
point. (a) Mental; and (b) physical. MCS, mental component score; PCS, physical component score. (continued )
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These results were extracted from mixed-effects models in which participant was treated as a random
effect and observations over time (6 and 12 months) were nested within participant. The effect of
randomised treatment group was assessed while adjusting for time, group-by-time interaction, baseline
SF-12 mental/physical component score and baseline smoking severity as fixed effects, and site as a
random effect. Different covariance structures were applied to the model. An unstructured pattern that
models all variances and covariances separately resulted in the lowest AIC for both models and so was
used. Diagnostics of model fit revealed that the standardised residuals were normally distributed, and were
uniform against fitted values; therefore, data transformation was not required.
Body mass index
Body mass index is summarised by randomised group and time point in Table 20. Adjusted BMI means and
group differences are presented in Table 21 and displayed in Figure 11. The adjusted mean difference at
6 months was 0.16 (95% CI –0.54 to 0.85) and at 12 months was 0.25 (95% CI –0.62 to 1.13), both
marginally favouring usual care, but neither statistically significantly (p = 0.65 and 0.57, respectively).
0 6 12
Assessment time point (months)
BSC intervention
Usual care
30
32
34
36
38
40
42
44
46
48
50
(b)
A
d
ju
st
e
d
 m
e
a
n
 S
F
-1
2
 P
C
S
FIGURE 10 Adjusted means for the SF-12 mental and physical health components by treatment group and time
point. (a) Mental; and (b) physical. MCS, mental component score; PCS, physical component score.
TABLE 20 Body mass index by treatment group and time point
Time point BMI BSC (N= 265) Usual care (N= 261) Overall (N= 526)
Baseline Mean (SD) 30.2 (7.1) 29.7 (6.3) 29.9 (6.7)
Median (min., max.) 29.0 (16.6, 59.8) 29.4 (16.9, 48.4) 29.3 (16.6, 59.8)
Missing, n (%) 2 (0.8) 3 (1.1) 5 (1.0)
Month 6 Mean (SD) 30.5 (7.0) 29.9 (6.0) 30.2 (6.5)
Median (min., max.) 30.0 (14.8, 60.7) 29.1 (16.6, 48.5) 29.4 (14.8, 60.7)
Missing, n (%) 49 (18.5) 56 (21.5) 105 (20.0)
Month 12 Mean (SD) 30.4 (7.2) 29.7 (6.7) 30.0 (6.9)
Median (min., max.) 29.7 (0.0, 61.9) 29.3 (0.0, 45.8) 29.4 (0.0, 61.9)
Missing, n (%) 57 (21.5) 60 (23.0) 117 (22.2)
Max., maximum; min., minimum.
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TABLE 21 Adjusted means and group differences for continuous secondary outcomes
Time point BSC, mean (95% CI) Usual care, mean (95% CI) Difference (95% CI), SE p-value
FTND
Month 6 5.25 (5.00 to 5.50) 5.43 (5.19 to 5.67) –0.18 (–0.53 to 0.17), 0.18 0.32
Month 12 5.42 (5.14 to 5.70) 5.43 (5.16 to 5.69) –0.01 (–0.39 to 0.38), 0.20 0.97
MTQ
Month 6 13.1 (12.6 to 13.5) 12.5 (12.0 to 12.9) 0.58 (–0.01 to 1.17), 0.30 0.06
Month 12 12.9 (12.4 to 13.4) 12.3 (11.8 to 12.7) 0.64 (0.04 to 1.24), 0.31 0.04
PHQ-9
Month 6 9.6 (8.7 to 10.4) 9.4 (8.5 to 10.2) 0.20 (–0.85 to 1.24), 0.53 0.72
Month 12 9.3 (8.4 to 10.1) 9.4 (8.5 to 10.2) –0.12 (–1.18 to 0.94), 0.54 0.82
GAD-7
Month 6 7.0 (6.3 to 7.7) 7.4 (6.7 to 8.1) –0.32 (–1.26 to 0.62), 0.48 0.50
Month 12 7.1 (6.4 to 7.8) 7.2 (6.5 to 7.9) –0.10 (–1.05 to 0.86), 0.49 0.84
SF-12 MCS
Month 6 37.9 (36.2 to 39.5) 38.6 (36.9 to 40.3) –0.73 (–2.82 to 1.36), 1.07 0.49
Month 12 38.6 (37.0 to 40.1) 39.0 (37.4 to 40.5) –0.41 (–2.35 to 1.53), 0.99 0.68
SF-12 PCS
Month 6 45.2 (44.1 to 46.3) 43.5 (42.4 to 44.6) 1.75 (0.21 to 3.28), 0.78 0.03
Month 12 43.6 (42.4 to 44.8) 43.0 (41.8 to 44.2) 0.59 (–1.07 to 2.26), 0.85 0.48
BMI
Month 6 30.3 (29.8 to 30.8) 30.1 (29.6 to 30.6) 0.16 (–0.54 to 0.85), 0.35 0.65
Month 12 30.2 (29.5 to 30.8) 29.9 (29.3 to 30.5) 0.25 (–0.62 to 1.13), 0.45 0.57
MCS, mental component score; PCS, physical component score; SE, standard error.
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These results were extracted from a mixed-effects model in which the participant was treated as a random
effect and observations over time (6 and 12 months) were nested within participant. The effect of randomised
treatment group was assessed while adjusting for time, group-by-time interaction, baseline BMI and baseline
smoking severity as fixed effects, and site as a random effect. Different covariance structures were applied to
the model. An unstructured pattern that models all variances and covariances separately resulted in the lowest
AIC and so was used in the final model. Diagnostics of model fit revealed a minor violation: the ‘body’ (centre)
of the distribution of the standardised residuals was normal, but the distribution was short-tailed; however,
the residuals were uniform against fitted values. Data transformations of the outcome (log, square root and
square) did not substantially improve the model fit and so analyses were conducted on untransformed data.
Summary of results for secondary outcomes
Use of e-cigarettes and lifestyle data at 6 and 12 months
Participant-reported use of e-cigarettes and lifestyle data collected at 6 and 12 months are summarised in
Tables 22 and 23. Fifty-four per cent of randomised participants reported having ever tried an e-cigarette
at the 12-month time point (66.7% of those with valid response to this question). Of these, however,
most (64.7%) reported that they had not used an e-cigarette in the past month. Approximately half said
that their use of tobacco had not changed since they started to use e-cigarettes. Of those with valid data,
59.0% of the BSC group and 56.6% of the usual-care group reported leading a fairly or very healthy life at
6 months. Of those with valid data, 57.1% of the BSC group and 56.8% of the usual-care group reported
leading a fairly or very healthy life at 12 months. At month 12, a similar proportion of participants in each
group reported that they drank alcohol (48.4% in the BSC group and 47.7% in the usual-care group),
with the BSC group consuming an average of 8.7 units in the last week (11.9 units in the usual-care group).
TABLE 22 Use of e-cigarettes at 6 and 12 months by randomised group
Characteristic, n (%)
Month 6 Month 12
BSC
(N= 265)
Usual care
(N= 261)
Overall
(N= 526)
BSC
(N= 265)
Usual care
(N= 261)
Overall
(N= 526)
Ever tried an e-cigarette
Yes 157 (59.3) 155 (59.4) 312 (59.3) 135 (50.9) 151 (57.9) 286 (54.4)
No 69 (26.0) 59 (22.6) 128 (24.3) 79 (29.8) 64 (24.5) 143 (27.2)
Missing 39 (14.7) 47 (18.0) 86 (16.4) 51 (19.3) 46 (17.6) 97 (18.4)
If yes: n = 157 n = 155 n = 312 n = 135 n = 151 n = 286
Use of e-cigarette in last 30 days
Never 86 (54.8) 98 (63.2) 184 (59.0) 89 (65.9) 96 (63.6) 185 (64.7)
Less than once per week 14 (8.9) 12 (7.7) 26 (8.3) 6 (4.4) 11 (7.3) 17 (5.9)
Less than daily but at least once
per week
21 (13.4) 13 (8.4) 34 (10.9) 11 (8.1) 17 (11.3) 28 (9.8)
Every day 36 (22.9) 32 (20.6) 68 (21.8) 28 (20.7) 27 (17.9) 55 (19.2)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0) 1 (0.3)
Length of use of e-cigarettes
< 1 month 48 (30.6) 56 (36.1) 104 (33.3) 36 (26.7) 39 (25.8) 75 (26.2)
1–6 months 30 (19.1) 30 (19.4) 60 (19.2) 25 (18.5) 36 (23.8) 61 (21.3)
6–12 months 21 (13.4) 16 (10.3) 37 (11.9) 23 (17.0) 22 (14.6) 45 (15.7)
> 1 year 40 (25.5) 40 (25.8) 80 (25.6) 37 (27.4) 36 (23.8) 73 (25.5)
Missing 18 (11.5) 13 (8.4) 31 (9.9) 14 (10.4) 18 (11.9) 32 (11.2)
continued
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TABLE 22 Use of e-cigarettes at 6 and 12 months by randomised group (continued )
Characteristic, n (%)
Month 6 Month 12
BSC
(N= 265)
Usual care
(N= 261)
Overall
(N= 526)
BSC
(N= 265)
Usual care
(N= 261)
Overall
(N= 526)
Nicotine levels in cartridges used in e-cigarette
None (0 mg) 6 (3.8) 10 (6.5) 16 (5.1) 4 (3.0) 6 (4.0) 10 (3.5)
Low (< 8mg) 22 (14) 25 (16.1) 47 (15.1) 28 (20.7) 39 (25.8) 67 (23.4)
Medium (8–16mg) 39 (24.8) 41 (26.5) 80 (25.6) 39 (28.9) 32 (21.2) 71 (24.8)
High (> 16mg) 34 (21.7) 37 (23.9) 71 (22.8) 28 (20.7) 40 (26.5) 68 (23.8)
Missing 56 (35.7) 42 (27.1) 98 (31.4) 36 (26.7) 34 (22.5) 70 (24.5)
Use of tobacco changed since using e-cigarettes
Yes, I smoke less tobacco 70 (44.6) 61 (39.4) 131 (42.0) 63 (46.7) 56 (37.1) 119 (41.6)
Yes, I smoke more tobacco 4 (2.5) 9 (5.8) 13 (4.2) 4 (3.0) 3 (2.0) 7 (2.4)
No, it has not changed 65 (41.4) 75 (48.4) 140 (44.9) 55 (40.7) 78 (51.7) 133 (46.5)
Missing 18 (11.5) 10 (6.5) 28 (9.0) 13 (9.6) 14 (9.3) 27 (9.4)
Reason started using e-cigarettes
To quit smoking tobacco 67 (42.7) 71 (45.8) 138 (44.2) 74 (54.8) 84 (55.6) 158 (55.2)
To try a safer alternative to
tobacco
28 (17.8) 18 (11.6) 46 (14.7) 16 (11.9) 12 (7.9) 28 (9.8)
To try something new 18 (11.5) 9 (5.8) 27 (8.7) 7 (5.2) 18 (11.9) 25 (8.7)
To smoke less tobacco 23 (14.6) 33 (21.3) 56 (17.9) 21 (15.6) 20 (13.2) 41 (14.3)
Other 11 (7.0) 14 (9.0) 25 (8.0) 10 (7.4) 9 (6.0) 19 (6.6)
Missing 10 (6.4) 10 (6.5) 20 (6.4) 7 (5.2) 8 (5.3) 15 (5.2)
TABLE 23 Lifestyle data at 6 and 12 months by randomised group
Characteristic
Month 6 Month 12
BSC
(N= 265)
Usual care
(N= 261)
Overall
(N= 526)
BSC
(N= 265)
Usual care
(N= 261)
Overall
(N= 526)
Healthy life, n (%)
A very healthy life 18 (6.8) 7 (2.7) 25 (4.8) 12 (4.5) 12 (4.6) 24 (4.6)
A fairly healthy life 116 (43.8) 117 (44.8) 233 (44.3) 113 (42.6) 109 (41.8) 222 (42.2)
A not very healthy life 72 (27.2) 72 (27.6) 144 (27.4) 70 (26.4) 71 (27.2) 141 (26.8)
An unhealthy life 21 (7.9) 23 (8.8) 44 (8.4) 24 (9.1) 21 (8.0) 45 (8.6)
Missing 38 (14.3) 42 (16.1) 80 (15.2) 46 (17.4) 48 (18.4) 94 (17.9)
Eat five portions of fruit and vegetables a day, n (%)
Yes 107 (40.4) 104 (39.8) 211 (40.1) 109 (41.1) 100 (38.3) 209 (39.7)
No 121 (45.7) 114 (43.7) 235 (44.7) 110 (41.5) 115 (44.1) 225 (42.8)
Missing 37 (14.0) 43 (16.5) 80 (15.2) 46 (17.4) 46 (17.6) 92 (17.5)
Exercise for ≥ 20 minutes, n (%)
Daily 94 (35.5) 94 (36.0) 188 (35.7) 98 (37.0) 77 (29.5) 175 (33.3)
Weekly 61 (23.0) 42 (16.1) 103 (19.6) 61 (23.0) 60 (23.0) 121 (23.0)
Monthly 3 (1.1) 6 (2.3) 9 (1.7) 4 (1.5) 6 (2.3) 10 (1.9)
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Compliance with intervention
Intervention session attendance
A total of 1654 treatment sessions were arranged for 238 of the 265 intervention participants between
November 2015 and December 2017, of which 1483 (89.7%) were attended. A total of 48 sessions
were cancelled and in 123 cases the participant did not attend the session (Table 24). Overall, 234 out
of the 265 intervention participants (88.3%) attended at least one treatment session (the remaining
27 did not partake in any intervention sessions as they withdrew from the trial or were unwell). For these
234 participants, the mean number of sessions attended was 6.4 (SD 3.5, median 6, range 1–14). Sessions
lasted an average of 39.4 minutes (SD 17.2 minutes, median 35, range 5–120 minutes). Most (85.0%)
sessions took place face to face, 4.1% took place over the telephone and 10.9% took place via another
mode. The majority (81.1%) took place at the participant’s home.
Complier-average causal effect analysis
The CACE estimate of attending one additional intervention session was a small, non-statistically
significant, increase in the likelihood of being a CO-verified quitter at 12 months (OR 1.07, 95% CI 0.97 to
1.18; p = 0.20).
Use of usual-care stop smoking services
The most used usual-care smoking cessation services were consultations with the GP, the pharmacist and
the SSS. In the first 6 months of the trial, 100 out of the 212 responders (47.2%) in the usual-care group
reported not using any of them, while 144 out of the 218 responders (66.1%) in the intervention group
reported having used them. Among those who reported any use, the mean number of consultations was
2.8 (SD 3.5, median 2, range 1–31) in the usual-care group and 3.3 (SD 2.8, median 2, range 1–13) in the
intervention group. In the second half of the trial, 142 out of 213 responders (66.7%) in the usual-care
group reported not using any of the three services, while 141 out of 213 responders (66.2%) in the
intervention group reported so. Among those who reported any use, the mean number of consultations
was 3.3 (SD 3.4, median 2, range 1–18) in the usual-care group and 2.7 (SD 3.2, median 2, range 1–24) in
the intervention group. Participants also reported consulting with other health-care professionals, such as
practice nurse and health-care assistant, but these were rare cases.
TABLE 23 Lifestyle data at 6 and 12 months by randomised group (continued )
Characteristic
Month 6 Month 12
BSC
(N= 265)
Usual care
(N= 261)
Overall
(N= 526)
BSC
(N= 265)
Usual care
(N= 261)
Overall
(N= 526)
Seldom 30 (11.3) 25 (9.6) 55 (10.5) 21 (7.9) 36 (13.8) 57 (10.8)
Never 40 (15.1) 51 (19.5) 91 (17.3) 35 (13.2) 35 (13.4) 70 (13.3)
Missing 37 (14.0) 43 (16.5) 80 (15.2) 46 (17.4) 47 (18.0) 93 (17.7)
Drink alcohol, n (%)
Yes 119 (44.9) 106 (40.6) 225 (42.8) 106 (40.0) 103 (39.5) 209 (39.7)
No 110 (41.5) 113 (43.3) 223 (42.4) 113 (42.6) 113 (43.3) 226 (43.0)
Missing 36 (13.6) 42 (16.1) 78 (14.8) 46 (17.4) 45 (17.2) 91 (17.3)
If yes, units in last week
Mean (SD) 10.2 (18.5) 9.9 (18.3) 10.0 (18.4) 8.7 (11.5) 11.9 (27.2) 10.3 (20.8)
Median (min., max.) 5 (0, 164) 4 (0, 126) 4 (0, 164) 4 (0, 58) 4 (0, 220) 4 (0, 220)
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Max., maximum; min., minimum.
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TABLE 24 Intervention details for the BSC group
Intervention details BSC (N= 265)
Number of sessions attended, n (%)
0 31 (11.7)
1 19 (7.2)
2 23 (8.7)
3 23 (8.7)
4 22 (8.3)
5 16 (6.0)
6 15 (5.7)
7 16 (6.0)
8 25 (9.4)
9 24 (9.1)
10 22 (8.3)
11 12 (4.5)
12 12 (4.5)
13 3 (1.1)
14 2 (0.8)
Attended at least one session 234 (88.3)
Number of sessions attended
Mean (SD) 6.3 (3.5)
Median (min., max.) 6 (1, 14)
Total number of sessions attended 1483
Length of sessions (minutes)
Mean (SD) 39.6 (17.2)
Median (min., max.) 35 (5, 120)
Mode, n (%)
Face to face 1260 (85.0)
Telephone 61 (4.1)
Other 156 (10.5)
Missing 6 (0.4)
Location, n (%)
Home 1202 (81.1)
Other 276 (18.6)
Missing 5 (0.3)
Max., maximum; min., minimum.
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Withdrawals
Some of the information reported in this section is given in Peckham et al.1 This contains information
licensed under the Non-Commercial Government Licence v2.0.
There were four categories of participant withdrawal:
1. Full withdrawal – participant withdrawn from the trial with regard to completion of both postal
questionnaires and collection of GP data.
2. Withdrawal from follow-up – participant withdrawn from the completion of postal questionnaires but
agreed to the continuing collection of GP data.
3. Withdrawal from treatment – participant withdrawn from trial intervention treatment, but agreed to
continuing completion of postal questionnaires and collection of GP data.
4. Too unwell to continue – participant was deemed too unwell by medical staff to complete any
questionnaires. This generally occurred only when a participant has been hospitalised.
Overall, there were 93 (17.7%) participant withdrawals (all types) during the trial: 23 participants (8.8%)
from the usual-care group and 70 participants (26.4%) from the BSC group.
A total of 47 participants (8.9%) withdrew fully from the trial, two participants (0.4%) withdrew from
follow-up, two (0.4%) were too unwell to continue and 42 (15.8%) withdrew from the intervention
(Table 25).
Adverse events
There were 365 adverse events among 174 participants during the course of the trial. Of these, 111 were
classed as serious. More participants in the BSC group (42.1%) experienced one or more adverse events
than those in the usual-care group (24.5%). All adverse events (n = 58) that were deemed to be definitely
or probably related to the intervention or trial participation were all non-serious adverse events (Table 26).
This includes three events, related to NRT side effects, which were experienced by usual-care participants
as part of a routine care quit attempt.
Of the 111 serious adverse events reported, the majority were related to unplanned hospital admission
due to a deterioration in the participant’s mental health condition (n = 98). The remaining serious adverse
events were associated with unplanned hospital admissions associated with comorbidities (n = 6) or death
(n = 7). The one event deemed to be possibly related was an inpatient hospitalisation due to infective
chronic obstructive pulmonary disease.
TABLE 25 Withdrawals by type
Withdrawals type Usual care BSC Total
Full withdrawal 21 26 47a
Withdrawal from follow-up 1 1 2
Withdrawal from treatment 0 42 42
Too unwell to continue 1 1 2
Total 23 70 93
a Includes five participants who initially withdrew from treatment and subsequently withdrew in full.
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Of the 254 non-serious adverse events reported, the majority of events were associated with participant
comorbidities (n = 124). Sixty-six events were associated with NRT side effects and 57 with the participant’s
mental ill health. Of the remaining events, five were associated with accident and emergency or emergency
ambulance use, but no information was available with regard to the reasons for this and two were unable
to be classified (smoking teabags, n = 1; media coverage of family member, n = 1). Of the 56 events deemed
to be probably related, the majority were associated with NRT side effects (n = 50) and of those possibly
related, the majority were associated with participant comorbidities (n = 14). The two events deemed to be
definitely related were both associated with NRT side effects (nausea following Champix use, n = 1; itching
and redness caused by NRT patch, n = 1).
Summary of findings
Attempts were made to contact a total of 1606 people for eligibility and consent to partake in the trial,
of which 526 were randomised (a rate of 33%). A primary reason for ineligibility, besides being unable to
contact the person and non-consent, was that the person did not smoke or did not smoke at least five
tobacco cigarettes a day. Over two-thirds of the participants were recruited from CMHT direct referral
(72%). Between October 2015 and December 2016, 265 participants were randomised to BSC and
261 participants were randomised to usual care. This was over our original sample size target of 400 participants.
Almost 60% of the participants were male and the average age was 46 years (range 19–72 years). The most
common mental health diagnosis was schizophrenia or other psychotic illness (65%), followed by bipolar
disorder (22%) and schizoaffective disorder (12%). The mean number of cigarettes smoked per day at
baseline was 25, and the most commonly reported reasons for wanting to quit smoking were that it is bad
for your health (88%) and is expensive (72%).
Retention rates in the trial were high. At the primary time point of 12 months, 450 (94%) of the 480
participant questionnaires intended to be completed were returned (86% of 526 randomised participants),
with most (98%) being completed face to face with the MH-SCP. In total, 442 participants were included
in the primary analysis (i.e. provided a CO breath measurement and completed the self-reported smoking
TABLE 26 Relationship of adverse events to trial procedures
Adverse event Relationship BSC Usual care Total
Serious adverse event Definitely related 0 0 0
Probably related 0 0 0
Possibly related 1 0 1
Unlikely to be related 36 18 54
Unrelated 31 24 55
Unclassifieda 1 0 1
Non-serious adverse event Definitely related 2 0 2
Probably related 53 3b 56
Possibly related 28 3 31
Unlikely to be related 52 33 85
Unrelated 56 24 80
Total 260 105 365
a One serious adverse event unclassified (participant deceased, no cause of death available).
b Side effects related to use of NRT as part of usual-care quit attempt.
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status question on the 12-month participant questionnaire). A total of 34 out of 223 participants (15%;
13% of 265 randomised participants) fulfilled the definition for CO-verified smoking cessation in the
BSC group, and 22 out of 219 participants (10%; 8% of 261 randomised participants) in the usual-care
group. Therefore, participants in the BSC group were more likely to be a CO-verified 1-week quitter at
12 months post randomisation than participants in the usual-care group, but this difference was not
statistically significant (OR 1.6, 95% CI 0.9 to 2.8; p = 0.12). A larger difference was, however, observed
at the 6-month time point and this was statistically significant (OR 2.4, 95% CI 1.2 to 4.7; p = 0.01),
perhaps suggesting an early benefit of the intervention, which waned over time.
The trial was originally powered at 80% to detect a relative increase of 1.7 in quitting from 20% in the
usual-care group to 34% in the BSC group, allowing for a 20% loss to follow-up at 12 months. Ultimately,
526 participants were randomised and 442 (84%) were included in the primary analysis, so the loss to
follow-up rate was lower than 20%. However, the quit rate was half that expected in the usual-care
group (10% as opposed to 20%); therefore, the power needed to detect a relative increase in quit rate
of 1.7 (to 17% in the BSC group) was ultimately 58%. Although this was not statistically significant at
12 months, the difference (10% vs. 15%) may still be clinically meaningful.
The primary result was robust to sensitivity checks, both the pre-planned and post hoc analyses, and similar
results were seen when considering only self-reported smoking cessation. There was no evidence of a
difference between the two groups in secondary outcomes at any time point except for the MTQ, which
statistically significantly favoured the BSC group at 12 months, with a borderline p-value of 0.06 at
6 months. The physical component of the SF-12 also statistically significantly favoured the BSC group at
6 months (but not at 12 months).
The proportion of participants reporting that they had ever used e-cigarettes remained reasonably stable
throughout the trial, as did the proportion reporting use in the previous month, suggesting that e-cigarettes
were not frequently used as a NRT for those attempting to quit in the trial.
The uptake of the BSC intervention was reasonable, with 88% of participants randomised to the BSC
group attending at least one session (median 6, range 1–14 sessions). The majority of sessions took place
in the participants’ homes.
A total of 111 serious adverse events were reported in the trial and more participants in the BSC group
(42%) reported one or more adverse events than in the usual-care group (25%); however, none of the
SAEs was deemed to be related to trial participation.
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Chapter 5 Health economic analysis
Costs
Intervention costs
Training and supervision
The initial training session delivered by the NCSCT was invoiced at a total of £5325. The opportunity
cost for time attended by team members was estimated at £43 per hour59 for 15 hours, costing £2589.
The 2-day training sessions for the MH-SCPs were delivered by two trainers at £43 per hour,59 costing
£1290. In total, eight 2-day training sessions were held, amounting to £10,320. The time costs spent by
the practitioners were costed at £28 per hour,59 resulting in £23,520 for 56 people for 2 days in total. The
total printing cost was recorded as £105. Therefore, the total training costs were £41,850. The training
costs were then allocated evenly to the participants in the BSC group. Training costs per participant were
therefore estimated at £158.
Supervisors recorded the supervision sessions and estimated approximately 30 minutes of supervision per
participant. The cost of supervision was estimated at £22 per participant. The first-year depreciation value
of 56 CO monitors was £6720. It gave a cost of £10 per participant. In total, training, supervision and
material cost per participant was £190 in the BSC group.
The control treatment was usual care that required no special training. The costs of training and
supervision were considered zero for the usual-care group.
Intervention delivery
There were two parts of intervention delivery: (1) the BSC session in the BSC group and (2) usual care in
both groups.
Bespoke smoking cessation delivery in the bespoke smoking cessation group
Attendance of bespoke smoking cessation sessions For the BSC support sessions, among the
265 participants randomised to the BSC group, two participants attended one session but the session
records were missing. There were 27 participants who had withdrawn or been otherwise uncontactable
before the treatment began, and four participants who had been contacted but failed to attend the first
support session.
Among the 231 participants who had at least one support session, 28% attended one to three support
sessions, 22% attended four to six support sessions, 28% attended seven to nine support sessions, and
22% attended ≥ 10 sessions. There were 1481 sessions delivered in total. The duration of the sessions
varied hugely, ranging from 5 minutes to 120 minutes. There were 695 (47%) sessions that lasted
5–30 minutes and 715 (48%) sessions that lasted 35–60 minutes. There were 65 (4%) sessions that lasted
65–90 minutes and only six sessions (< 1%) that were > 90 minutes.
For each attended session, an estimated 10 minutes of administration time was added to account for
the necessary paperwork for the session. There were 1370 appointments that entailed travel by the
practitioners, including some of the did not attend (DNA) or late cancellation. Owing to the difficulty in
collecting travel time for all individual appointments, an estimated 40 minutes of travel time for a return
journey was added to the appointments that required travelling.
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There were 149 participants who recorded no DNA or cancellation during the trial period and 89 participants
who recorded 171 occasions of DNA/cancellation, the majority of whom recorded only once (47/89). Once a
DNA or cancellation occurred, attempts were often made to re-establish contact or reschedule appointments.
The time spent on these attempts ranged from 5 to 30 minutes per DNAs/cancellations but it should be
noted that not all DNAs/cancellations entailed this staff time. The majority (87%) of these attempts were
within 10 minutes.
Mean cessation session time and cost in the bespoke smoking cessation group In total, among
the 263 participants whose session data were not missing, the mean number of attended sessions was
5.6 (SD 3.8) per participant and the duration of total session time per participant was 222 minutes (SD
166 minutes, range 0–775 minutes). The total time on rearrangement in the case of DNA/cancellation was
5 minutes (SD 10 minutes, range 0–65 minutes) per participant, while the mean number of DNAs/cancellations
was 1 (SD 1). The total travel time per participant was 208 minutes (SD 155 minutes, range 0–560 minutes).
The total administration time per participant was 56 minutes (SD 38 minutes, range 0–140 minutes).
Excluding the two participants whose session data were missing, the mean total BSC delivery time was
492 minutes (SD 339 minutes, range 0–1425 minutes) per participant in the BSC group. Applying an hourly
cost of £28, the mean cost of BSC delivery was estimated at £229 (SD £158).
Usual-care delivery in both groups
Mean use and cost of usual-care services for smoking cessation based on structured questions
For usual GP care, both groups reported asking for help/advice for smoking cessation from GPs, pharmacists,
SSSs and stop smoking helplines. The mean usage was low in both groups, with large standard deviation,
indicating a wide variance on a participant level (Table 27). The usage of individual services did not appear
to differ between groups, except for SSS. The mean usage of SSSs in the usual-care group was twice as
high as that in the BSC group in months 1–6 post randomisation. In months 7–12 post randomisation, the
mean usage of SSSs was still higher in the usual-care group than in the BSC group, but not as considerable.
TABLE 27 Mean usage and mean cost of usual GP care services based on structured questions, by group
Usual GP care services Unit cost
BSC UC
Mean usage
(SD)
Mean
cost (SD)
Mean usage
(SD)
Mean
cost (SD)
Months 1–6 n = 218 n = 212
Cessation consultation with GP £40/session 0.50 (1.38) £20 (£55) 0.62 (1.65) £22 (£46)
Cessation consultation with pharmacist £7/session 0.35 (1.00) £2 (£7) 0.33 (1.78) £2 (£12)
Smoking cessation service £19/session 0.27 (1.07) £5 (£20) 0.62 (1.65) £12 (£31)
NHS stop smoking helpline £7/call 0.07 (0.54) £1 (£4)a 0.08 (0.38) £1 (£3)
Total – £28 (£62)a – £37 (£60)
Months 7–12 n = 213 n = 213
Cessation consultation with GP £40/session 0.35 (1.09) £14 (£43) 0.36 (0.96) £14 (£38)
Cessation consultation with pharmacist £7/session 0.22 (0.75) £2 (£5) 0.28 (0.88) £2 (£6)
Smoking cessation service £19/session 0.35 (1.81) £7 (£34) 0.45 (1.60) £8 (£30)
NHS stop smoking helpline £7/call 0.02 (0.14)b £0 (£1)b 0.08 (0.47)b £1 (£3)b
Total – £22 (£56)c – £25 (£59)
a n = 217.
b n = 214.
c n = 212.
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The mean cost of these services for smoking cessation was £37 (SD £60) per participant among the
212 responders in the usual-care group and £28 (SD £62) per participant among the 217 responders in
the BSC group in months 1–6 post randomisation. In months 7–12 post randomisation, the mean cost of
these services for smoking cessation was £25 (SD £59) per participant among the 213 responders in the
usual-care group, and £22 (SD £56) per participant among the 212 responders in the BSC group.
Mean use and cost of usual-care services for smoking cessation based on open questions In addition
to responses to the structured questions, there were individual participants who reported asking for help/
advice from community psychiatric nurses, practice nurses, support workers, family therapists, hospital nurses,
psychiatrists and dentists. The report of these service uses was rare, with only one or two participants in
one group.
Costing was undertaken for a 10-minute brief advice session for stop smoking as equivalent to the length
of opportunistic brief advice session by GPs and practice nurses;59 the unit costs of these SSSs are shown in
Table 30. Applying the unit, an estimated cost was calculated and added to the costs estimated from the
structured questions.
Mean total cost of usual-care services for smoking cessation in both groups Accounting for both
structured and open questions, the mean cost of usual care for SSSs was £37 (SD £60) per participant
among the 212 responders in the usual-care group and £28 (SD £62) per participant among the 217
responders in the BSC group, during months 1–6 post randomisation. The mean cost of usual care for
SSSs was £26 (SD £59) per participant among the 213 responders in the usual-care group and £23
(SD £56) per participant among the 212 responders in the BSC group, during months 7–12 post
randomisation.
Participants’ prescription of pharmacotherapies for smoking cessation Practices were contacted
to extract participants’ prescription information on pharmacotherapies for smoking cessation. The
prescription information for 160 (61%) participants was returned in the usual-care group and the
prescription information for 156 (59%) participants was returned in the BSC group. Of the participants
with returned data collection, 45 participants in the usual-care group and 100 participants in the BSC
group recorded being prescribed pharmacotherapies at some point during the trial period. There were
four participants in the usual-care group and 17 participants in the BSC group who had prescription
data insufficient for cost estimation.
Therefore, the mean NIC of pharmacotherapy prescription was £26 (SD £73) per participant among the
156 respondents in the usual-care group and £92 (SD £198) per participant among the 139 respondents
in the BSC group.
Health-care and social services costs
Mean use of emergency and hospital services Table 28 presents the number of participants who
responded to the questions regarding emergency and hospital services, and their mean use of each service.
More than 80% of the participants in either group responded to the questions at either follow-up.
In months 1–6 post randomisation, the usual-care group reported nearly twice as many hospital admissions
as the BSC group among the responders, both in number of times (0.14 vs. 0.08) and number of nights
(1.59 vs. 0.88), while the BSC group reported nearly twice as many use of emergency ambulance as the
usual-care group (0.28 vs. 0.15). In months 7–12 post randomisation, the usual-care group reported
many more hospital admissions than the BSC group (0.80 vs. 0.13). However, the relatively large SD (8.68)
of the mean number of admissions in the usual-care group indicated that there was a small group of
responders being admitted frequently.
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Mean use of primary and community services Over 80% of the participants in either group responded
to the questions regarding the primary and community services at follow-ups. The mean use of the services
was generally lower than once per responder in both groups with a few exceptions (Table 29). The highest
mean usage was reported for community psychiatric nurse, with over five times in the usual-care group in
both follow-up periods and over six times in the BSC group. This was followed by CMHT visits. The mean
number of visits by CMHT was close to five per responder in the usual-care group throughout the trial
period. In the BSC group, the mean number of visits was over five per responder in months 1–6 and over
four per responder in months 7–12. The third highest used service was day care. Both groups reported a
mean number of use over three times during a 6-month period. Both groups reported over two visits to
a GP in surgery during a 6-month period and over one visit to a practice nurse. The large SDs indicated a
skewed distribution of service use.
TABLE 28 Number of responders and their mean use (SD) of emergency services and hospital services, by group
Services
BSC Usual care
Months 1–6 Months 7–12 Months 1–6 Months 7–12
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
A&E department 218 0.39 (0.81) 211 0.34 (0.80) 212 0.37 (0.95) 209 0.43 (0.96)
Hospital admission
Times 221 0.08 (0.29) 211 0.13 (0.51) 214 0.14 (0.58) 209 0.80 (6.24)
Nights 219 0.88 (6.77) 212 1.00 (4.68) 210 1.59 (10.61) 208 1.58 (8.68)
Hospital outpatient appointment 217 1.40 (2.79) 212 1.43 (3.15) 213 1.72 (4.04) 208 1.66 (3.49)
Day case/procedure 219 0.13 (0.57) 211 0.18 (0.70) 213 0.14 (0.43) 209 0.12 (0.42)
Emergency ambulance 219 0.28 (0.73) 213 0.22 (0.67) 215 0.15 (0.43) 210 0.25 (1.32)
A&E, accident and emergency.
TABLE 29 Mean use (SD) of primary and community services in months 1–6 and months 7–12, respectively,
by group
Services
BSC Usual care
Months 1–6
(n= 220)
Months 7–12
(n= 214)
Months 1–6
(n= 214)
Months 7–12
(n= 213)
GP home visit 0.21 (1.14) 0.20 (0.87) 0.26 (1.43) 0.29 (1.39)
GP surgery 2.34 (2.97) 2.37 (3.46) 2.63 (3.69) 2.69 (3.69)
GP telephone 0.51 (1.39) 0.61 (1.70) 0.73 (2.21) 0.56 (1.26)
Practice nurse 1.16 (2.38) 1.06 (2.19) 1.42 (2.93) 1.15 (2.28)
District nurse 0.20 (1.36) 0.07 (0.60) 0.17 (1.07) 0.20 (1.53)
Community psychiatric nurse 6.25 (10.58) 6.33 (10.55) 5.24 (7.13) 5.48 (10.80)
Health visitor 0.17 (1.79) 0.15 (1.76) 0.19 (1.30) 0.89 (12.33)
Clinical psychologist 1.05 (3.77) 0.65 (2.97) 0.81 (3.47) 0.58 (1.99)
NHS counsellor 0.29 (2.21) 0.12 (1.64) 0.18 (1.24) 0.05 (0.44)
NHS dentist 0.63 (1.20) 0.78 (1.33) 0.74 (1.54) 0.79 (1.42)
Podiatrist 0.26 (0.81) 0.20 (0.71) 0.22 (0.76) 0.15 (0.61)
Occupational therapist 0.64 (3.53) 0.72 (5.33) 0.32 (1.48) 0.49 (2.60)
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Other services reported by open question In addition to the structured service questions, there were
a few participants who reported other services used. These included support worker, psychotherapist,
specialist nurse, art therapist, forensic community team, health-care assistant, rehabilitation facility, outreach
team, phlebotomist and midwife. The most reported service was support worker. There were 11 participants
who reported 578 visits in months 1–6 in the usual-care group and 12 participants who reported 1498 visits
in the BSC group. In months 7–12, there were nine participants who reported 611 visits in the usual-care
group and nine participants in the BSC group reported 994 visits. Some of these participants reported daily
visits by a support worker during the entire period. There was one participant in the usual-care group who
stayed in a rehabilitation facility for 171 days and another reported 24 visits to a psychotherapist. The other
services were reported by only one or two participants for no more than 10 visits.
According to the additional services reported by the participants, the corresponding unit costs were
estimated from published resources (Table 30).
Summary of costs of health-care and social services use Applying the unit costs to the quantities
reported, the estimated costs of emergency and hospital services were £1443 (SD £6470) per responder in
the usual-care group and £932 (SD £4228) per responder in the BSC group in months 1–6 post randomisation
(Table 31). The estimated costs of primary and community care were £2367 (SD £2893) per responder in the
usual-care group and £2529 (SD £3178) per responder in the BSC group in months 1–6 post randomisation.
In months 7–12 post randomisation, the estimated costs of emergency and hospital services were £1317
(SD £5330) per responder in the usual-care group and £953 (SD £3027) per responder in the BSC group.
During the same period, the estimated costs of primary and community care were £2303 (SD £3234) per
responder in the usual-care group and £2429 (SD £3458) per responder in the BSC group.
Participants’ prescription of antipsychotics Practices were contacted to extract participants’ prescription
information on antipsychotic medication. There were 223 (85%) participants for whom prescription information
was returned in the usual-care group and 229 (86%) participants for whom prescription information was
returned in the BSC group. Of the participants with returned data collection, 207 participants in the usual-care
group and 219 participants in the BSC group recorded being prescribed antipsychotics at some point during
the trial period. There were 28 participants in the usual-care group and 25 participants in the BSC group who
had prescription data that were insufficient for cost estimation. Therefore, the mean NIC of antipsychotic
prescription was £736 (SD £1081) per participant among the 195 respondents in the usual-care group and
TABLE 29 Mean use (SD) of primary and community services in months 1–6 and months 7–12, respectively,
by group (continued )
Services
BSC Usual care
Months 1–6
(n= 220)
Months 7–12
(n= 214)
Months 1–6
(n= 214)
Months 7–12
(n= 213)
Physiotherapist 0.22 (1.83) 0.20 (1.23) 0.19 (1.00) 0.23 (1.27)
CBT 0.19 (1.26) 0.38 (2.27) 0.50 (3.11) 0.18 (1.85)
MBCT 0.24 (1.51) 0.69 (8.26) 0.19 (1.75) 0.13 (0.82)
Crisis team 0.47 (2.41) 1.10 (5.02) 0.59 (2.09) 0.62 (2.04)
CMHT 5.67 (10.54) 4.74 (10.77) 4.91 (8.17) 4.98 (8.31)
Day care service 3.72 (19.56) 4.14 (23.97) 3.64 (19.46) 3.54 (20.89)
Social worker 1.66 (12.68) 0.68 (2.56) 1.23 (5.96) 0.73 (2.62)
Family support worker 0.12 (1.02) 0.76 (7.92) 1.48 (13.17) 1.20 (10.44)
Drug/alcohol support worker 0.73 (8.15) 0.23 (1.68) 0.37 (2.59) 0.46 (2.52)
CBT, cognitive–behavioural therapy; MBCT, mindfulness-based cognitive therapy.
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£820 (SD £1296) per participant among the 204 respondents in the BSC group, including those reported
for whom no antipsychotics were prescribed.
Wider societal costs
Other sources of smoking cessation advice
In addition to the smoking cessation services provided by the NHS and Personal Social Services, the participants
reported their use of other sources of help. These included a smoking cessation helpline run by non-NHS
TABLE 30 Unit cost of other health-care personnel for stop smoking advice, and other health care and social
services reported by the participants
Services Unit cost (2016/17) Sources
Other health-care personnel for stop smoking advice
Community psychiatric nurse £6/10-minute brief advice for smoking 59
Practice nurse £6/10-minute brief advice for smoking 59
Support worker £4/10-minute brief advice for smoking 59
Nurse at hospital £15/10-minute brief advice for smoking 59
Psychiatrist £18/10-minute brief advice for smoking 59
Family therapist £6/10-minute brief advice for smoking 59
Other health care and social services
Dentist £21 59
Support worker £13/30-minute visit 61
Early intervention team £184/contact 61
Psychotherapist £194/contact 60
Specialist nurse £64/contact 60
Outreach team £132/contact 61
Pharmacist £7/contact 61
Speech and language therapist £96/one-to-one contact 60
Arts therapist £40/40-minute contact 61
Forensic community team £238/contact 60
Health-care assistant £12/30-minute contact 61
Phlebotomist £3/contact 60
Midwife £62/contact 60
TABLE 31 Estimated costs of emergency and hospital services and primary and community care in months 1–6 and
months 7–12, by group
Services
BSC Usual care
n Mean cost (SD) n Mean cost (SD)
Months 1–6
Emergency and hospital services 211 £932 (£4228) 208 £1443 (£6470)
Primary and community care 220 £2529 (£3178) 214 £2367 (£2893)
Months 7–12
Emergency and hospital services 203 £953 (£3027) 202 £1317 (£5330)
Primary and community care 214 £2429 (£3458) 213 £2303 (£3234)
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organisations, the internet and books. These were reported by only a small group of participants. The most
often used source of advice was the internet. In the 6 months post randomisation, 18 participants reported,
in total, 82 times of internet use for advice on smoking cessation in the BSC group, and 22 participants
reported a total of 61 times of use in the usual-care group. From 6 months to 12 months post randomisation,
21 participants in the usual-care group reported a total of 86 times of internet use and 16 participants in the
BSC group reported 64 times of use. Among them, the highest number of uses appeared in the usual-care
group where one participant reported 28 times of use in the 7–12 months post randomisation. It was
followed by two participants who reported 25 times of use and 26 times of use in the BSC group in the
6 months post randomisation. The costs of internet use were not estimated because of the lack of details.
In the 1–6 months post randomisation, books were used by 18 participants in the BSC group and 10 participants
in the usual-care group. In the 7–12 months post randomisation, 10 participants in the BSC group and
nine participants in the usual-care group used books. Only two participants in the BSC group and five in the
usual-care group called another smoking cessation helpline during the 12-month period.
Participants’ out-of-pocket expenses in relation to smoking cessation
Participants were asked about their expenses for the purchase of NRT products, the purchase of
e-cigarettes and travel to GP/SSS at the follow-ups.
There were 157 participants (81% of 195 responders) in the BSC group who reported not purchasing any
NRT products and 152 participants (77% of 197 responders) in the usual-care group in the 12 months
post randomisation. Among the 38 participants who reported any purchase in the BSC group, 27 purchased
a single form of NRT product, eight purchased two forms of NRT products and three purchased three forms of
NRT products. Among the 45 participants who reported any purchase in the usual-care group, 27 purchased
a single form of NRT product, 13 purchased two forms of NRT products and three purchased three forms
of NRT products.
Among all the NRT products asked about the most purchased one was the nicotine patch. There were
27 participants who reported purchasing patches in the usual-care group, compared with 14 in the BSC
group (Figure 12). The next most purchased were the lozenge and mouth spray. There were 12 participants
who reported purchase of a lozenge in either group and the purchase of mouth spray was almost the same
(11 in the usual-care group and 12 in the BSC group). These were followed by nicotine gum, which was
reported by nine participants in the usual-care group and 11 participants in the BSC group. There were
five participants who reported purchasing an inhalator in the usual-care group and two in the BSC group.
Only one participant reported purchasing nasal spray (in the BSC group). None of the participants reported
purchasing microtabs.
Comparing the sources of NRT products in those who had both self-report response and prescription
records (132 in the usual-care group and 129 in the BSC group), the majority of the NRT products in the
BSC group were acquired on prescription, whereas the usual-care group acquired their NRT products, if
any, over the counter. A small number of participants in both groups acquired their products via both
prescription and purchase.
Given that the majority of the responders reported no purchase at all during the 12 months post
randomisation, the mean amount of purchase of individual forms of NRT products was low and the SD
was comparatively large, indicating a skewed distribution of purchase (Table 32).
Applying Table 2 to the quantities in Table 32, the mean expense of NRT products was £8 (SD £30)
among 209 responders in the usual-care group and £13 (SD £83) among 206 responders in the BSC
group in months 1–6 post randomisation. In months 7–12, the mean expense for NRT products was
£5 (SD £22) among 209 responders in the usual-care group and £17 (SD £97) among the 214 responders
in the BSC group.
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There were 136 participants who reported no purchase of e-cigarettes in the usual-care group and
152 participants in the BSC group in months 1–6 post randomisation. In months 7–12, there were
143 participants in the usual-care group and 148 participants in the BSC group who reported no purchase
of e-cigarettes. The mean expense of e-cigarettes was £21 (SD £47) among 208 responders in months 1–6
and £21 (SD £59) among 205 responders in months 7–12 in the usual-care group. In the BSC group, the
TABLE 32 The mean amount of purchase of NRT products (SD) in months 1–6 and months 7–12, by group
NRT products BSC, mean (SD) Usual care, mean (SD)
Months 1–6 n = 206 n = 209
Patches (pack) 0.02 (0.14) 0.20 (0.90)
Gum (pack) 0.20 (1.79) 0.09 (0.91)
Lozenges (pack) 0.64 (5.97) 0.11 (0.80)
Microtabs (pack) – –
Inhaler (bottle) – 0.08 (0.75)
Nasal spray (bottle) 0.01 (0.21) –
Mouth spray (bottle) 0.07 (0.57) 0.05 (0.33)
Months 7–12 n = 214 n = 209
Patches (pack) 0.11 (0.58) 0.19 (1.01)
Gum (pack) 0.02 (0.17) 0.03 (0.22)
Lozenges (pack) 0.62 (5.28) 0.13 (1.16)
Microtabs (pack) – –
Inhaler (bottle) 0.01 (0.15) 0.00 (0.07)
Nasal spray (bottle) – –
Mouth spray (bottle) 0.35 (3.40) 0.03 (0.21)
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FIGURE 12 Number of participants who acquire NRT products on prescription, purchase or both, by group.
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mean expense on e-cigarettes was £17 (SD £64) among 219 responders in months 1–6 and £19 (SD £68)
among 210 responders in months 7–12.
The majority of the responders reported walking as their way of travelling to see their GP or SSS, followed
by driving, taking a bus or taking a taxi. Fewer than five responders reported taking trains to see their GP
or SSS. In the usual-care group, 173 responders in months 1–6 and 171 in months 7–12 reported no
expense on travel. In the BSC group, 187 in months 1–6 and 176 in months 7–12 reported no expense on
travel. The mean expense on travel to GP/SSS was £6 (SD £30) among 203 responders in months 1–6 and
£3 (SD £11) among 199 responders in months 7–12, in the usual-care group. In the BSC group, it was £3
(SD £12) among 213 responders in months 1–6 and £2 (SD £9) among 205 responders in months 7–12.
However, this expense might have been underestimated because some of the participants did not take
into account when they used cars and others did.
Health-related quality of life
The EQ-5D-5L was returned by 260 participants in the usual-care group at baseline and 265 participants
in the BSC group. The mean VAS score was 54.2 (SD 20.5) in the usual-care group and 54.8 (SD 22.9) in
the BSC group. Two participants in the usual-care group had missing items on the descriptive system of
EQ-5D-5L and, therefore, utility could not be calculated. Among the rest of the participants, the mean
utility was 0.640 (SD 0.304) in the usual-care group and 0.638 (SD 0.280) in the BSC group. At 6 months,
217 participants in the usual-care group and 224 participants in the BSC group returned the questionnaire.
The mean VAS score was 55.6 (SD 21.2) in the usual-care group and 58.3 (SD 21.8) in the BSC group.
The mean utility was 0.659 (SD 0.307) in the usual-care group and 0.682 (SD 0.269) in the BSC group.
At 12 months, 213 participants in the usual-care group and 216 participants in the BSC group returned
information. The mean VAS score was 55.9 (SD 20.9) in the usual-care group and 55.8 (SD 23.9) in the
BSC group. Three participants in the usual-care group and two in the BSC group had missing items on the
descriptive system of EQ-5D-5L. Among the remaining participants, the mean utility was 0.662 (SD 0.306)
in the usual-care group and 0.688 (SD 0.275) in the BSC group.
Missing data
The percentage of missing data varies from variable to variable (Table 33). As expected, the lowest missing
percentage occurs among the variables at baseline. Missing data level ranges between 20% and 30% on
participants’ self-reported items at follow-ups, which is consistent with the overall follow-up rate of the
trial. The highest percentage of missing values is that of the costs of pharmacotherapy prescriptions in
the trial period, which was collected from practices directly. This percentage of missing values is 44%; the
number of multiple imputations was therefore set to 45. The missing values in the continuous variables
were imputed using the predictive mean matching method, with 10 nearest neighbours to draw from.
Binary variables were imputed using the logit method.
There were five participants who died before the 6-month follow-up and another two died before the
12-month follow-up. All of them were unable to be followed up at both follow-up points. For those who
died before the 6-month follow-up, the costs and expenses in the first 6 months of the trial were to be
imputed as others, while the costs and expenses in months 7–12 were set to zero. For the two who died
after the 6-month follow-up but before the 12-month follow-up, their costs and expenses were to be
imputed as others. The utility and VAS from EQ-5D-5L were set to zero at 6 months and 12 months for
those died before the 6-month follow-up, and those who died after 6 months were to have 6-month values
imputed but 12-month values set to zero. Other measures including cigarettes per day, alcohol drinking and
FTND score were to be imputed conditioned on the death status at that time point.
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TABLE 33 Number and percentage of missing data in the variables included in the imputation model
Variables
Number of
missing values
Percentage of
missing values
Characteristics
Age 1 0
Gender 0 0
Study centre 0 0
Pre-existing medical condition 4 1
Duration since first diagnosis of SMI 10 2
Duration since start of smoking 2 0
Costs
Cost of BSC training and supervision 0 0
Cost of BSC delivery 2 0
Cost of usual smoking cessation in 6 months before baseline 9 2
Cost of usual smoking cessation in months 1–6 97 18
Cost of usual smoking cessation in months 7–12 101 19
Costs of pharmacotherapy prescriptions in months 1–12 231 44
Cost of emergency and hospital services in 6 months before baseline 14 3
Cost of emergency and hospital services in months 1–6 107 20
Cost of emergency and hospital services in months 7–12 121 23
Cost of primary and community services in 6 months before baseline 2 0
Cost of primary and community services in months 1–6 92 17
Cost of primary and community services in months 7–12 99 19
Costs of antipsychotics in months 1–12 127 24
Other measures
Cigarettes per day at baseline 0 0
Cigarettes per day at 6 months 140 27
Cigarettes per day at 12 months 159 30
FTND score at baseline 14 3
FTND score at 6 months 146 28
FTND score at 12 months 171 33
Outcomes
VAS at baseline 1 0
VAS at 6 months 85 16
VAS at 12 months 97 18
EQ-5D-5L utility at baseline 3 1
EQ-5D-5L utility at 6 months 85 16
EQ-5D-5L utility at 12 months 102 19
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Analysis
The BSC intervention cost, consisted of a fixed training cost and delivery cost, was estimated at £418
[standard error (SE) £10] per participant. The cost of usual GP care during the trial period was £65 (SE £6) per
participant in the usual-care group and £52 (SE £6) per participant in the BSC group. The BSC group received
more pharmacotherapies for smoking cessation on prescription than the usual-care group. The mean cost of
pharmacotherapies on prescription was £91 (SE £13) in the BSC group, three times the mean cost in the
usual-care group [£29 (SE £6)]. The total smoking cessation costs during the trial period were therefore £93
(SE £9) per participant in the usual-care group and £561 (SE £19) per participant in the BSC group.
In the 6 months before randomisation, both groups had similar levels of cost of smoking cessation from
usual GP care [£38 (SE £4) vs. £37 (SE £4)]. The mean costs of emergency and hospital services were higher
in the BSC group [£2030 (SE £494), compared with £1507 (SE £406) per participant in the usual-care
group]. The costs of primary and community services were the first cost drive in both groups, with £2614
(SE £260) per participant in the usual-care group and £2746 (SE £223) per participant in the BSC group.
The total health resource use costs were estimated at £4160 (£512) per participant in the usual-care group
and £4813 (£548) per participant in the BSC group in the 6 months before randomisation.
Throughout the trial period, primary and community services remained the first cost driver in both groups,
with the mean costs never dropping below £2000 per participant, and the mean costs of emergency
and hospital services in the same period never reaching this threshold. The mean costs of emergency and
hospital services were £1513 (SE £492) per participant and costs of primary and community services were
£2391 (SE £204) in the usual-care group in the first 6 months of the trial. In the same period, the mean costs
of emergency and hospital services were £982 (SE £285) per participant and costs of primary and community
services were £2597 (SE £218) in the BSC group. In the second 6-month period of the trial, the mean costs
of emergency and hospital services were £1404 (SE £361) per participant in the usual-care group and costs
of primary and community services were £2320 (SE £232). In the BSC group, the mean costs of the mean
costs of emergency and hospital services were £1004 (SE £211) per participant and costs of primary and
community services were £2504 (SE £245) in the second 6-month period of the trial. The mean cost of
antipsychotics on prescription in the trial period was estimated at £768 (SE £81) per participant in the
usual-care group and £799 (SE £84) in the BSC group. The total health resource use costs were therefore
£8396 (£774) per participant in the usual-care group and £7886 (SE £594) in the BSC group.
TABLE 33 Number and percentage of missing data in the variables included in the imputation model (continued )
Variables
Number of
missing values
Percentage of
missing values
Out-of-pocket expenses
Travel expenses to GP surgery/stop smoking clinic in 6 months before baseline 21 4
Travel expenses to GP surgery/stop smoking clinic in months 1–6 110 21
Travel expenses to GP surgery/stop smoking clinic in months 7–12 122 23
Purchase of e-cigarette in 6 months before baseline 10 2
Purchase of e-cigarette in months 1–6 99 19
Purchase of e-cigarette in months 7–12 111 21
Purchase of NRT products in 6 months before baseline 13 2
Purchase of NRT products in months 1–6 111 21
Purchase of NRT products in months 7–12 103 20
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In the usual-care group, the mean VAS score was 54.2 (SE 1.3) at baseline, 54.9 (SE 1.9) at 6 months and
55.3 (SE 1.4) at 12 months. In the BSC group, the mean VAS score was 54.8 (SE 1.4) at baseline, 57.3
(SE 1.5) at 6 months and 55.1 (SE 1.6) at 12 months. In the usual-care group, the mean utility value was
0.640 (SE 0.019) at baseline, 0.647 (SE 0.020) at 6 months and 0.654 (SE 0.020) at 12 months. In the BSC
group, the mean utility value was 0.638 (SE 0.017) at baseline, 0.670 (SE 0.018) at 6 months and 0.678
(SE 0.019) at 12 months. The mean QALYs were estimated at 0.647 (SE 0.017) in the usual-care group and
0.664 (SE 0.015) in the BSC group.
Primary analysis
There were 442 participants (219 in the usual-care group and 223 in the BSC group) who had CO-verified
smoking status at 12-month follow-up. Without imputing missing data on this outcome, the quit rate at
12 months was 10.0% (SE 2.0%) in the usual-care group and 15.3% (SE 2.4%) in the BSC group. The
mean intervention cost among these participants was £93 (SE £9) per participant in the usual-care group
and £584 (SE £21) in the BSC group. The mean intervention cost per quitter was £906 (95% CI £612 to
£1456) in the usual-care group and £3828 (95% CI £2901 to £5409) in the BSC group. The incremental
intervention cost per additional quitter was £9472 (95% CI –£44,016 to £73,503).
Combining costs of smoking cessation and health resource use during the trial period, the total costs were
estimated at £8489 (SE £775) per participant in the usual-care group and £8446 (SE £596) per participant
in the BSC group (Table 34). The mean total costs were similar between groups during the trial period.
After adjusting for age, gender, pre-existing medical conditions, duration since first diagnosis of SMI and
health resource use costs in the 6 months before randomisation, the adjusted difference in mean total
costs was –£270 (95% CI –£1817 to £1297), with the BSC group lower than the usual-care group.
Although the unadjusted difference in QALYs between groups was 0.017, after adjusting for the same set
of baseline covariates with the exception of replacing health resource use costs with EQ-3D-5L utility value
at baseline, the adjusted difference became 0.026 (95% CI –0.008 to 0.045).
With the incremental costs being negative (BSC was less costly) and the incremental QALYs being positive
(BSC was more effective), the BSC group dominated the usual-care group and was cost-effective based
on the point estimation. However, both incremental costs and incremental QALYs have wide 95% CIs
including zero, indicating the presence of high uncertainty.
TABLE 34 Results of primary analysis
Results BSC (n= 265) Usual care (n= 261)
Costs
Smoking cessation, mean (SE) £561 (£19) £93 (£9)
Health resource use, mean (SE) £7886 (£594) £8396 (£774)
Total, mean (SE) £8446 (£596) £8489 (£775)
Adjusted difference,a mean (95% CI) –£270 (–£1817 to £1297)
QALYs, mean (SE) 0.664 (0.015) 0.647 (0.017)
Adjusted difference,b mean (95% CI) 0.026 (–0.008 to 0.045)
Incremental cost-effectiveness ratio
ICER, mean BSC dominates (uncertainty: Figure 13)
a Adjusted for health resource use in the 6 months before randomisation, age, gender, pre-existing medical conditions,
duration since first diagnosis of SMI, with study centre as random effect.
b Adjusted for EQ-5D-5L utility value at baseline, age, gender, pre-existing medical conditions, duration since first
diagnosis of SMI, with study centre as random effect.
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Sensitivity analysis
Mapping incremental costs and incremental QALYs estimated from 5000 bootstrapped replicates onto the
cost-effectiveness plane, Figure 13a shows the overall majority (92%) of dots that represented ICERs of the
replicates, scattered on the right side of the y-axis (zero effect), indicating that the BSC is very likely to
achieve higher QALYs. The distribution of these dots in relation to incremental costs is less clear, where
62% are scattered below zero and 38% above. This suggests that the BSC is likely to be cost-saving, but
the uncertainty is higher. Taking into account the combination of both, 57% fall in the south-east quadrant,
where the BSC group dominates the usual-care group (less costly but more effective). Figure 13b is the
cost-effectiveness acceptability curve with WTP thresholds at £20,000/QALY and £30,000/QALY as
reference line. For the probability of BSC being cost-effective, compared with usual care, although it starts
high (> 60%) and rises with the increase of WTP, the increase in the probability shows a trend of becoming
smaller. This leads to a gradual upwards curve and almost flat line close to 90%.
£30,000/QALY
£20,000/QALY
–3500
In
cr
e
m
e
n
ta
l 
co
st
s 
(£
)
–3000
–2500
–2000
–1500
–1000
–500
0
500
1000
1500
2000
2500
3000
(a)
–0.04 –0.03 –0.02 –0.01 0.00 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09
Incremental QALYs
76%
80%
0
0 10 20 30 40 50 60 70 80 90 100
P
ro
b
a
b
il
it
y
 c
o
st
-e
ff
e
ct
iv
e
 (
%
)
20
40
60
80
100
(b)
Willingness to pay (per QALY) (£000)
FIGURE 13 Cost-effectiveness plane and cost-effectiveness acceptability curve of primary analysis results.
(a) Cost-effectiveness plane; and (b) cost-effectiveness acceptability curve.
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Complete-case analysis
Taking into account the outcome measures and baseline variables for adjustment, there were 80
participants in the usual-care group and 88 participants in the BSC group included in the complete-case
analysis. The intervention cost was similar in the usual-care group between primary analysis (£93, SE £9)
and complete-case analysis (£92, SD £128) while in the BSC group it was slightly higher in complete-case
analysis (£593, SD £338) than in primary analysis (£561, SE £19). In the usual-care group, the mean costs
of health services were £4822 (SD £7881) in the 6 months before randomisation, £3440 (SD £3745) in
months 1–6 of the trial and £4293 (SD £8490) in months 7–12 of the trial, in complete-case analysis.
In the BSC group, the mean costs of health services were £4594 (SD £7449) in the 6 months before
randomisation, £3599 (SD £4173) in months 1–6 of the trial and £3555 (SD £5078) in months 7–12 of the
trial, in complete-case analysis. The difference between primary analysis and complete-case analysis was
more prominent in the usual-care group than in the BSC group.
For the BSC group, the mean costs in complete-case analysis did not vary from those in primary analysis by
much. For the usual-care group, however, the mean costs became higher than those in primary analysis in
the 6 months before randomisation and months 7–12 of the trial, and were lower than in primary analysis
in months 1–6 of the trial. This change led to a reverse of the relative position when comparing between
groups and the reduction of the difference in the 6 months before randomisation and months 1–6 of the
trial. In the second 6-month period of the trial, although the mean costs of health services were still higher
in the usual-care group, the difference between the mean costs in the two groups was widened.
For EQ-5D-5L utility value, the pattern of change was more consistent. In complete-case analysis, the mean
utility value was 0.595 (SD 0.319) at baseline, 0.612 (SD 0.336) at 6 months and 0.641 (SD 0.303) at
12 months in the usual-care group, while it was 0.661 (SD 0.257) at baseline, 0.686 (SD 0.254) at 6 months
and 0.684 (SD 0.262) at 12 months in the BSC group. Although in the usual-care group the mean utility
values were always lower in complete-case analysis than in primary analysis, the BSC group was the opposite.
The mean total cost was £911 (95% CI –£2769 to £2631) higher in the BSC group than in the usual-care
group, after adjusting for costs of health resource use in the 6 months before randomisation, age, gender,
pre-existing medical conditions and duration since first diagnosis of SMI (Table 35). The mean QALYs were
0.008 (95% CI –0.030 to 0.074) higher in the BSC group than in the usual-care group, after adjusting for utility
value at baseline, age, gender, pre-existing medical conditions and duration since first diagnosis of SMI. The
ICER ratio was therefore £113,875 (uncertainty: Figure 14) per QALY gained.
TABLE 35 Results of complete-case analysis
Results BSC (n= 88) Usual care (n= 80)
Costs
Smoking cessation, mean (SD) £593 (£338) £92 (£128)
Health resource use, mean (SD) £7741 (£8649) £8437 (£11,386)
Total, mean (SD) £8434 (£8642) £8530 (£11,405)
Adjusted difference,a mean (95% CI) £911 (–£2768 to £2631)
Quality of life
QALYs, mean (SD) 0.679 (0.219) 0.615 (0.283)
Adjusted difference,b mean (95% CI) 0.008 (–0.030 to 0.074)
Incremental cost-effectiveness ratio
ICER, mean £113,875 (uncertainty: Figure 14)
a Adjusted for health resource use in the 6 months before randomisation, age, gender, pre-existing medical conditions,
duration since first diagnosis of SMI, with study centre as random effect.
b Adjusted for EQ-5D-5L utility value at baseline, age, gender, pre-existing medical conditions, duration since first
diagnosis of SMI, with study centre as random effect.
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Compared with the primary analysis, Figure 14a shows the dots scattered more widely on the cost-effectiveness
plane, indicating a higher level of uncertainty. The BSC is still likely to achieve higher QALYs as 79% of the dots
fall to the right side of y-axis. The difference in costs, however, almost disappears as about half (49%) fall
below zero. Only 39% of the dots fall in the south-east quadrant, suggesting a less costly but more effective
intervention. The cost-effectiveness acceptability curve demonstrates that the probability of the intervention
being cost-effective was 61–65% between £20,000 and £30,000 per QALY (see Figure 14b). Similar to the
primary analysis, the increase of the probability becomes smaller the higher the WTP gets, and flattens close
to 80%.
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FIGURE 14 Cost-effectiveness plane and cost-effectiveness acceptability curve of complete-case analysis results.
(a) Cost-effectiveness plane; and (b) cost-effectiveness acceptability curve.
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Secondary analysis
Participants’ expenses
In months 1–6 of the trial, the participants’ expenses on travel were estimated at £5 (SE £2) per participant
in the usual-care group and £3 (SE £1) in the BSC group. In months 7–12, it was £3 (SE £1) in the usual-care
group and £2 (SE £1) in the BSC group. In months 1–6, the participants in the usual-care group spent on
average £22 (SE £3) per person on e-cigarettes, while the participants in the BSC group spent on average
£16 (SE £4) per person. In months 7–12, the expense on e-cigarette was £23 (SE £4) per participant in the
usual-care group and £20 (SE £5) per participant in the BSC group. The expense on NRT over the counter
was £8 (SE £2) per participant in the usual-care group and £12 (SE £5) per participant in the BSC group,
in the first 6 months of the trial. In the second half of the trial, this expense was £6 (SE £2) per participant
in the usual-care group and £16 (SE £6) per participant in the BSC group. The total expenses during the
trial period were £67 (SE £8) per participant in the usual-care group and £70 (SE £11) per participant in
the BSC group. In comparison with the huge health resource use costs, the participants’ expenses were
almost negligible.
Financial impact of smoking cigarettes
Excluding seven people who died during the trial period, there were 262 participants in the BSC group and
257 in the usual-care group as the basis for estimating the expenses on cigarettes. The average numbers
of cigarettes per day were 17.6 (SE 0.9) in the 1–6 months post randomisation and 19.7 (SE 0.8) in the
7–12 months post randomisation in the BSC group. In the usual-care group, average cigarettes per day
were 18.5 (SE 0.7) in the 1–6 months post randomisation and 18.5 (SE 0.8) in the 7–12 months post
randomisation. Assuming the number of cigarettes smoked per day was the average over the recall period
and did not vary day to day, an estimated price of £9.37 per 20 cigarettes was applied to estimate the
expenses.71 The estimated expenses on cigarettes over 6 months were over £1500 per participant in the
usual-care group [£1590 (SE £69) and £1596 (SE £70)]. In the BSC group, the estimated expenses were
£1516 (SE £76) per participant in the first half of the trial and £1691 (SE £72) per participant in the
second. Overall, smoking would add £3186 (SE £111) per person per year to the participants’ cost in the
usual-care group and £3207 (SE £128) per person per year in the BSC group.
Antipsychotics among quitters and non-quitters
Without imputing missing smoking status, there were 344 participants in total who had complete data
on CO-verified smoking status at both follow-ups and cost of antipsychotics in the trial period. Owing to the
incompliance to normality, a Wilcoxon signed-rank test was used to access if the cost of antipsychotics differed
from the first half of the trial to the second. Table 36 presents the mean cost of antipsychotics according to
participants’ CO-verified quit status. There were 286 participants who did not quit at both follow-ups, 14 quit
at 6 months but relapsed at 12 months, 23 did not quit at 6 months but quit at 12 months and 21 quit at
both follow-ups. Except for the first category, there was no evidence of significant change between the first
and the second half of the trial. However, this might be because limited numbers of participants fell into these
categories. The participants who did not quit at any time showed an increased cost on antipsychotics
(p = 0.0018).
TABLE 36 Cost of antipsychotics over 6-month periods, by CO-verified quit status
CO-verified quit status at 6- and
12-month follow-ups
Cost of antipsychotics [£, mean (SD)]
Wilcoxon signed-rank testMonths 1–6 Months 7–12
Not quit at both follow-ups (n = 286) 353 (509) 369 (511) z = 3.119; p = 0.0018
Quit at 6 months but not at 12 months (n = 14) 246 (212) 243 (216) z = –0.372; p = 0.7100
Not quit at 6 months but at 12 months (n = 23) 324 (409) 248 (418) z = 1.683; p = 0.0924
Quit at both follow-ups (n = 21) 582 (929) 713 (1298) z = 0.245; p = 0.8061
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Discussion
This study collected extensive data to provide a comprehensive picture of costs to the NHS and Personal
Social Services in this population. The mean intervention cost per quitter in the BSC group was around
four times the mean intervention cost per quitter in the usual-care group (£3828 vs. £906). Although the
cost per quitter of SSS in the general population was £690 per quitter for CO-validated 4-week quit in
2017/18 in England where data are available,72 this could not be compared directly. Our study offered
a more flexible timeline to suit the needs of people with SMI and, therefore, did not measure 4-week
smoking status. The participants in the usual-care group showed a more active engagement with usual
smoking cessation services, especially in months 1–6 of the trial. This is understandable as the participants
in the BSC group would have mostly been engaging with the intervention during that period while the
help-seeking behaviour in the usual-care group might have been triggered by participation in the trial.
Both groups became less engaged with usual-care services in months 7–12.
The use of various health-care and social services was highly intensive. The costs of primary and community
services were the largest component of the overall costs. These costs were relatively stable from before
the trial to the end of the trial and did not change significantly during the trial, indicating this population’s
constant demand for community support. The lower total costs of the BSC group were mainly the results of
the consistently lower costs of emergency and hospital services during the trial and higher costs in the
6 months before the trial, while the costs of emergency and hospital services remained on the same level in
the usual-care group. This difference in costs of emergency and hospital services was probably related to
the higher frequency and longer stay of hospital admission in the usual-care group than in the BSC group.
However, it is unclear if this difference is related to the intervention or smoking status, or if it happened by
chance. As the use of services was collected through self-report, the possibility of recall bias should be kept
in mind when interpreting the results.
The data on prescriptions of antipsychotics and pharmacotherapies for smoking cessation were extracted
from participants’ medical records. The information collected through this approach was more reliable and
accurate than participants’ self-report, especially when there were multiple medicines involved. However,
the information on prescriptions was completely missing for some participants because of the closure or
lack of capacity of their general practices. Although attempts were made to ensure a uniform extraction
of data, there were still discrepancies among data returns. As a result, clinic supervision and therefore staff
cost necessitated by some antipsychotics [e.g. clozapine (Clozaril®, Sandoz Pharmaceuticals)] were not
included in the analysis as individual visits to the clinic could not be identified for all participants. For the
same reason, the prescription charge was also not included in the participants’ expenses as individual
prescription items were not always identifiable. The cost of pharmacotherapies for smoking cessation
might be overestimated. As we extracted data from GPs’ prescription records, it should be noted that not
all people redeem their prescriptions.
With the development and increased accessibility of the internet, people become rapidly used to seeking
information online. The level and costs of smoking cessation help available online vary. The publicly
available information provided by the NHS or charities costs only individuals’ internet charge, whereas the
private organisations might offer more intensive online treatment for a fee. It is not clear if this particular
population has a preference for internet use or not and to what extent they rely on the internet for
smoking cessation help. A brief browse of free information might be negligible in terms of costs but more
intensive help could add to participants’ financial burden.
Both groups had an upwards trend of EQ-5D-5L scores, although the BSC group’s increase was more
drastic. This resulted in the positive QALY gains of the BSC intervention. This might be related to the lower
frequency and shorter stay of hospital admission in the BSC group. Both appeared to reflect a better
general health of the participants in this group. However, within such a short period, participants’ smoking
status, successfully quit or not, is unlikely to have contributed to their better general health.
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A disadvantage of collecting comprehensive service use data is that data are more likely to be missing because
of the length of the questionnaire. However, owing to a high follow-up rate, the missing data level was not
unacceptably high. When comparing primary analysis (multiple imputation of missing data) and complete-case
analysis (remove all incomplete observations), it appears that missing data on costs have a larger impact on
costs in the usual-care group than in the BSC group. The impact of missing data on EQ-5D-5L is less
straightforward. In the usual-care group, it appears that the participants who managed better dropped out,
whereas in the BSC group the participants who did not do well were the source of missing data.
The biggest impact of smoking on the individual’s private costs came from purchase of cigarettes itself.
On average, the participants in the in the trial were estimated to spend > £3000 per year on cigarettes
and there did not appear to be any difference between groups. Because the amount of money spent on
cigarettes was estimated based on the data collected at three time points, the change in smoking patterns
in between was not captured. The assumption of unchanging number of cigarettes per day throughout
the estimated period might not hold. Another thing to keep in mind is that we estimated the expenses
on smoking by converting all tobacco to cigarettes and costing it based on market price of manufactured
cigarettes. This might lead to an overestimate as there are cheaper options available for purchasing
tobacco. Although there were some participants purchasing e-cigarettes during the trial, the expenses
did not appear significant in comparison to those of cigarettes. Previous evidence has recommended
that people with SMI could reduce their antipsychotics intake if they stop smoking. Although the results
showed that the participants who smoked throughout the trial had a significant increase in their costs of
antipsychotics, the current study did not find evidence to support the reverse situation. One of the reasons
might be that there were insufficient numbers of quitters in the trial to draw meaningful conclusions.
Moreover, the quit status was measured by asking the question ‘have you smoked in the last week’,
which is not a measure of abstinence. Clinical guidelines suggest that if a person makes a quit attempt
their antipsychotic medication should be closely monitored as smoking affects the way these drugs are
metabolised and the person may need to reduce their antipsychotic medication and if they subsequently
relapse back to smoking their dose of antipsychotic medication may need to be increased. Finally, this
comparison was undertaken based on the participants whose costs of antipsychotics and smoking status
were both available. There is a possibility of selection bias.
The primary analysis showed a higher than 50% probability of the BSC intervention being cost-effective,
compared with usual care, at a WTP threshold of £0 per QALY gained. This was largely attributable to
the lower level of health-care services costs offsetting the intervention costs in the BSC group and a QALY
gain with relatively high level of certainty. Although the likely cost-saving effect in the primary analysis
disappeared in the complete-case analysis, the offset effect remained. This suggested that in the complete-
case analysis, the mean health-care services costs in the BSC group remained lower than those in the
usual-care group. Given that the primary outcome of CO-validated quit at 12 months post randomisation
did not show a statistical significance, it could raise concerns over the more favourable results of the
economic evaluation. As a perfect association between smoking status and health services and quality of
life is not expected in 1 year, it is possible that the analysis shows a better outcome in terms of costs and
QALYs. However, unless there were some unknown factors in participants’ life affected by the intervention
that could be identified later, the result of this study might be hard to generalise.
Conclusion
The BSC intervention for people with SMI is likely (57%) to dominate usual GP care, from a NHS and Personal
Social Services perspective. Although neither the difference in costs nor in QALYs was statistically significant,
the probability of cost-effectiveness could reach 80% at a threshold of £30,000 based on the primary analysis
and 65% based on the complete-case analysis. However, it remains uncertain whether or not this was the
result of smoking cessation, as the smoking status at 12 months did not show a significant difference
between groups. Furthermore, the impact of smoking cessation on health and wider health services use is
unlikely to be observed in a short period of 12 months. A longer-term follow-up would be ideal to observe
the sustainability of quit and impact on health.
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Chapter 6 Discussion
Some of the information in this section is reported in Peckham et al.
1 This contains information licensed
under the Non-Commercial Government Licence v2.0.
This report presents the results of the first UK trial of a BSC intervention designed specifically for people
with SMI. The SCIMITAR+ trial was commissioned by the National Institute for Health Research Health
Technology Assessment programme in view of the clinical need of this population and the widening health
inequalities that exist in relation to smoking and smoking-related illness. We have previously reported
the results of the SCIMITAR pilot trial, which demonstrated acceptability but was not sufficiently powered
to estimate clinical effectiveness and cost-effectiveness. The SCIMITAR programme has followed a
developmental pathway to produce a feasible intervention to the point where we were able to judge
the value of an evidence-informed smoking cessation intervention within the context of a definitive trial.
We drew on existing evidence (taken from high-quality systematic reviews) of ‘what works’ in helping
people to cut down or quit smoking.23 In linked work, we have also conducted a systematic review of
‘what works’ in relation to people with SMI, and have shown that the same pharmacological and behavioural
approaches to smoking cessation are effective among people with SMI as with the rest of the population.39,40
Despite this evidence, it is clear that people with SMI do not access conventional NHS quit smoking services,
and a coherent response is to design a service and intervention that ensures that evidence-supported
pharmacotherapies and behaviour change techniques are applied with specific reference to the needs of
people with SMI.
The BSC intervention at the centre of the SCIMITAR+ trial was designed to address the unmet needs of
and barriers to accessing smoking cessation interventions for this population. We will now review the main
findings and address the main objectives of the SCIMITAR+ trial in turn.
Main findings
The main finding of the SCIMITAR+ trial is that smoking cessation can be achieved among people with
SMI, and that, in people who express a desire to quit smoking, the use of a BSC intervention increased
the chances of sustained quitting as estimated by a gold-standard biologically verified outcome measure
(exhaled CO).73 The observed odds of successful quitting at 12 months was higher among those who
received BSC but this was not statistically significant. However, the observed odds of successful quitting at
6 months were higher among those who received BSC and this was statistically significant. The SCIMITAR+
trial used quitting as measured at 12 months post randomisation as its primary end point, and although
there was a trend in favour of the BSC intervention, the difference in quit rates was no longer statistically
significant at 1 year. This finding is in line with research in the general population, which shows that
long-term quit rates are difficult to achieve, and this remains a challenge for the wider evidential basis of
treatment for nicotine dependence in any population.74 The results of the effect of the BSC intervention
were seen in secondary outcomes, and we found an improvement in short-term physical health (as measured
by the SF-12) and some evidence of reduced numbers of cigarettes smoked per day and increased motivation
to quit. We also found that there were no between-group differences on measures of mental health,
including depression and anxiety, supporting the notion that offering a smoking cessation intervention is
not detrimental to mental health.
To our knowledge, this is the first large-scale UK RCT of a bespoke intervention designed for people
with SMI. Trials to date have been small scale and with short periods of follow-up, and have focused on
pharmacological treatments, with limited consideration of behavioural approaches.40 The SCIMITAR+ trial
adapted and enhanced an evidence-supported smoking cessation strategy that has been developed and
forms the mainstay of successful UK SSSs. This structured intervention was delivered by a mental health
professional and a ‘cut down to quit’ approach was also offered. The results of the SCIMITAR+ trial,
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alongside trials35 and systematic review evidence34,39,40 of the safety and effectiveness of pharmacological
treatments for nicotine dependence in people with SMI, represents accumulating evidence of the
effectiveness of smoking cessation interventions for people with severe mental ill health. Across both arms
of the trial, people smoked a higher number of cigarettes per day and had a higher mean number of years
of smoking history than those in the general population (25.5 per day compared with 11.3 per day in the
general population).75 This adds to the justification for the need to intervene and develop new and novel
interventions for this population.
Is the treatment acceptable to participants?
The SCIMITAR+ trial found that participants generally engaged with BSC services. The levels of engagement
were high, with 88% taking up treatment and with an average of six sessions attended. In an earlier
qualitative evaluation conducted in the developmental phase of the SCIMITAR pilot trial, it was found that
participants valued the fact that smoking cessation therapists were drawn from staff working within mental
health services.76 Smoking cessation practitioners therefore had a familiarity with SMI and the specific needs
of that group, and this was seen as a positive aspect of the intervention by participants. By addressing these
factors, the participants felt that their smoking was more readily addressed and they felt less stigmatised
than might have been the case in conventional services. Participants were attracted to a service that offered
the prospect of cutting down prior to quitting and they appreciated the opportunity to receive NRT prior
to setting a quit date. In the control group, there was a lack of engagement with conventional NHS quit
smoking services despite control participants being given smoking cessation literature and encouraged to
visit their GP or NHS quit smoking service. The intervention was clearly more intensive than what would be
offered in conventional NHS services, and the overall cost of BSC was higher than usual care.
Within the SCIMITAR+ trial, participants were encouraged to choose an appropriate form of smoking
cessation medication in collaboration with their GP. The mainstay of treatment was NRT and only a small
number of participants were prescribed varenicline. None was prescribed bupropion. There were, however,
some difficulties observed within the trial with regard to access to NRT, partly because provision (e.g. via
SSSs, local councils or GP practices) varied across the trial sites. In some settings, access to provision was
restricted, either by a requirement to attend all elements of a SSS provision or by restricting access to
specific groups (e.g. pregnant women, those with respiratory disorders). Where this occurred this was often
driven by funding being linked with smoking cessation accruals, and through discussions with services it was
possible to access NRT provision, without accessing behavioural intervention components provided by the
service, once a mechanism was implemented to provide accruals data to the relevant organisation. In some
locations it was, however, almost impossible for participants to receive NRT through local provision and in
the limited number of cases where this could not be facilitated, NRT was prescribed by the secondary care
provider as is recommended by the 2013 NICE guidance on smoking cessation provisions for people with
mental ill health,17 which recommends that mental health services make this provision for smokers who use
their services. Where NRT was provided, in some instances only one product was prescribed, and in some
cases the preferred product identified by the patient in discussion with the smoking cessation practitioner
was not prescribed. In both instances this was often attributed to cost implications. There were also some
delays in initial prescribing that resulted in participants having to delay their quit attempt. These delays or
changes in prescribing had potential to demoralise patients and so reduce their interest in and willingness to
make a quit attempt. It is important to note that this was not observed within the trial. NRT was also often
not prescribed as a repeat medication or was prescribed only for a fixed duration, which had an impact
on longer-term abstinence from smoking. Contact with GPs, councils or SSSs by members of the core
SCIMITAR+ trial team helped to identify and to facilitate implementation of methods or routes to remove
barriers and so to enable access to NRT provision. Previous qualitative interview data have shown that GPs
can be reluctant to prescribe smoking cessation products other than NRT, and, as described, this was
evident in the SCIMITAR+ trial. GPs therefore welcomed this direct contact as this enabled the team to
provide assurance that GPs would retain oversight for their patient’s care, and to directly tackle concerns or
misconceptions with regard to prescribing of pharmacological treatments for patients with SMI.
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The advice from the NCSCT regarding e-cigarettes when the SCIMITAR+ trial began in 2015 was that,
if people wished to use e-cigarettes in their quit attempt specific advice on their use should not be given,
but that behavioural support could still be provided (NCSCT, 2015, personal communication). This was the
advice that was followed when the trial began. MH-SCPs in the trial neither encouraged nor discouraged
the use of e-cigarettes. A subsequent briefing produced by the NCSCT, Electronic cigarettes: A Briefing for
Stop Smoking Services,77 led to a change in the advice MH-SCP gave and although they could not provide
advice on which e-cigarette to use, they did give more information about e-cigarettes in line with NCSCT
guidance. This updated advice was published towards the end of the recruitment period and, therefore,
only the participants recruited towards the end of the trial were given the amended advice. This may have
resulted in fewer participants using e-cigarettes than would be the case if the trial was conducted now.
Is bespoke smoking cessation cost-effective?
The results of the SCIMITAR+ trial provide preliminary evidence that a BSC intervention is likely to be
cost-effective in terms of total health-care costs and quality of life. However, it is uncertain if this
conclusion is the result of the intervention as an approach to nicotine dependence for people with SMI.
The BSC intervention for people with SMI probably dominates usual GP care, from a NHS and Personal
Social Services perspective. Depending on the relevant WTP threshold, the probability of cost-effectiveness
could be higher (80% at £30,000). Although neither difference in total costs nor difference in QALYs was
significant, there is an indication that the reduction of health-care services costs might offset the
intervention costs.
Limitations of the SCIMITAR+ trial
There were limitations to the SCIMITAR+ trial. First, we lost 16% of participants to follow-up, but note that this
was better than we achieved in our pilot trial43 and that there was non-differential loss to follow-up. Second,
a lower 12-month cessation rate was observed in the usual-care group than was hypothesised in the sample
size calculation (10% vs. 20%), and the actual percentage increase was lower (5 vs. 14 percentage points).
Therefore, although the trial recruited more participants than originally planned and the loss to follow-up
rate was lower (16% vs. 20% hypothesised), the trial was ultimately underpowered to detect a difference
in quit rates from 10% to 15%. Third, we noted difficulties in ensuring that some participants received
pharmacological treatment, as are detailed previously. Given that smoking is the single most modifiable
risk factor for early mortality, we recommend that local services have in place robust mechanisms to remove
barriers to the provision of medication both when implementing the results of the SCIMITAR+ trial and to
support smoking cessation more generally. Last, we were not able to ensure that all follow-up was blind to
treatment allocation. However, we also put in place a biochemically verified end point that is less susceptible
to observer biases.
Given the trial could not conclude that the intervention is effective in terms of smoking cessation at
12 months, it is uncertain if the result of the economic evaluation was associated with cessation itself.
It is possible that the intervention triggered some changes in aspects other than smoking behaviour, which
had a positive impact on health, or the differences in health-care costs occurred by chance. In addition,
we lacked the capacity to conduct a longer follow-up and a well-correlated relationship between smoking
status and health is not expected in the short term.
Conclusions
In the face of significant health inequalities for people with SMI, smoking is the most important modifiable
risk factor for poor health and reduced life expectancy.78 At 12 months we did not find a statistically
significant difference between the intervention and usual care; however, we did find that there was an
increased quit rate in the intervention at 6 months. Quitting smoking did not appear to have had any
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impact on mental health and there were no statistically significant differences between PHQ-9 scores in
the intervention and control group at 6 or 12 months. Those in the intervention group had a slightly
higher number of quit attempts than those in the usual-care arm.
In this trial, we have shown that people with SMI more readily engage with a bespoke intervention that
results in increased 6-month quit rates; however, this difference was not sustained at 12 months. Further
research is needed to establish how long-term quitting can be supported.
Implications for health care
Clinicians are sometimes reluctant to offer smoking cessation advice to patients under their care and this
is in part because of concerns that treatment is ineffective, or that quitting might cause deterioration
in mental health. The results of the SCIMITAR+ trial will be helpful in informing clinical practice, as we
have shown that quitting can be achieved for people who use mental health services just as it can for all
smokers. As per Public Health Guidance 48,17 clinicians should ask all of their patients about smoking
status and offer referral to effective smoking cessation services. The SCIMITAR+ intervention could provide
a candidate model for such a service. The results of this trial will provide clinicians with increased
confidence that smoking cessation is likely to be either beneficial or not harmful to mental health.
The SCIMITAR+ trial experienced a range of difficulties in procuring NRT provision for participants ahead
of, or during, their quit attempt. Given that smoking is the single most modifiable risk factor for early
mortality, both within the general and SMI populations, it is suggested that policy and practice should be
reviewed and revised so as to facilitate ease of access to NRT for any person wishing to make a smoking
cessation attempt. Ensuring adequate provision to support smoking cessation is likely to reduce NHS
expenditure in the longer term, by virtue of limiting potential for comorbidities attributable to tobacco use.
Furthermore, consideration should be given to ensuring sufficient provision to ensure that a quit attempt is
sustained; this is particularly imperative for SMI patients where additional support may be required.
The results of the SCIMITAR+ trial will be helpful for service commissioners who seek to implement
guidance for smoking cessation among hard-to-reach groups, such as people with SMI.79
Recommendations for future research
Following on from the SCIMITAR+ trial, further research is needed to establish how quitting can be
sustained among people with SMI who engage with an evidence-supported quit smoking intervention.
In addition, although the SCIMITAR+ trial explored the use of e-cigarettes, we suggest that research is
needed to evaluate the role of e-cigarettes in helping people with SMI to cut down or to quit smoking.
Additional research is also needed to complement the findings of the SCIMITAR+ trial, specifically to
establish the clinical effectiveness and cost-effectiveness of very brief opportunistic interventions for
smoking cessation among people with SMI, such as people with SMI being offered advice on giving up
smoking in a routine appointment or other opportunistic encounter with a clinician.80
It may also be useful to explore NRT update and the barriers to this in this population through qualitative
research.
In future trials, conducting a process evaluation to analyse aspects of the intervention that did not work,
for which groups and in which contexts, may be helpful.
It may be helpful to explore if there are other factors that affect the health of people with SMI and that
can be influenced by a BSC intervention.
Finally, in order to capture the whole impact of smoking cessation intervention in this population, a long-term
follow-up is needed to establish the cost-effectiveness.
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Appendix 2 Patient information sheet and
consent form
We would like you to take part in a research study. Before you decide, you need to
understand why this study is being done and what it will involve for you. 
Please take time to read the following information carefully.
Talk to others about the study if you wish. 
 Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
Thank you for taking the time to read this. 
What is the purpose of the research?
Smoking is a major cause of poor physical health, but stopping smoking is not easy. 
There are no quit smoking support services especially for people with mental health
problems. So we have created a support service designed specifically for people who 
have had problems with their mental health. The aim of this service is to help people
to cut down smoking until they are ready to quit. We need to know if this service is any 
better than current NHS services for smoking. We will also compare the costs of the 
support service with current NHS services for smoking to see if the support service 
represent a good investment. 
Participant Information Sheet
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Why have I been chosen? 
You have been chosen because you are a smoker and you have received care from
mental health services either recently or in the past. 
Do I have to take part? 
No, it is up to you whether or not you decide to take part. If you do decide to be included
you will be asked to sign a consent form. If you decide to take part you are still free to
withdraw at any time and without giving a reason. If you decide to withdraw you will 
not be followed up and you will have no further part in the study. A decision not to take
part will not affect any of the care you receive now or in the future. 
What will be involved if I decide to take part? 
Once we receive your permission to contact form a study researcher will telephone 
you to tell you about the study and ask a few questions to see if you are eligible to
participate. Unfortunately, we cannot include people who are or become pregnant or
are breast-feeding because they would require some additional support which we
cannot provide as part of this study. We also need to check that your GP is happy for 
you to take part in the study. If you are eligible to take part in the study we will invite
you to meet with a researcher where you will have an opportunity to ask any questions 
about the study. This meeting will last about one hour.
At this meeting the researcher will ask you to complete some questionnaires about
your smoking habits, your general health and ask to measure your height, weight and 
breath carbon monoxide levels (this is a commonly used method to find out how much
you smoke). 
You will be asked to attend to further meetings with the researcher 6 and 12 months 
after joining the study. At these meetings you will be asked to complete some
questionnaires about your smoking habits, your general health and we will measure
your height, weight and breath carbon monoxide levels. We will ask you to give us the 
names of up to three family members/friends/carers who we can contact to ask if you 
have given up smoking if we are unable to contact you for the 6 months and 12 months
follow up meetings. At the 6 and 12 month meetings we will give you a £10 voucher as 
a gesture of thanks.
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
90
After your first meeting with the researcher you will be allocated to one of two groups, 
you will have an equal chance of being allocated to either: 
Group 1 - Participants receive visits from a smoking cessation practitioner plus 
continue with usual GP care.
Group 2 -   Participants continue to receive usual GP care. 
We cannot say which of these treatments you will receive as this will be randomly
selected and completely down to chance. 
Group 1 - Smoking Cessation Practitioner group
If you are allocated to this group you will be assigned a smoking cessation practitioner
who will advise on the best way to cut down or give up smoking. They will tailor the 
advice they give you to your individual needs. The smoking cessation practitioner is
someone with a background in mental health care and is an accredited level 2 Quit 
smoking officer. 
We will arrange your first appointment with your smoking cessation practitioner at your
convenience either at your home, local GP clinic or hospital. The smoking cessation 
practitioner will try to arrange regular meetings with you and/or visits to the GP to see 
how things are working and whether you need to change your treatment as necessary. 
It is important that you tell the practitioner if you have any side effects from cutting
down your smoking or if you change your medication. This will affect how your
treatment is managed by your GP. 
We may ask you for permission to record some of your sessions with the smoking 
cessation practitioner; you do not have to give permission for your sessions to be
recorded. Any recordings made will only be used for analysis as part of the research.
If you do not wish to be recorded you can still take part in the study and meet with the 
smoking cessation practitioner. 
Group 2 - Usual GP care treatment group
If you are allocated to this group you will be provided with some advice produced by 
the NHS about what to do if you are interested in stopping smoking and encouraged 
to make an appointment with your GP. You will receive the care that is usually offered 
to all people in your practice or community. 
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What do I have to do now? 
If you would like to take part in this study you need to complete and return the 
enclosed permission to contact form in the pre-paid envelope provided. 
What are the possible benefits of taking part? 
Stopping smoking is the single most helpful thing you can do to improve your own 
health. Smoking causes serious illnesses such as lung cancer and heart disease. 
Cutting down the total number of cigarettes you smoke is a step in the right direction.
Giving up smoking completely will not only improve your own well being, it will help
protect the health of your friends and family around you. Stopping smoking also has 
the added benefit of saving you a lot of money that you would have spent on cigarettes. 
We cannot promise that the study will directly help you but the information we get from
this study will help health professionals decide the best way to help people with mental
health problems to quit smoking in the future. 
What are the disadvantages of taking part? 
When you stop smoking you may experience withdrawal symptoms. These symptoms
may include feeling depressed, anxious or irritable, having difficulty concentrating or 
feeling restless. You may also feel hungry and put on weight. These are normal
symptoms which may be particularly strong when you first quit but should lessen over 
time. The smoking cessation practitioner will help and support you so that when you 
are ready to quit smoking you will be motivated and able to cope.
There may be other risks from mixing smoking cessation drugs with medication used 
to manage your mental illness. The risk of side effects are low, but if you get headaches
or worsening of your mental health symptoms, you should tell your GP or smoking 
cessation practitioner immediately.
What happens when the study ends? 
The study will last for 12 months, once you have had your 12 month follow up the 
smoking cessation practitioner will no longer be funded to help manage your smoking.
Your GP will continue managing any smoking cessation drugs you may be taking and 
you will still be able to access your local Quit smoking clinics and services. You will still
be entitled to your usual GP care including prescription medication.
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What will happen if I don’t want to carry on with the study? 
Your participation is voluntary and you are free to withdraw from the study at any time
without giving any reason. If you withdraw from the study we will delete your contact
details from our records but we will need to use the data collected up to your
withdrawal. You may also choose to withdraw from treatment but continue being 
followed up. This will not affect your rights or your future care in any way.
Will my taking part in this study be kept confidential? 
All information that you give us will be kept strictly confidential. Your name will not be
mentioned in any reports. Only members of the research team and your GP will know
that you have agreed to take part in the study. As we will be sending you further 
questionnaires we need your name and contact details. These personal details will be
stored in locked filing cabinets and all electronic copies will be stored on a secure
server accessed by password protected computers. 
Some parts of your medical records may need to be looked at by authorised persons 
from the research team to check medication and medical history. Your information will
not be disclosed to any unauthorised person. Your GP and mental health team will be
informed of your participation in this study and they may be approached if
circumstances occur where we may be concerned for your health and safety. 
Results of the research study
The results of this research study will be available after we have analysed the data and 
we will send you a copy of the results if you would like us to. 
What happens if something goes wrong?
This research only includes treatments that you would normally receive. The clinicians
and health care professionals will take every opportunity to reduce risk. If something
were to go wrong, they would offer you the best possible solution to resolve it. If you 
believe that you have been harmed by taking part in the study, you have the right to
pursue a complaint through the usual NHS procedures.
Who reviewed the study 
This study has been reviewed by Leeds East Research Ethics Committee. 
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Who is organising and funding this research?
This study is being funded by the Health Technology Assessment Programme. The 
trial is sponsored by the University of York and managed by researchers at the York
Trials Unit, University of York. 
Who can I contact for more information?
If you have any queries or wish to obtain further information about this study, please
contact Emily Peckham, phone: , email: .
For independent information about participating in this study, contact your local <insert
local Patient Advisory Liaison Service (PALS) details or equivalent (if not known locally 
as PALS) here>, <local contact details entered here>, <local contact detail entered
here>.
If you are unhappy with any aspect of this study, you can speak with any study 
researcher (contact details above) or your care coordinator who can relay your
dissatisfaction to the lead investigator, Prof Simon Gilbody. You can also file a formal
complaint with the NHS complaints procedure (Tel: or free phone: 
). Taking part in this study in no way affects your right to complain about any 
aspect of the way in which you have been treated during the course of this study.
Thank you for taking this the time to read this information sheet. 
 Please keep this copy. 
What to do now 
If you do not want to take part – do nothing 
If you do want to take part - complete:
The permission to contact form 
Then post it in the prepaid envelope provided. 
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
94
Participant consent form
Participant Identification number: 
Title of Study: The SCIMITAR trial - Smoking Cessation In Mental Ill health Trial.
Please read carefully. If you agree with each point please initial each box below:
1. I confirm that I have read the information sheet version <no> dated <date> for the 
above study and have had the opportunity to consider the information, to ask 
questions and to have these answered satisfactorily.
2. I understand that my participation is entirely voluntary and that I am free to withdraw
at any time without giving any reason, if I chose to withdraw I will not be followed
up and will have no further part in the study, and that my medical care and legal 
rights will not be affected. 
3. I give permission to members of the research team, regulatory authorities and NHS
trust where relevant to access my medical records and data collected from the 
study. Information held at the General Register Office may be used to keep in touch 
with me and follow up my health status for the duration of the study.
4. I agree to complete the relevant questionnaires at the start, 6 and 12 months follow-
up, and also have my weight, height and breath carbon monoxide measured during
the study.
5. I agree to my GP and mental health care professionals being informed of my
participation in the study. They may also be approached during the study if
information or advice is required for my health and safety. 
6. I agree to this consent form and other data collected as part of this study being 
kept by researchers at the University of <York/Manchester>. I understand that my
participation in this study is confidential and that no materials which could identify
me will be used in any reports of this study.
7. I agree to up to three family members/friends/carers being contacted to ask 
whether I have quit smoking in the event that the researcher has been unable to
contact me. 
Patient Consent Form 
8. I understand that I may be asked for permission to record treatment sessions and 
that I am free to refuse, and that I can still take part in the study if I refuse to be
recorded and that any recordings made will only be used for analysis as part of the 
research. 
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9. I agree to take part in the SCIMITAR study.
……………………………………………. …/…/……
……………………
Name of participant (BLOCK CAPITALS) Date Signature
……………………………………………. …/…/……
……………………
Name of researcher (BLOCK CAPITALS) Date Signature
Other research studies 
Researchers from the SCIMITAR team would like to contact people who agree to take
part in the main SCIMITAR study to see if they are interested in helping with other
related studies – these are entirely optional. If you would like to be sent information
related to other studies, please tick this box 
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Appendix 3 Adverse events and risk protocol
Adverse event SOP 
TITLE:  Adverse Event Reporting 
VERSION: 1.2
Prepared by: Catherine Arundel 
Date: 11.12.15
Approved by: Emily Peckham
Date: 17.12.15
PURPOSE: To describe the process of adverse event reporng and follow up 
of adverse events for all staﬀ involved in the SCIMITAR+ Study 
1) PURPOSE 
To describe responsibilities and procedures for identifying, collecting, recording and 
reporting of Serious and Non Serious Adverse Events occurring in the SCIMITAR+ trial.
2) DEFINITIONS
The definitions listed comply with ICH GCP guidance (1996)
SERIOUS ADVERSE EVENT – Any untoward medical occurrence that results in one of the 
following criteria:
- Life threatening (i.e. event in which patient is at risk of death at the time of the event 
occurring). 
- Is fatal (i.e. results in death). 
- Requires unplanned or prolonged hospitalisation*.
- Results in persistent or significant disability or incapacity. 
- Results in a congenital abnormality or birth defect.
- Any other medical condition not listed above, which may require medical or surgical
intervention to prevent the above criteria occurring. 
*Unplanned refers to emergency hospitalisations resulting in an inpatient stay. 
Prolonged hospitalisation is deemed to be where a patient’s stay is longer than expected
(e.g. patient is operated on as day case but remains in hospital overnight). 
NON SERIOUS ADVERSE EVENT – This is any untoward medical occurrence in a participant to
whom an intervention has been administered, including occurrences not necessarily caused 
by or related to that intervention. 
EVENT OUTCOME - For any adverse event the outcome of the event must be detailed.
Events may be:
RECOVERED: e.g. Participant is no longer experiencing any unfavourable symptoms related 
to the event.
RECOVERED PARTIALLY: Participant is still experiencing some unfavourable symptoms
related to the event however the impact of these has improved since the event.
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DEATH: Participant is deceased as a result of the event.
ONGOING: Participant continues to experience unfavourable symptoms which currently 
remain unresolved.
3) SCIMITAR+ REPORTING PROCEDURE
WHO 
1) All trial staﬀ that are in contact with patients are responsible for nong adverse events 
that are reported by the patient and making them known to York Trials Unit in a mely
fashion. Patients entered into SCIMITAR+ must be encouraged from the outset to
contact their researcher at the time of an event occurring. 
2) The Trial Coordinator at York Trials Unit is responsible for the processing and reporng 
of serious and non-serious adverse events in line with procedure detailed below. 
3) Clinical staﬀ members at the University of York are responsible for the reviewing of
Serious Adverse Events.
4) The Chief Investigator (Professor Simon Gilbody) is responsible signing off all Serious 
Adverse Events. Any events deemed to be related and unexpected will be reported to
the REC and Sponsor by the Chief Investigator. 
WHEN
- At each visit adverse events that might have occurred since the previous visit or
assessment should be elicited from the patient. In many cases this will be captured at 
the point of data collection and further elaboration by the participant may be required
to assist with recording.
- Adverse Events reported at any other time should also be reported to York Trials Unit
within the time frames set out below.
- Adverse events which are related to the research and are ‘On-going’, when a participant 
completes their study involvement, should be followed up as required by the protocol 
and as clinically indicated.
- Adverse Events which are not related to the research and remain ‘On-going’ do not need
to be followed up after study completion. 
HOW
STUDY SITE
1) Document details of the event clearly, using the SCIMITAR+ Adverse Events form. 
Please ensure that the following are clearly documented;
- Date of Event. (If the participant cannot remember please indicate as closely as possible) 
- Acon taken including treatment and/or medication and dates that this commenced 
and/or stopped or was changed.
- Whether the event is deemed to be Serious or Non Serious (using the criteria as detailed 
in Section 4). 
- The outcome of the event.
Please ensure that no patient identifiable detail is provided on the Adverse Event Form. 
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2) Events that are serious must be reported to York Trials Unit within 24 hours of study
staff being made aware of the event. 
Events that are non-serious must be reported to York Trials Unit within 5 days of study 
staﬀ being made aware of the event.
Reporting of adverse events should be completed by sending the Adverse Event form to
York Trials Unit by fax on e University of York Drop Oﬀ. Events
should be marked for the attention of/sent to Catherine Arundel 
and Emily Peckham   . 
3) Study sites should respond promptly to any requests made for further information.
4) Copies of all correspondence and notes relating to an adverse event should be retained 
in the individual patient’s research records or master site file. Reasons for late reporng 
must be documented on the SAE form and in the patient’s research records or the 
master site ﬁle. 
YORK TRIALS UNIT
Upon receipt of completed adverse event form(s), the form will be processed as described 
below.
1) The adverse event forms will be reviewed by trial staff at York Trials Unit. In the event 
that the event is deemed to be ‘Serious’ this will be provided to Professor Ian Watt for 
initial review. 
2) All correspondence about the adverse event will be saved and held securely at York 
Trials Unit.
Should a site provide patient identifiable details on any adverse event form (other than
participant date of birth), this will be destroyed upon receipt at York Trials Unit. The site
will be contacted to inform them of this breach of Data Protection and the need to
destroy any copy that they have and to recomplete and resend the Adverse Event form
removing any patient identifiable informaon. 
3) The frequency of all adverse events will be reported internally to the DMEC and TSC at 
regular meetings. The DMEC will be responsible for completing immediate review of
serious, unexpected and related events. They will then see unrelated SAE and NSAE at 
the next scheduled meeting. Details of serious and non-serious adverse events will also
be reported externally to the HTA in regular progress reports. 
4) YTU, in conjunction with the Chief Invesgator, will complete an NRES SAE form for any
related AND unexpected SAEs and will nofy the REC, Sponsor and Funder within 15
days. 
or via th
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CHIEF INVESTIGATOR/DELEGATED CLINICIAN
1) The Chief Investigator will, upon receipt of a copy of a Serious Adverse Event form, 
review the event and complete a CI Sign Off Form.
2) A signed copy of the CI Sign Off Form should be returned to York Trials Unit.
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Appendix 1: SCIMITAR+ Adverse Event Reporng Guidelines
Is the event serious? 
SITE CHIEF INVESTIGATOR YTU
Site to
report to
YTU 
within*:
Chief Investigator to report to
REC 
YTU to report to
DMEC /TSC 
YTU to report to Funder 
SERIOUS 24 hours of
being made
aware of
the event.
Only if event is related AND 
unexpected. 
Within 15 days.
Event is related
AND unexpected: 
To be reported
and reviewed
immediately.
All other events
to be reported at 
next scheduled
meeting. 
YTU to provide details for roune funder 
progress reports.
Is the event non serious?
SITE YTU
Site to report to YTU 
within: 
Chief Investigator to
report to REC 
YTU to report to
DMEC/TSC
YTU to report to Funder 
NON SERIOUS 5 days of being made aware 
of the event.
Not required. To be reported at next 
scheduled meeting.
YTU to provide details 
for routine funder 
progress reports.
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Appendix 2: SCIMITAR+ – Site Adverse Event Reporting Flowchart 
Study site receives notification that SCIMITAR+ participant has experienced an adverse 
Adverse Event form to be completed, clearly documenting
all necessary information.
Please ensure that no patient identifiable detail is provided
on the Adverse Event Form 
EVENT IS SERIOUS 
- Results in death.
- Is life threatening.
- Requires unplanned or prolonged hospitalisation.
- Results in persistent or significant disability or
incapacity. 
- Is a congenital anomaly or birth defect. 
- Any other medical condition requiring medical or
surgical intervention to prevent the above.
Event to be reported to York Trials Unit within 24 hours of
the site being made aware of the event.
The Serious Adverse Event form should be faxed to York
Trials Unit (                       ) via University of York
Drop Off to Catherine Arundel and Emily Peckham
Event to be reported to York Trials Unit within 5 days
of the site being made aware of the event.
The Adverse Event form should be faxed to York
Trials Unit (                       ) or sent via University of
YORK CTU 
SAEs processed within 24 hours of receipt of notification. 
All SAEs deemed to be related and expected/ unrelated and 
expected or unexpected to be sent to the CI for sign off within
14 days.
DMEC and TSC to be immediately informed of the event.
All related 
Sponsor and Funder within 15 days.
and unexpected SAEs to be notified to REC,
EVENT IS NON SERIOUS 
Event does not fulfil ‘Serious’ criteria.
Adverse Event form to be completed, clearly 
documenting all necessary information.
Please ensure that no patient identifiable detail is 
provided on the Adverse Event Form
CHIEF INVESTIGATOR
SAEs to be signed off and copy of form sent to YTU.
Adverse Events Contacts
York CTU 
Fax: 
Catherine Arundel 
Tel: 
Email:
In the absence of Catherine, please
contact:
York Drop Off to Catherine Arundel and Emily 
Peckham 
event.
Emily Peckham, 
Email:              
or sent 
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1) To access the University of York Drop Off service go to:
https://dropoff.york.ac.uk
2) To access the system, click on ‘Drop Off’
3) Enter your name, your organisation and email address and enter the 
numbers/letters displayed 
4) You will receive an email from University of York Drop Off. Click on the 
link which will take you to the following page
Appendix 4: How to use University of York Drop Off
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5) Enter Catherine and Emily’s email addresses in the ‘To’ box
6) Select the files you need to upload using the ‘Choose File’ button. This will 
allow you to browse to access the relevant files. NB: please ensure files are 
password protected/encrypted before uploading.
Please note the system can only upload one file at a time.
7) Once all relevant files have been uploaded, click the ‘Drop Off Files’ button. 
This will send the files back to York Trials Unit.
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Suicide Protocol
Suicide risk identified during face-to-face or telephone
interview
The PHQ-9 questionnaire asks if the patient has had ‘Thoughts that you 
would be better off dead or hurting yourself in some way’ (Question 9).
If the participant indicates a response of 3 for this item, then you should 
ask whether the patient has talked to their GP, psychiatrist or care 
coordinator/CPN about these feelings. If the patient has spoken of these 
thoughts to their GP or psychiatrist, then no action is required.
If not, you should ask the patient whether it is OK for you to contact their GP
and inform them of the situation. If the patient refuses, contact the relevant
designated psychiatrist/health professional. If the patient agrees, you should 
immediately get in touch with the patients GP or psychiatrist.
If unable to contact the patients GP or psychiatrist contact any of the
designated centre psychiatrists/health professionals, if unable to contact any
If at any time you believe that there is significant suicide risk with a patient who 
is participating in the study that has not been recently communicated to their 
GP, psychiatrist or care coordinator/CPN, you must contact the relevant
designated centre psychiatrist or health professional or Prof Simon Gilbody
(Consultant psychiatrist) if the relevant designated centre psychiatrist or health
professional is unavailable.
Contact numbers can be found on the back page of this protocol.
The designated psychiatrist/ health professional or Prof Gilbody, will then 
assess the patient and if it believed necessary, and if there is a significant risk, 
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of the designated centre psychiatrists/health professionals contact Prof
Gilbody, if unable to contact Prof Gilbody, contact the Trial manager, Emily 
Peckham or the Trial Intervention Co-ordinator, Della Bailey. If unable to
contact any of the above contact any other of the co-investigators who will
advise further. 
Please also complete the attached Suicidal Intent Form, if the patient agrees 
to you contacting their GP/psychiatrist and inform the Trial Manager. If
relevant, Professor Gilbody or the relevant designated centre
psychiatrist/health professional should also complete the Suicidal Intent Form: 
Psychiatrist/ Health Professional. These forms should be stored with the 
patient’s trial records and a copy faxed to York Trials Unit on                        .
If any other responses during the face-to-face or telephone interview give you 
cause for concern, raise this with the relevant designated psychiatrist/health
professional. 
Suicide risk identified on a postal  questionnaire
At 6 month and 12 month follow up points, some patients can choose to 
receive and return questionnaires by post. If you receive a PHQ-9 in which the 
patient has indicated a score of 3 for question 9, you will need to follow the 
suicide protocol. 
Contact the patient by phone and say that you are concerned with their 
response to this question. Ask if they have discussed these feelings with their 
GP or psychiatrist. If the patient has spoken of these thoughts to their GP
or psychiatrist, then no action is required. 
If not, you should ask the patient whether it is OK for you to contact their GP
and/or psychiatrist and inform them of the situation. If the patient refuses, 
contact the relevant designated psychiatrist/health professional or if unable to 
contact the relevant designated psychiatrist/health professional contact Prof
Gilbody. If the patient agrees, you should immediately get in touch with the 
appropriate GP and/or health professional. 
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If unable to contact the patients GP or psychiatrist contact any of the
designated centre psychiatrists/health professionals, if unable to contact any
of the designated centre psychiatrists/health professionals contact Prof
Gilbody, if unable to contact Prof Gilbody, contact the Trial manager, Emily 
Peckham or the Trial Intervention Co-ordinator, Della Bailey. If unable to
contact any of the above contact any other of the co-investigators who will
advise further. 
If any other written responses on the questionnaires give you cause for
concern, raise this with the relevant designated psychiatrist/health
professional. 
If you are unable to contact the patient within 24 hours, contact the patient’s 
GP or psychiatrist. Inform them of the patient’s questionnaire response and 
that you have been unable to contact the patient to assess the situation
further. 
At this point also check the patient’s contact telephone number is correct. It
may be that the telephone number on the database is out of date. If an 
alternative number is provided and the GP/ health professional agrees, 
attempt to contact the patient again.
If still unable to contact the patient and if no alternative contact details are 
available, confirm with the GP/ health professional that they will follow up with
the patient as they feel appropriate based on their clinical knowledge of the 
patient. 
Inform the relevant designated psychiatrist/health professional or Prof Gilbody 
of the patient’s questionnaire response and details of resultant contacts with
the patients GP/psychiatrist.
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Non- Suicide risk
If any other areas of risk arise in the interviews that are not related to suicide
or self-harm but that give cause for concern please complete the non-suicide 
risk form. 
If a non-suicide risk is identified check whether the participants care
coordinator/ GP/ psychiatrist is aware of the risk and document this on the 
non-suicide risk form. If the none of the above are aware contact the site PI
for advice and complete the non-suicide risk form. Note the Site PI only needs
to sign the non-suicide risk form if the researcher/ mental health smoking
cessation practitioner has contacted the site PI. 
If a participant has a very high CO reading (above 100ppm), they should be 
given advice about possible acute CO poisoning, and should be advised to
attend their local Accident and Emergency department. A non-suicide risk 
form should be completed.
If a participant has a reading between 51ppm and 100ppm please
recommend that they get their car and home appliances etc serviced in order 
to check they are not being exposed to CO via other means and advise them
to speak to their GP. 
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Suicidal Intent Form
The patient below has shown thoughts of suicidal intent on the PHQ-9 
Questionnaire and has agreed for their GP and/or psychiatrist to be contacted 
by the researcher.
Date of birth:  / / 
SCIMITAR Participant ID: __ __ __ __
Action taken
Name of GP/Psychiatrist contacted:  
Date of contact: / / Time: ___:___ am/pm 
Outcome of contact/Action/Comments:
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Suicidal Intent Form: Psychiatrist/Health Professional 
Name of Participant:  
Date of birth:  / / 
Name of Psychiatrist/trial health professional notified: 
Date notified:  / / 
Action taken
Patient contacted: Yes No
GP/Psychiatrist contacted   Yes No
If yes, GP/psychiatrist contacted with Patient’s consent?
Yes No
Name of GP contacted:
Date: __/__/___
Name of Psychiatrist contacted:  
Date: __/__/___
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Outcome of contact/Action/Comments:
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Non-Suicide Risk Form 
The participant below has been identified as being a risk other than self- 
harm/ suicide during a SCIMITAR+ follow up or meeting with a mental health
smoking cessation practitioner (MH-SCP). 
Participant ID Code:   
Date of Assessment: 
Assessment: Baseline / 6 month follow up / 12 month follow up / meeting 
with MH-SCP
Risk identified and how: 
Summary of how risk protocol implemented: 
(Which clinician gave advice, what advice was given, was risk judged as
passive or active? If advised to contact GP/mental health professional –
name of practice/team, name of GP/mental health professional spoken to, 
date of contact)
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Research Signature:  ……………………………………  Date: ………………...
Name of Clinical Contact: …………………………...........................................
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Appendix 4 Flow chart for the SCIMITAR+ trial
Potential participant
not eligible 
Potential participant does not consent
A baseline interview is booked with
potential participants who are eligible
and wish to take part in the trial
Participant consents, completes baseline
questionnaire and is randomised 
Participant receives BSC
and usual care
Participant continues to receive
their usual care
Participant’s GP receives notification of their participation in the study.
The participant is followed up at 1, 6 and 12 months
Potential participant identified by GP
database search, care co-ordinator caseloads,
at annual review or annual health check and
sent participant information sheet and
consent to contact form 
Potential participant sees advertisement
and contacts researcher, who sends them
a participant information sheet and
consent to contact form
Potential participant’s GP
contacted to confirm
suitability for trial
Potential participant 
phoned by researcher, who
carries out eligibility screen 
Potential participant does not
return consent to contact form
Potential participant returns
consent to contact form 
Potential participant
not eligible 
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